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Abstract 
Renal ischaemia reperfusion injury (IRI) is a common contributor to acute kidney injury, 
arising from clinical conditions such as kidney transplantation, sepsis and cardiac bypass 
surgery. Any condition leading to a reduction in renal blood flow followed by reintroduction 
of perfusion leads to a characteristic pattern of tubular injury worsened by the cascade of 
inflammatory and immune events triggered by reperfusion.  This can have significant 
consequences including death and need for dialysis and there is no known specific 
treatment.  Mesenchymal stromal cells (MSC) are rare immunomodulatory cells which 
have been shown to skew the immune response towards an anti-inflammatory response, 
inhibit dendritic cell (DC) maturation and suppress T cell function.  Early literature 
suggested that MSC may be renoprotective in IRI.  The goal of this study was to examine 
the effect of MSC in an in vitro human tubular epithelial cell (TEC) model and in an in vivo 
murine IRI model, with particular emphasis on the impact of MSC on CD4+ T cells and DC. 
Firstly, a model mimicking IRI was developed using an immortalised proximal TEC line 
exposed to hydrogen peroxide.  Human MSC were isolated from placenta and bone 
marrow and characterised to ensure they were consistent with literature descriptions of 
MSC.  Cell viability of TEC in this model was assessed by annexin V and propidium iodide 
in a transwell model and cytotoxicity by lactate dehydrogenase (LDH) release in a co-
culture model, at the time of hydrogen peroxide administration, with or without MSC.  
Exposure of TEC to MSC or prestimulated MSC did not alter cell viability or cytotoxicity at 
24 hours.  TEC exposed to MSC conditioned media were found to have reduced 
cytotoxicity by LDH release but no difference in cell viability.   
The next goal of this work was to assess the impact of exposure of TEC to MSC or MSC 
conditioned media in the presence of CD4+ cells and DC.  CD4+ cells and DC were 
isolated from donated peripheral blood mononuclear cells using magnetic cell sorting.  
Addition of CD4+ cells and/or DC to TEC or TEC/MSC in the model of IRI did not lead to 
any reduction in cell viability or cytotoxicity.  The protective effect of MSC conditioned 
media against cytotoxicity was confirmed but there was no additional apparent effect 
mediated by immune cells.   
The aim of the second half of this study was to study MSC in renal IRI in an in vivo murine 
model (C57 Bl/6 mice).  A model of bilateral IRI using flank incisions and clamping of the 
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renal hilum for 20 minutes followed by reperfusion was validated.  A pilot study was 
undertaken administering green fluorescent protein (GFP+) murine MSC either 
intravenously (IV), intraperitoneally (IP) or via subcapsular (SC) injection.  GFP+ MSC 
were located in the kidney after IP and SC injection but not after IV administration.   Renal 
histology was unchanged by any MSC administration method compared to the control 
groups. There was a non-significant reduction in creatinine and urea in the SC group.  A 
larger experiment compared MSC with vehicle administered SC.  MSC were not protective 
against renal IRI as analysed by renal histology or serum renal function tests.  A third 
experiment was undertaken using a model of unilateral nephrectomy and then 
contralateral ischaemia-reperfusion with administration of GFP+ MSC via intra-arterial 
injection into the carotid artery.  MSC were found in the kidney and were generally located 
near the tubules – either within the tubular lumen or in the peritubular interstitium.  
However, there was no change in the severity of renal histopathology or renal function 24 
hours post IRI.   
In summary, in these models, MSC conditioned media led to a reduction in cytotoxicity 
without change in overall cell viability although MSC were not protective against renal IRI.  
This is consistent with previous studies which have demonstrated mixed findings in murine 
studies with MSC, although more consistent renoprotection in rat MSC IRI studies. 
Analysis of the literature reveals very few human in vitro studies of MSC/TEC with which to 
compare this work.  Recently, MSC have been found to secrete extracellular vesicles (EV) 
which can be characterised and quantified.  These EV range in size and in protein content.  
Direct administration of MSC-derived EV have been consistently protective against 
damage from renal IRI.  It is possible that the protective effect of MSC conditioned media 
seen in the in vitro work of the current study was due to EV.  Results from the current work 
would suggest that further investigation into EV use and application may be of more 
benefit than continuing to study MSC as a cellular therapy. 
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Chapter 1  
Introduction 
1.1 Study rationale 
Acute kidney injury (AKI) secondary to ischaemia reperfusion injury (IRI) is a common 
disease process with no specific therapy, carrying a 20% mortality.  AKI has been reported 
in 7.2% of all hospitalised patients (1) and up to 25% of patients in intensive care units (2).  
Renal IRI (reduction in perfusion to the kidney, followed by re-establishment of blood 
supply) accounts for approximately 60% of all AKI (1, 2).   Renal transplantation is the 
classic model of renal IRI, but there are many non-transplant causes including 
cardiopulmonary bypass surgery, aortic surgery, multiple organ failure and systemic 
sepsis.   
AKI is important as it is associated with significant negative outcomes.  In one cohort of 
patients with AKI, 39.3% were discharged from hospital with renal impairment, 2.7% were 
discharged dialysis dependent and 19.4% died (1).  Another study looked at nearly 30,000 
intensive care unit patients in 23 countries. In this study only 5.7% met the criteria for AKI 
but most of these (4.3% of original cohort) received dialysis.  There was extremely high 
hospital mortality (60.3%) in the patients with AKI and 13.8% of the patients receiving 
dialysis remained dialysis dependent at hospital discharge (3).  Although mortality from 
AKI has declined since the 1980s (4), it remains an independent risk factor for hospital 
mortality (5).   IRI after renal transplantation is universal, but is more severe in some 
patients due to logistical factors surrounding transplantation and donor issues.  Delayed 
graft function (defined as requirement of dialysis within one week of transplantation), which 
is largely due to IRI, has been shown to be associated with an increased risk of acute 
rejection; reduction in nephron mass after recovery; and impairment in long term graft and 
patient survival (6).  The prevalence of delayed graft function is likely to increase, as donor 
shortage and increasing demand leads to the use of extended criteria donors and donation 
after cardiac death. 
Mesenchymal stromal cells (MSC), an adult stem cell population normally residing in the 
bone marrow, are an exciting approach in the field of regenerative and inflammatory 
medicine. In the last 20 years MSC have been extensively studied in multiple fields from 
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cerebral ischaemia to cardiac ischaemia, bone marrow transplantation, bone regeneration 
and prevention of diabetes, to name a few.  There is an increasing body of literature 
suggesting that MSC may be protective against AKI in animal models.  While the 
mechanism of action of MSC in this setting has not been defined, it is likely that paracrine 
effects involving inflammatory cytokines and immune modulators are involved.   
It has become increasingly clear in the past two decades that renal IRI is an inflammatory / 
immune process (7).  There is a wealth of information about MSC, which have been 
studied since the late 1960s, indicating that their primary function in the body is to support 
haematopoietic stem cells (HSC) and they have significant effects on the immune system, 
particularly the innate immune system, dendritic cell function and T cells (8).  It was 
considered likely that any potential effect seen of MSC in renal IRI would occur at this 
junction of immune response to IRI and immune modulation by MSC.   
The purpose of this study was to examine MSC in an in vitro and in vivo model of renal IRI, 
with a particular focus on immune mediated pathways in IRI.   
1.2 Overview 
The literature review provides a synopsis of the pathophysiological changes which occur 
after renal IRI, followed by a more in depth examination of the evidence around 
inflammation and activation of the immune system in renal IRI.  Following this, MSC were 
introduced, with a review of the key characteristics of MSC, highlighting their 
immunomodulatory effects. Finally, studies examining the effect of MSC in renal IRI which 
were available at the time of the research design were reviewed.  It is this literature which 
led to the design of the current study and the research hypotheses, namely, that MSC 
would be renoprotective against IRI and that this renoprotection may be mediated by 
modulation of the immune system. 
Individual study aims and results were presented in subsequent chapters, with each 
chapter including a brief background to the specific experimental design, including 
methodology which was not previously described, and the results of the experiments 
conducted. 
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The final chapter is a thorough discussion of the results of the research presented, with 
reference to the literature.  There is extensive reference to literature which was not 
published at the onset of this work; the ways in which this new literature has changed the 
focus of the field in this area; and the space in which the current work sits with respect to 
the whole body of literature available.  The work concludes with identification of the 
pathway forward in this exciting and rapidly changing research area. 
1.3 Research hypotheses and aims 
The research hypotheses were: 
1 MSC are renoprotective against IRI 
2 This protective effect is mediated by dendritic cells (DC) and Cluster of 
Differentiation (CD) 4+ T helper cells.   
 
The research aims are: 
1 Establish an in vitro model of human renal IRI 
2 Investigate the efficacy of MSC in renoprotection in the in vitro model  
3 Assess the impact of DC and CD4+ T helper cells in this model 
4 Establish an in vivo model of murine renal IRI, and 
5 Investigate the efficacy of MSC in renoprotection in the in vivo model. 
1.4     Significance 
Renal IRI places a heavy burden on the health dollar and impacts significantly on patients.  
It is imperative to identify safe and effective therapeutic responses, particularly when such 
a large proportion of renal IRI cases are predictable prior to onset.  MSC show great 
promise in this area.  However, at present, practical considerations limit the use of MSC in 
the human population, including the very large number of cells required; the heterogeneity 
of the cell population when cultured ex vivo; and the difficulty in ensuring migration in an 
ex vivo cultured population.  Although using MSC as therapy for kidney injury is the current 
long term goal, the practical considerations listed above may limit this application.  Further 
investigation into how MSC may protect kidneys from IRI may direct alternative therapeutic 
strategies for the future, leading to reduction of the burden of disease and death 
associated with AKI. 
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Chapter 2   
Literature review: renal ischaemia reperfusion injury 
and mesenchymal stem cells 
2.1 Pathogenesis of renal IRI 
Renal ischaemia reperfusion injury (IRI) is a complex process involving many different cell 
types and pathophysiological pathways.  Renal IRI is a two staged process, initially 
involving an abrupt reduction in oxygenation of the kidney secondary to poor blood flow 
followed by restoration of perfusion.  For the purpose of this review, the haemodynamic 
changes and structural changes within the kidney tubules will be discussed briefly.  The 
natural history of regeneration and repair after injury will be explored, followed by a review 
of the current understanding of renal IRI as an inflammatory / immune process.  
2.1.1 Structural changes within the kidney as a consequence of renal IRI  
2.1.1.1 Haemodynamic factors 
Renal IRI causes extensive functional changes to the microvasculature, which result in 
medullary congestion and significant reduction in renal blood flow.  This has the effect of 
prolonging the tubular hypoxic injury and is most prominent in the outer medulla (9, 10).  
The significant post-reperfusion reduction in renal blood flow is seen as early as 1 minute 
after reperfusion and varies in duration between capillaries, producing a patchy injury (9, 
11).  Hypoxia causes loss of endothelial autoregulation, which manifests as 
vasoconstriction (12) and leads to increased renal vascular resistance.  Reactive oxygen 
species (ROS), increased cytosolic calcium (13), inducible nitric oxide synthase (iNOS) 
(14) and increased levels of endothelin (15) all contribute to renal vasoconstriction.  The 
hypoxic injury causes changes in the coagulation pathway, predisposing to fibrin 
deposition and also contributing to increased renal vascular resistance (12).  Upregulation 
of multiple adhesion molecules and chemokines, including the selectins, integrins, 
intracellular adhesion molecule and fractalkine (16) leads to leukocyte recruitment, causing 
increased viscosity, sluggish blood flow and trapping of red blood cells within the 
endothelial lumen (17).   
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Importantly, there are long term consequences of the vascular effects of renal IRI.  Studies 
have shown a 30-50% loss of peritubular capillaries after a significant ischaemic insult 
(18).  This contributes to chronic hypoxia of the surrounding tubules, stimulation of 
transforming growth factor β (TGFβ) and tubulointerstitial fibrosis, which can itself 
contribute further to chronic hypoxia.  The mechanisms for the vascular drop-out remain 
unclear, but it is possible that the inflammatory milieu after renal IRI inhibits angiogenesis 
by reducing vascular endothelial growth factor (VEGF) levels and increasing specific 
VEGF inhibitors (12).  
2.1.1.2 Tubular injury and dysfunction 
Renal tubular epithelial cells (TEC) control the final concentration of the urine.  Therefore 
the body’s handling of electrolyte balance, volume balance and toxin removal depends on 
the ability of the TEC to function.  Healthy TEC are highly polarised, with an apical and a 
basolateral surface.  The apical surface of proximal tubules consists of microvilli, forming a 
brush border visible on histology.  The basolateral surface contains transmembrane 
integrins bound to extracellular matrix proteins causing strong adherence to the basement 
membrane.  Both surfaces contain solute transport mechanisms, such as channels, 
carriers and active pumps, which may require electrochemical gradients to function.  Cells 
are connected by junctional complexes at the apical surface, and between cells exist tight 
junctions, which contain proteins that function to enable or disable paracellular transport 
(19). 
Ischaemic acute kidney injury has traditionally been thought of as being associated with 
acute tubular necrosis, although it is now clear that apoptosis and sublethal damage are 
also characteristic features (17).  Sublethal injury results in disruption of the tight junctions, 
increased paracellular reabsorption (termed “backleak of glomerular filtrate”), cytoskeletal 
disruption and loss of cell polarity.  The loss of cell polarity occurs at the same time as 
sloughing of the microvilli into the tubular lumen, and in the proximal tubule results in a 
translocation of the sodium-potassium adenosine triphosphatase (Na/K/ATPase) 
transporter from the basolateral surface to the apical surface.  This decreases the proximal 
tubule’s ability to reabsorb sodium, and a large amount of sodium is lost in the urine.  An 
increase in intraluminal sodium concentration at the distal tubule signals the afferent 
arteriole to the glomerulus, via the macula densa (a cellular area of the distal tubule in 
close proximity to the glomerular arterioles), resulting in constriction of the afferent 
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arteriole, leading to decreased glomerular filtration rate (GFR), a hallmark of AKI.  In 
ischaemic AKI the fall in GFR is more than would be expected from this feedback loop, 
possibly due to enhanced endothelial vasoconstriction.  Another mechanism contributing 
to the fall in GFR seen in ischaemic AKI is that of intraluminal obstruction by cast formation 
from apoptotic and necrotic epithelial cells, brush border membranes and extracellular 
matrix proteins.   
Whether a cell undergoes apoptosis or necrosis involves complex processes that are 
incompletely understood.  It appears that protracted and severe ischaemia is more likely to 
result in necrosis than apoptosis, but milder ischaemia can lead to either apoptosis or 
sublethal injury (20).  The cell itself is important, as is its location in the nephron.  S3 cells 
of the proximal tubule are the most vulnerable to hypoxic injury.  This is partly because 
they tend to lie in the relatively hypoxic outer medulla (13).  However the distal tubule and 
parts of the loop of Henle also lie in the outer medulla and these cells are relatively 
resistant to ischaemic injury as they retain greater ability to generate ATP in the same 
conditions and may have less severe increases in ATP requirement after injury (20).   
2.1.2 Natural history of acute kidney injury:  regeneration and repair 
Unlike many other organs, the kidney is able to regenerate and recover after an ischaemic 
insult.  The extent of the recovery depends on the duration and degree of ischaemia and 
the underlying renal structure.  IRI leads to loss of epithelial cells within each tubule, but 
over a period of several days the majority of the tubules become repopulated and recover 
function.  Controversy has centred on the source of the repopulating cells.  Possibilities 
include extrarenal cells (such as bone marrow derived stem cells) and intrarenal cells 
(either intrarenal adult stem cells or proliferation from the surviving renal tubular 
epithelium).  Early support for the involvement of bone marrow derived cells came from 
reports of microchimerism in the tubules of human renal transplant biopsies with 
documented AKI (21-23) and one report of tubular chimerism in a bone marrow transplant 
recipient who developed acute renal failure (24).  However, a larger study involving 72 
biopsies from 36 renal transplant recipients has shown a small degree of tubular 
microchimerism in 88% of patients, from as early as 8 days post-transplant to as late as 8 
years, unrelated to AKI (25).  Interestingly, this study evaluated the relationship between 
chimerism and graft function at 18 months post-transplant and found that there was no 
correlation.   
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Animal models have demonstrated co-localisation of donor cells and renal tubular markers 
in mice after bone marrow transplant, confirming a small role (2-5% of total tubule cells) of 
bone marrow derived cells in normal renal tubular turnover (22, 26).  Unilateral IRI led to 
an increase in the number of donor derived tubular cells to 20% within 48 hours (26).  
Other animal studies have been unable to replicate these results, finding a marked 
increase in donor derived interstitial cells but not tubular cells (27).  Lin et al elegantly 
quantitated the proportion of bone marrow derived regenerating renal tubular cells after IRI 
and found that only 11% of the proliferating cells originated from bone marrow cells, the 
vast majority of which (81%) were in the interstitium (28).  Therefore, although there is 
certainly evidence that a small percentage of bone marrow derived cells will migrate to 
damaged renal tissue and differentiate into renal tissue, these cells are unlikely to 
contribute significantly to functional repair in vivo.    
 Although Duffield et al and Lin et al show convincingly that the vast majority of the 
repopulating cells come from an intrarenal source, these studies do not address the 
question of whether there is a population of adult intrarenal stem cells which are able to 
differentiate in response to injury (27, 28).  Support for the existence of intrarenal stem 
cells has come from several studies over the last few years, but little consistency is shown 
between these studies.  Four papers identify different cell populations, each of which are 
very rare in vivo, have the ability to differentiate into TEC and have some ability to migrate 
to injured parenchyma but none of which have shown sustained self-renewal or 
clonogenicity (29-32).  An intrarenal cell population that responded to IRI within 24 hours 
(33, 34) was probably a population of differentiated, mature cells (35), rather than the 
“renal progenitor like TEC” that the authors claimed.  Approximately 40% of proximal TEC 
are in the G1 phase of cell division (between mitosis and DNA replication) (36) and  30% 
of these cells were able to progress in the cell cycle upon a strong mitotic stimulus.  This 
identifies a large reserve of epithelial cells which can rapidly undergo division if required.  
Humphreys et al used transgenic mice to permanently label TEC with red fluorescent 
protein (RFP) (37).  After transient unilateral renal ischaemia, at 2 days, half of the 
epithelial cells expressed both RFP and the proliferation marker Ki67.  By 7 days, nearly 
70% of epithelial cells had incorporated bromideoxyuridine (BrdU) (injected daily after IRI), 
but over 90% of the TEC retained the RFP labelling, indicating that the origin of the 
majority of the repopulating cells after injury had clearly been the surviving TEC.  Another 
study followed clonal populations of cells within the kidney through normal maintenance 
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and after IRI repair. It found that clones were restricted to their own cellular segment, and 
did not cross over to other nephrons or tubules (38).  
Dedifferentiation and proliferation of TEC is comprehensively reviewed by Bonventre (39) 
and this theory fits with much of the more recent work (38, 40, 41).  Essentially, epithelial 
cells which undergo apoptosis or necrosis are sloughed off the basement membrane into 
the tubular lumen.  The remaining sub-lethally injured cells are separated by denuded 
basement membrane.  These cells then dedifferentiate into mesenchymal cells and spread 
along the basement membrane (42).  As de-differentiated cells, they acquire stem-cell-like 
potential.  When they come in contact with each other along the basement membrane, 
they undergo proliferation and then re-differentiation into epithelial cells, possibly under the 
same signalling conditions to which they are exposed in the developing kidney (43).  A 
large number of growth factors have been shown to be important for the regenerating 
kidney (44). 
In summary, it appears that in vivo, the predominant cell type contributing to repopulation 
of the injured tubular epithelium is the epithelium itself.  However, there is clear evidence 
that bone marrow derived stem cells can migrate to the injured tissue, and current 
evidence does not rule out their contribution to renal recovery by paracrine effects.  The 
existence and role of intrarenal stem cells remains unclear.  This body of work is important 
in the context of the current project, which will analyse the effect of MSC (exogenous adult 
stem cells) in AKI.  
2.1.3 Inflammation as a key pathogenetic event in renal IRI 
The structural changes which take place in the renal tubules after IRI have been long 
established.  However in the last two decades, the role of the immune system in renal IRI 
has been increasingly recognised (45).  Not only do cells of the immune system mobilise in 
response to IRI, they secrete cytokines which can contribute to ongoing damage, and may 
also be involved in stopping the immune response.  There is a large amount of 
redundancy and pleiotropism in the immune response to IRI, which makes it both complex 
to study and problematic to develop therapeutic strategies.  This section will review the 
mechanisms by which the innate and adaptive immune systems are stimulated by renal 
IRI.  Briefly, inflammatory mediators such as chemokines, cytokines, adhesion molecules, 
complement fragments and stress proteins are released into the environment by damaged 
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endothelial cells, tubular cells and local monocytes.  Innate immune cells infiltrate the 
damaged area, bind to stress proteins through toll like receptors, upregulate inflammatory 
mediators and become activated.  The antigen presenting cells then stimulate and 
mobilise the cells of the adaptive immune system, specifically T cells and B cells, which 
contribute to further injury. 
2.1.3.1 Endogenous “danger” signals activate the innate immune system 
It is difficult to find the earliest initiating factor in the inflammatory cascade associated with 
renal IRI.   Upregulation of cytokines, chemokines and adhesion molecules occurs very 
early and stimulates further upregulation through positive feedback loops.  A cytokine is a 
cell signalling molecule important in intercellular communication.  Cytokines are released 
by one cell and bind to receptors on another cell initiating an intracellular cascade resulting 
in an appropriate response to the environment.  Cytokines act locally and tend to have 
short half-lives.  There are two ways cytokines are activated in renal IRI (46).  Firstly, 
hypoxia induces activation of nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB), heat shock factor 1 (HSF1) and hypoxia inducible factor 1 (HIF1), all of which are 
transcription factors for cytokines such as interleukin (IL) 1.  Secondly, cytokines are 
activated by other cytokines.  For example, IL1 acts on TEC which then produce tumour 
necrosis factor alpha (TNFα) and IL6.  Cytokines which have been shown to be 
upregulated early (usually within 1 hour) in renal IRI include IL1(α and β), TNFα, interferon 
gamma (IFNγ)  and IL6 (47-50).  IL10, an anti-inflammatory cytokine, is not upregulated 
until 6 hours of injury (50).  In renal IRI experiments, blocking IL1 by two different methods 
(IL1 receptor antagonists, IL1 knock out mice) leads to protection from renal impairment at 
48 and 72 hours, reduced number of apoptotic tubular cells, reduced chemokine and 
adhesion molecule secretion and reduced leukocyte infiltration  (51, 52).  Cau et al used 
the TNFα and IL1β inhibitor FR167653 in pig renal IR experiments and showed protection 
from both acute and chronic renal failure as well as mortality (53).  Both IL4 and IL10 are 
anti-inflammatory cytokines which are protective of renal IRI (54).  Treatment with IL10 at 
the time of renal IRI reduced TNFα and oxidative stress (55) and gene therapy with IL13 
(an anti-inflammatory cytokine) was protective against renal injury and also reduced TNFα 
levels (56).  Thus there are pro-inflammatory and anti-inflammatory cytokines at work in 
the pathogenesis of renal IRI.  These groups loosely fit into the T helper 1 (Th1) and T 
helper 2 (Th2) pathways, which will be discussed further in the context of the adaptive 
immune system below.          
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Chemokines are a subgroup of cytokines with two functions: chemotaxis and leukocyte 
activation.  They are secreted by resident interstitial monocytes and damaged TEC and 
endothelial cells, attracting macrophages and neutrophils to the site of injury.  Chemokines 
known to have increased renal expression within 24 hours of IRI include monocyte 
chemoattractant protein 1 (MCP1), fractalkine, macrophage inflammatory protein 1 (MIP1), 
MIP2, regulated upon activation, normal T cell expressed and secreted (RANTES), 
keratinocyte chemoattractant (KC, a murine homologue of IL8), IL8 and epithelial 
neutrophil activating protein 78 (45, 48, 50, 57-60).  Blockade of these chemokines has 
been shown to reduce macrophage and neutrophil infiltration after IRI and to ameliorate 
renal dysfunction.   
Adhesion molecules are cell surface proteins which bind to receptors on circulating cells 
leading to adhesion and aggregation.  There are three families of adhesion molecules 
important in renal IRI: integrins, selectins and the immunoglobulin superfamily (which 
includes intercellular adhesion molecule 1, ICAM1, and vascular cell adhesion molecule, 
VCAM).  Expression of both ICAM1 and VCAM was increased in renal IRI (60) and 
blockade of ICAM1, E-selectin and P-selectin has been shown to protect against renal IRI 
(44, 54, 60-62).   
Complement is another early mediator of ischaemic injury.  Complement activation in renal 
IRI is due to both the mannose binding lectin (MBL) pathway (63) and the alternative 
pathway (64).  Activation of these pathways leads to increase in circulating complement 
component 3a (C3a) and C5a as well as tubular deposition of C3 and formation of the 
membrane attack complex (MAC).  In renal IRI C3a and C5a are known to increase 
chemokine expression (MIP2 and KC) (65), cytokine expression (TNFα) and adhesion 
molecules.  These effects lead to chemotaxis and activation of neutrophils, causing further 
complement activation (66-68).  The MAC has been identified as a key component of 
complement in renal IRI (69).  The MAC can insert into the membrane of damaged cells, 
causing sublethal injury, apoptosis and necrosis (70).  It stimulates the TEC to increase 
production of TNFα and IL6 (71), release ROS and activate adhesion molecules (69).  It 
also increases the pro-coagulant properties of the endothelium and has been shown to 
contribute to medullary capillary thrombosis (72).  A murine study has found that inhibition 
of the complement system using human C1 inhibitor protected against renal failure, 
fibrosis and mortality (73).  Furthermore, the membrane bound complement regulators 
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CD55 and CD59 have been shown to be important, with deficiency producing worse renal 
IRI (72) and overexpression ameliorating IRI (74).  In summary, the complement system 
detects hypoxic injury within the TEC, generates inflammatory mediators, recruits 
neutrophils and macrophages and contributes to TEC damage and probably long term 
fibrosis.  
Toll like receptors (TLR) are a family of membrane bound proteins which are rapidly 
upregulated in response to pathogens such as bacteria and viruses.  On binding to 
pathogen associated molecular patterns (PAMPs) TLR initiate an intracellular signalling 
cascade resulting in transcription of pro-inflammatory and immune activating molecules 
(75, 76).  A number of TLR also respond to endogenous danger signals released by IRI, 
such as fibrinogen, fibronectin, heparin sulphate, messenger ribonucleic acid (mRNA), 
biglycan, hyaluron, Tamm Horsfall protein and heat shock proteins (75-77).  These 
endogenous danger signals are known as danger associated molecular patterns (DAMPs). 
TLR interaction with either PAMPs or DAMPs leads to activation of DC and thereby 
stimulation of naïve T cells.  TLR are known to be expressed on renal parenchymal cells 
(TLR1-TLR4 only) and on both resident monocytes and circulating haematopoietic cells 
(77).  Binding of TLR 2 and TLR4 on TEC and macrophages leads to transcription of 
cytokines (including IL1β and IL6), chemokines (MCP1, KC) and adhesion molecules (78, 
79).  TLR4 is markedly upregulated after IRI, peaking at day 5.  TLR4 and TLR2 knock out 
mice are protected from renal IRI as evidenced by reduced serum creatinine and urea, 
reduced apoptosis, increased tubular epithelial proliferation and reduced kidney injury 
score by immunohistochemistry (80-83).  One study has been published using a small 
molecular compound designed to inhibit myeloid differentiation primary response 88 
(MyD88).  MyD88 is a signalling marker used by almost all TLR and its inhibition in a 
mouse model of unilateral severe IRI led to an increase in survival at five days from 0% to 
58.3% (84). Use of a TLR2 inhibitor protected against renal IRI by reducing NK cell 
recruitment, thereby reducing neutrophil infiltration (85).   
Thus, renal IRI leads to upregulation of inflammatory mediators and activation of the 
complement system, through redundant mechanistic pathways.  This inflammatory and 
damaging environment, as well as the direct effects of hypoxia, cause release of 
endogenous danger signal proteins.  These endogenous ligands bind to TLR thereby 
stimulating the innate immune system and activating dendritic cells.   
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Natural killer (NK) cells are cytotoxic lymphocytes which target and kill cells directly rather 
than requiring antigen presentation.  They are activated by cytokines including INFγ and 
secrete further IFNγ (46).  They contribute to apoptotic cell death, with NK cell depletion  
being renoprotective after IRI (86).  It has been shown that the interaction between CD137 
on the NK cell and its ligand CD137L on TEC stimulates the chemokines C-X-C motif 
ligand (CXCL) 1 and 2 to recruit neutrophils to the injured kidney (87).    
Natural killer T (NKT) cells have characteristics and cell surface receptors of both NK cells 
and T cells.  Their T cell receptor interacts with glycolipid rather than a formally presented 
antigen, and in this way they can respond much more rapidly to events (88).  They are 
seen in the kidney by as little as 3 hours after renal IRI and numbers decrease by 24 
hours, suggesting they are involved in early response to injury (89).  Supporting the 
importance of their role in AKI is their ability to secrete large quantities of cytokines (TNFα, 
IFNγ, IL4, IL10) and the evidence that both depleting NKT cells and blocking their 
activation is renoprotective (90).  Knocking out HIF2α promoted infiltration of NKT cells into 
the ischaemic kidney which worsened the effect of renal IRI (91). However one study 
looking at two subsets of NKT cells found that in mice deficient in these cells, the severity 
of renal IRI was increased, and that repletion of NKT cells attenuated injury (92).  
The role of neutrophils in AKI is controversial, with conflicting reports regarding the effect 
of neutrophil depletion in IRI (49, 93).  They do appear to cause indirect damage through 
phagocytosis, production of ROS and obstruction of the microvasculature after IRI (88). 
Many of the innate responses to injury listed above (complement, TLR and NK cells) 
modulate their effects through neutrophil recruitment and inhibition of these signalling 
molecules and cells has led to protection against renal injury and reduction in neutrophil 
damage (74, 85, 87). It has been pointed out that given that there are many different 
pathways of stimulating neutrophils in renal IRI, and blocking any one of them has only 
been partially renoprotective, blocking multiple steps may well be protective (94).  
Chaturvedi et al studied Slit2 protein, known to inhibit the chemotaxis of neutrophils, 
macrophages, T cells and DC to many different chemoattractants.  They found Slit2 
inhibited many pathways in neutrophil recruitment after renal IRI and it prevented tubular 
injury, renal failure and neutrophil recruitment, without a concomitant risk of infection.      
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Macrophages/ monocytes are known to infiltrate the kidney in under 1 hour following IRI 
(88), stimulated by IFNγ.  Macrophage cell numbers increase markedly within the first 24 
hours, and remain elevated for 5 days (95).  Activated macrophages secrete cytokines 
which contribute to the inflammatory milieu and promote an environment suitable for T cell 
and B cell activation and proliferation (IL1α, IL6, IL12, TNFα) (57). One study found that, 
although macrophage depletion was partially protective of ischaemia at 24 hours, it was 
actually detrimental at 72 hours, suggesting that macrophages may have a role in 
regeneration (59). Another study showed that macrophages were required for renal IRI, 
with evidence of renoprotection when macrophages were depleted, which was lost 
following adoptive transfer of macrophages into the model (96).  This is consistent with 
more recent work showing that CD169+ monocytes and macrophages reduced ICAM1 
expression on vascular endothelial cells, and that depleting mice of CD169+ cells led to 
increased ICAM1 levels, worsened renal damage and significant neutrophil accumulation 
(97). Of note there are different phenotypes of macrophages, and one study showed that 
macrophages ameliorated renal IRI by switching from a pro-inflammatory (M1) phenotype 
to an anti-inflammatory (M2) phenotype (98). 
DC make up 40% of resident renal leukocytes (57) and are known to be situated between 
the tubular epithelium and the peritubular capillaries (58).  In the normal situation, they 
make up only 0.1% of circulating leukocytes (99).  Therefore resident DC are ideally 
placed to respond early to IRI and to contribute to inflammation.  However, a recent study 
found that the majority of the renal mononuclear phagocytes found in the kidney after IRI 
were newly recruited monocyte-derived DC (100).  The function and capability of DC 
depends completely on their maturation state.  Resident DC are quiescent, immature cells, 
and as such have a high capacity for phagocytosis and antigen uptake and a low capacity 
for T cell activation, due to low cell surface expression of major histocompatibility complex 
(MHC) class II and costimulatory molecules (101).  DC stimulation by TLR engagement or 
HIF1α (102) upregulation leads to release of chemokine receptors and cytokines (DC are 
the primary TNFα secreting cells after renal IRI (58) and upregulation of costimulatory 
molecules and MHC class II.  This stimulated DC then acquires the phenotype of a mature 
DC, losing the high phagocytic capability and becoming a potent T cell activator.  
Maturation of DC leads to the loss of E-cadherin (an adhesion molecule expressed on 
immature DC preventing migration to lymph nodes) and upregulation of C-C chemokine 
receptor type 7 (CCR7) (required for migration to chemokine (C-C motif) ligand 19 
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(CCL19) in lymph nodes) (103).  Thus mature DC migrate to the renal lymph nodes where 
they present antigen via MHC molecules to T cells (104).  The highly expressed 
costimulatory molecules (specifically, CD80 and CD86) (105) and appropriate 
environmental signals are required for complete T cell activation and proliferation to occur 
(106).  This process occurs on a continuum, as a severe injury will lead to wholly mature 
DC and a strong adaptive immune response, but a more mild injury may lead to semi-
mature DC and only a weak adaptive response or possibly tolerance. 
2.1.3.2 Role of the adaptive immune system in IRI 
There is now a wealth of evidence attesting to the importance of T cells in renal IRI.  The 
conventional wisdom was that activation of T cells from DCs is delayed following injury due 
to the need for antigen presentation, and thus T cells were thought to be unlikely to be 
involved in very early injury.  However, this idea has been debunked by studies showing 
firstly, that CD4+ T cells infiltrate the kidney within 1 hour, peaking at 6 hours (107, 108)  
and secondly, that T cell depletion is renoprotective within 24 hours.  A number of studies 
have now shown protection from renal IRI by T cell interference, including 
immunosuppressive T cell blockade (109, 110), total T cell depletion (111), CD4 depletion 
(112), T cell receptor depletion (113), costimulatory blockade (114) and inhibition of T cell 
activation via NFκB (115).  Two mechanisms exist for T cell activation in the absence of 
foreign antigen, and they both may be important.  It is increasingly recognised that the 
immune response also has a role in injured “self” tissue, referred to as the “danger model” 
(116).  Activation of T cells in this setting could be due to antigen presentation by DCs of 
endogenous tissue fragments which are not normally exposed to the immune system.  
Alternatively, T cells may be activated without antigen presentation, and in fact, it has been 
shown that ROS and RANTES both stimulate T cells through antigen independent 
mechanisms (117).  RANTES does this by mobilising calcium which has the initial effect of 
inducing chemotaxis, and the following effects of upregulating IL2 receptor expression, 
cytokine release and T cell proliferation.  This may explain the very early effect of T cells 
that has been seen in IRI models.  Of note, RANTES deficient mice have been found to be 
protected from renal IRI (118). 
T cell activation stimulates differentiation into a number of effector T cells which have 
markedly different outcomes.  The T cell phenotype expressed depends on the cytokine 
environment.  CD4+ cells, which are the critical T cell subset involved in IRI, are largely 
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divided into Th1 and Th2 cells.  It is well understood that Th1 cells produce pro-
inflammatory cytokines (IFNγ, TNFα, IL2) under the influence of IFNγ and IL12.  Th2 cells 
produce anti-inflammatory cytokines (IL4, IL5, IL6, IL10) under the influence of IL4.  
STAT4 is the transcription activator for Th1 cells and STAT6 is the Th2 transcription 
activator.  STAT4 knock out mice (119) and IL12 knock out mice (120) are almost 
completely protected from renal IRI, suggesting that the Th1 effect is deleterious.  STAT6 
knock out mice (119) and IL4 knock out mice (120) developed a very severe injury after 
renal IRI, suggesting that the Th2 phenotype is protective.  This is exciting as it suggests 
targeting T cell phenotype aiming for a Th2 response may be a valid therapeutic model.  It 
is  important for the current project, as it will be shown below that MSC alter the cytokine 
profile and appear to upregulate Th2 cytokines while downregulating Th1 cytokines.   
T regulatory cells (Tregs) are a subset of CD4+ T cells. They have been shown to 
suppress the maladaptive immune responses that occur after inflammatory stimuli and to 
infiltrate the kidney within 24 hours of renal IRI (121).  Depletion of CD4+CD25highCD127low 
Tregs in vivo, using the anti-CD25 monoclonal antibody (mAb) PC61, led to a more severe 
phenotype of renal IRI (121, 122).  The mAb CD28sa (superagonist) leads to significant 
expansion of Tregs after administration.  When administered prior to renal IRI, it was 
renoprotective.  However, this effect was abrogated when the mAB PC61 was co-
administered (123).  Similarly, the IL2 mAb JES 6-1 is a potent IL2 mediated expander of 
Tregs and led to a marked protection from IRI induced renal injury, which was again 
abrogated by PC61 co-administration (124).  Taken together, these results show that 
Tregs play an important role in renal IRI immunopathophysiology. 
There has been very little work done on the role of B cells in the pathogenesis of AKI, but 
there is some evidence to suggest that they are pathogenic.  B cell deficient mice have 
been shown to be protected against renal IRI, although adoptive transfer of B cells did not 
restore injury (125).  There is also evidence of direct B cell activation by HSP60, which is 
upregulated after IRI.  HSP60 has been shown to act through TLR4 to induce B cell 
cytokine secretion (IL6 and IL10) and increase the capacity of B cells to stimulate T cells 
(126). 
Having systematically reviewed the pathogenesis of renal IRI, it is important to find a 
therapeutic strategy which may be clinically relevant for patients with IRI.  As will be 
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discussed, MSC have been shown to be renoprotective and are known to be 
immunomodulatory, making them a biologically plausible treatment strategy. 
2.2 Definition and immunomodulatory effects of MSC 
2.2.1 Definition and characteristics of mesenchymal stromal cells 
Stem cells have been defined as self-renewing clonogenic cells, which retain the ability to 
differentiate into cells of more than one lineage (127).  They may be totipotent, defined as 
having the ability to differentiate into all the cells in the body (fertilised oocytes, some 
embryonic stem cells), pluripotent (all embryonic stem cells) or multipotent (adult stem 
cells) (128).  There are many different adult stem cells, including haematopoietic, 
mesenchymal, adipose, placental, neural, hepatic, pancreatic and skeletal muscle stem 
cells.  The non-bone marrow cells commonly reside in their tissue of origin and are thought 
to differentiate into this tissue when stimulated by the microenvironment (129).  Only HSC 
and MSC routinely reside in the bone marrow compartment.  HSC give rise to 
lymphohaematopoietic cells.  MSC are a population of cells residing in the non-
haematopoietic compartment of bone marrow.  They surround the vasculature and project 
towards the HSC compartment, where since the 1970s they have been known to 
contribute to the growth and development of HSC (130).  More recently they have been 
shown to have extramedullary functions such as immunomodulation and tissue 
regeneration (131).   
The working definition for MSC is an in vitro cultured cell population which can be isolated 
by plastic adherence, differentiated into adipocytes, chondrocytes and osteocytes under 
appropriate stimulation (132, 133) and phenotypically defined by certain cell surface 
markers (134).  In fact there is no universally accepted phenotypic definition of MSC, but it 
is generally accepted that human cells positive for CD73, CD90, CD105 and negative for 
CD45 (an HSC marker) are likely to be MSC.  The murine MSC phenotype is stem cell 
antigen 1 (Sca1) positive; CD90 positive and CD45 negative (131, 135).  MSC have been 
studied extensively both in vitro and in several clinical trials due to the relative ease of 
MSC isolation and expansion ex vivo and their apparent lack of immunogenicity (136, 
137). In fact more recently work has led to the idea that rather than being immune-
privileged, these cells are “immune-evasive” (138).   The ex vivo tissue culture and 
expansion is essential to gain adequate numbers of MSC, as they are such rare cells, but 
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it must be noted that after this expansion the cells may no longer be phenotypically 
identical to their progenitors (131).  This gives rise to some of the difficulties in interpreting 
studies of MSC, as it is likely that each cell culture contains a heterogeneous progenitor 
cell population. 
Although MSC usually reside in the bone marrow, where they make up between 0.01% 
and 0.001% of the cells (139), they have also been found in the circulation and in tissues 
(129).  In particular, they have been shown to home to sites of tissue injury and 
inflammation (140).  It is likely that the change in tissue microenvironment results in 
signals to the MSC via cell surface chemokine receptors (141).  At this stage the 
endogenous function of MSC in tissue injury is unclear, although there is evidence that 
exogenous administration may be beneficial in various injured tissues including the heart, 
brain, liver, kidneys and joints (142-145).   
In summary, MSC are a population of rare cells normally residing in bone marrow, which 
can be easily cultured ex vivo, isolated by plastic adherence and phenotypic 
characterisation and differentiated into adipocytes, osteocytes and chondrocytes on 
appropriate stimulation.  They secrete growth factors and support haematopoietic stem 
cells but also migrate to sites of inflammation where they may be involved in tissue 
regeneration and repair.  They are exciting to study both in terms of their potential clinical 
application and their role in expansion of our knowledge in regenerative medicine. 
2.2.2 Mesenchymal stromal cells are immunomodulatory 
Cells of the immune system are differentiated from HSC, which reside in the bone marrow 
in close contact with MSC.  The first known function of MSC was to support HSC growth.  
It has since become clear that MSC are involved in the maturation and development of T 
cells in and out of the thymus (146, 147) and in fact MSC and HSC are intimately related.  
MSC can also change the maturation and activation status of mature DC, and these 
effects will be summarised below.      
2.2.2.1 Effect of MSC on innate immune system 
MSC have been shown to suppress NK cell proliferation in a mixed lymphocyte reaction 
(MLR) (148) and significantly reduce NK secreted IFNγ, thereby changing the 
inflammatory environment 149, 150.  They may also impair the cytolytic function of NK 
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cells (149, 150).  This inhibition of NK cell proliferation and function is exaggerated if MSC 
are sorted for TLR+ MSC, suggesting a role for TLR in MSC immunomodulation (151). 
However, effects of MSC on NK cells may be complicated, with one report finding MSC 
increased NK effector function at an early time point, but inhibited NK function at a later 
time point, due to the induction of regulatory NK cells with a senescent phenotype (152). 
Of note, there is some evidence that under the right conditions, NK cells will actually target 
and kill MSC (153).  In a liver injury model, MSC were shown to change NKT cell 
phenotype, by altering the balance between the pro-inflammatory IL17 secreting NKT cells 
and regulatory NKT cells (154).  In a highly specific model of neutrophil activation in 
vasculitis, MSC were able to suppress “unrestrained neutrophil activation” (155). MSC 
have also been shown to impact macrophage phenotype, skewing the M1/M2 balance 
towards anti-inflammatory M2 macrophages and away from the pro-inflammatory M1 cells 
in a cardiac ischaemia model (156). 
It is well established in vitro that MSC inhibit differentiation and maturation of DC (158-
160).    Given the significance of DC in activation of the adaptive immune system in renal 
IRI, this effect of MSC may be important in the mechanism of their renoprotection.  English 
et al elegantly demonstrated the disruptive effects of MSC on DC maturation by 
investigating the critical steps in DC maturation: upregulation of costimulatory molecule 
expression, migration to draining lymph nodes and presentation of antigens (103).  In an in 
vitro co-culture of DC exposed to TNFα with and without MSC, it was seen that in the 
presence of MSC, DC did not upregulate CD86 or major histocompatibility complex (MHC) 
class II.  This was reversible, as the same cells re-exposed to TNFα without MSC 
succeeded in upregulating the costimulatory molecules necessary for T cell activation.  
The same experimental environment resulted in DC which did not upregulate CCR7 or 
downregulate E-cadherin and in a transwell experiment it was shown that these cells failed 
to migrate to CCL19, implying that they would be unable to migrate from injured tissue to 
draining lymph nodes.  Again, these changes were dependent on the presence of MSC in 
culture, and were reversible.  Finally, the ability of DC cultured with MSC to present 
antigen via MHC class II was shown to be impaired but not absent.  MSC are also known 
to alter the cytokine environment, in particular by downregulating IL12 (159), 
downregulating TNFα secreting DC and upregulating IL10 secreting DC (136), which are 
likely to impact DC activation of T cells.  It is highly biologically plausible that this MSC 
interference in DC contributes to renoprotection in IRI. 
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2.2.2.2 Effect of MSC on adaptive immune system 
MSC suppress T cell proliferation and impact T cell phenotype 
There has been extensive research into the interactions between T cells and MSC.  The 
literature is essentially unanimous in finding MSC suppression of T cell proliferation in a 
MLR (161-166).  There are significant variations on the size of the effect and the purported 
mechanisms, which may be explained by different experimental methods.  However, it is 
agreed by MSC researchers that no clonal mesenchymal cell population has been 
identified in a reproducible manner, and the heterogeneity of results may well reflect this.   
Following similar but not identical experimental protocols, both murine (161) and human 
(136) bone marrow derived MSC have been shown to suppress T cell proliferation in vitro 
and in vivo (161, 167), in both CD4 and CD8 T cells (165), with both cellular (136) and 
humoral stimulation (162), in autologous (161) and allogeneic experiments (168), in a 
specific (163) and a non-specific (162) manner and even across species (164).  The 
mechanisms of MSC induced suppression of T cell proliferation are important when the 
context of MSC protection in renal IRI is considered.  As discussed previously, T cell 
stimulation is an important contributor to IRI and modulation of this response is one of the 
strongest potential mechanisms of MSC induced renoprotection. 
Originally it was thought that MSC may be inducing apoptosis in the responder T cells.  
However, re-culturing the T cells in a second MLR without MSC has been repeatedly 
shown to produce normal T cell proliferation (161, 163, 169), refuting the concept of 
induced apoptosis.  Studies investigating expression of annexin V (AV, a marker of 
apoptosis) on T cells in MSC co-culture have been negative (164, 169).  Another proposal 
is that MSC may induce a tolerogenic state.  However if the responder T cell population is 
re-cultured with peripheral blood mononuclear cells (PBMC) from the same donor as the 
MSC (i.e. expressing the same MHC class I antigens)  in the absence of the MSC, a brisk 
responder cell proliferation was seen (168).  In fact, the peak response to PBMC in the 
second MLR occurred at day 3 rather than day 8, suggesting that there was a priming 
effect.  These results suggest that tolerance does not play a role in the suppression of T 
cell effector function.   
Finally, T cell anergy has been suggested as a mechanism of suppression of T cell 
function.  Although MSC express MHC class I antigens constitutively, they do not express 
MHC class II antigens, CD80, CD86 or CD40 at rest (168, 169).  The latter three are cell 
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surface costimulatory molecules required for T cell stimulation.  Treatment of MSC with 
IFNγ, an inflammatory molecule, induces expression of MHC class II, but not of CD80 or 
CD86 and at the most, induces only weak expression of CD40 (168, 169).  Antigen 
presentation to T cells without costimulatory molecules is known to induce T cell anergy.  
However, Klyushnenkova et al transduced MSC with CD80 or CD86 and found that this 
did not restore the ability of the T cells to proliferate in the presence of the MSC (168).  Of 
importance, MSC were able to suppress T cell function when added to an ongoing MLR, 
after T cell activation has been initiated and proliferation is underway, implying secretion of 
a soluble suppression factor (168).  In conclusion, MSC cause a reversible (non-apoptotic) 
variable reduction of T cell function, without inducing donor specific tolerance, by inducing 
a moderate state of clonal anergy, likely through secretion of a suppressor factor. 
Transwell studies, where MSC are physically separated from PBMC by a porous 
membrane, show that MSC remain able to cause significant T cell suppression without 
physical contact, but cell-cell contact does lead to an increased degree of T cell 
suppression (150, 161, 162, 164, 168).  Several groups have looked at the effect of MSC 
supernatant, or “conditioned media” (MSC-CM) (media extracted from an MSC culture and 
filtered to exclude cells).  These studies have found significant suppression of T cell 
proliferation, supporting the existence of soluble factors (161, 169).  The size of the 
inhibitory effect achieved by MSC-CM may depend on whether the supernatant is taken 
from a stimulated MSC population or a standard culture (163, 169).   In summary there is a 
significant body of evidence to suggest that cell to cell contact is not required for T cell 
inhibition, but that it can certainly enhance it.   
Clearly there are multiple soluble factors which contribute to the process of T cell 
suppression, but the largest body of evidence implicates IFNγ and indoleamine 2, 3-
dioxygenase (IDO).  Blocking IFNγ with a neutralising antibody completely restored CD4 
cell proliferation and partially restored CD8 cell proliferation in a direct cell culture and a 
transwell system with MSC (150).  This suggests IFNγ is required for T cell suppression, 
an observation confirmed by other studies (166).  However either TNFα, IL1α or IL1β  
were shown to be required with IFNγ in further experiments (166).  The IDO pathway has 
previously been found to be important in maternal-fetal tolerance.  IDO is an enzyme 
which converts tryptophan to kynurenine.  Tryptophan is required for ongoing T cell 
proliferation, so IDO effectively stops T cell proliferation.  Kynurenine has also been shown 
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to independently lead to inhibition of the T cell response (170, 171).  IFNγ is known to 
upregulate MSC expression of IDO and MSC in MLR with significantly increased IDO 
levels, reduced tryptophan levels and increased kynurenine levels, compared to either 
MLR or MSC alone (170).  Adding tryptophan to an MSC/MLR partially restores T cell 
proliferation (170, 172).  Competitive inhibitors of the IDO pathway have also been shown 
to partially restore T cell proliferation, suggesting at least a partial role of IDO in MSC 
induced inhibition of T cell proliferation (150, 170-173).  However, some groups have 
shown no effect on T cell proliferation with 1-methyl tryptophan (166, 169, 174) or 
tryptophan repletion (169).  There is significant redundancy in the mechanisms by which 
MSC suppress T cells, as other pathways have also been shown to be important, including 
the nitric oxide / inducible nitric oxide synthase pathway (166, 174), prostaglandin E2 and 
TGFβ (175) as well as ICAM1 and VCAM (176).  Additionally, it is possible that MSC use 
different mechanisms in different diseases or inflammatory environments. 
Given our understanding of the importance of the T cell phenotype in the pathogenesis of 
IRI, it is important to understand if MSC are likely to alter this T cell phenotype.  Naïve 
CD4+ cells are induced to differentiate into Th1, Th2 or Th17 effector cells, depending on 
the stimulus. Th1 cells are generally driven by IL12, IFNγ and IL27 (177).  They are pro-
inflammatory, activate macrophages and stimulate B cells, with a purpose in nature to 
eliminate intracellular pathogens and the ability in inflammatory conditions to create further 
harm and tissue damage. MSC and MSC-CM have been found to suppress Th1 cells in 
MLR (178), to inhibit DC maturation thereby indirectly inhibiting Th1 generation (136) and 
to significantly reduce IFNγ concentration in co-culture with Th1 cells, thereby altering their 
effector function (136). They have also been found to induce differentiation of regulatory T 
cells from Th1 cells (179). 
Th2 cells are activated by IL4 (which is secreted by Th2 cells in concert with IL5, IL9, IL10 
and IL13) and have an anti-inflammatory phenotype, with a role in nature to defend against 
extracellular pathogens and recruit eosinophils (177).  Co-culture of MSC and Th2 cells 
leads to a 500% increase in IL4 levels (136) which would be expected to lead to significant 
upregulation of Th2 cells.  Furthermore it has been shown that infusion of allogeneic MSC 
into NOD mice alters the Th1/Th2 balance towards a Th2 phenotype (180).  This is 
consistent with other work which found a significant reduction in TNFα and IFNγ with a 
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concomitant increase in IL5, IL3 and IL8 when an MSC-CD4+ co-culture was exposed to 
PBMC (181). 
Th17 cells are pro-inflammatory and are generated by exposure of naïve CD4+ cells to 
TGFβ and IL6. They act by recruiting neutrophils against external infectious pathogens 
(182). MSC have been found to reduce Th17 expression and lead to expression of the 
regulatory marker forkhead box P3 (FOXP3) creating an anti-inflammatory regulatory Th17 
phenotype (179, 183).  
In summary, MSC can impact on CD4+ cell phenotype both directly through cytokine 
expression and indirectly through their impact on DC phenotype and hence DC stimulation 
of T cells.  All of these cell types have been shown to be important in renal IRI, so there is 
biological plausibility for a renoprotective effect of MSC in renal IRI, mediated via DC and 
CD4+ cells. 
CD8+ cells are cytotoxic lymphocytes (CTL), which are activated by presentation of 
antigen on antigen presenting cells (eg DC) and when exposed to the antigen again by 
any cell type induce cell death by lysis.  MSC have been shown to prevent CTL formation 
in an MLR and subsequent cell death, but only if they are present at the time of the 
activation event.  MSC have not been found to reduce cell death with antigen exposure if 
the CTL had previously been activated (i.e. a memory CD8 cell) (184, 185).    
MSC may suppress B cell function directly and indirectly 
There are several studies demonstrating that MSC inhibit B cell proliferation in vitro, when 
B cells are stimulated by various methods (150, 161, 174, 186).  They appear to alter both 
antibody production and chemotaxis (186), but of note B cell proliferation has been 
restored by adding IFNγ to the culture (150).  A recent review highlights a number of 
studies showing similar cytokine related impact of MSC on B cell function in culture, but 
this seems more likely to be due to indirect effects (alteration in DC and CD4+ phenotype), 
rather than a direct effect on B cells (187). 
2.2.3 MSC have been found to be renoprotective in IRI  
An increasing number of studies have shown that MSC protect against AKI.  It is not within 
the scope of this work to examine the effect of MSC on all different models of kidney injury 
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but it is important to note that MSC have been studied in IRI (as reviewed here), toxic 
nephropathies such as cisplatin AKI (188), adriamycin induced AKI (189) and glycerol 
induced AKI (190), glomerulonephritis (191), sepsis related AKI (192), bladder outlet 
obstruction AKI (193), rhabdomyolysis (194), and transplantation (195).  As with all MSC 
studies, the results are as heterogeneous as the experimental methods and the cell 
populations.  However, a meta-analysis of MSC therapy for impaired renal function in 
small animal models published in 2013 found that overall the results favoured MSC over 
control (196).  
There have been very few studies of MSC in renal IRI using in vitro models despite many 
studies in animal models.  Togel et al examined the effect of MSC in a normoxic or hypoxic 
endothelial cell culture for 24 hours (197).  MSC stimulated increased endothelial cell 
growth in culture after 5 days, especially in hypoxic conditions.  Our laboratory looked at 
the effect of MSC on rat renal TEC exposed to H2O2 cultured with MSC in a transwell 
model and found significant reduction in apoptosis and increase in mitosis in the presence 
of MSC (198).   One recent study cultured murine TEC with or without MSC in a transwell 
model.  The MSC were either from standard culture or pretreated with hypoxia/reperfusion 
prior to application to the TEC (199).  The TEC were then exposed to the same 
hypoxia/reperfusion method.  This study found significant increase in the number of live 
TEC and reduction in necrosis if MSC were present, and this was even more apparent if 
the MSC had been pretreated.   
There are an increasing number of in vivo studies, perhaps because the complexities 
involved in the pathogenesis of AKI may only be well replicated in a whole organ/whole 
organism situation.  Renal IRI studies of MSC effect have primarily used rodent models.  
At the time the current work was commenced, the bulk of the published animal work in 
renal IRI and MSC were the 7 studies in rats, with 1 murine study (and another using 
“bone marrow cells”), 2 ovine studies and no human studies.  Interestingly at that time, a 
number of studies had been published in other murine models of AKI, particularly toxic AKI 
(188, 200).  Studies in rats consistently showed protective effect of MSC with reduction in 
serum creatinine and urea after renal IRI and also reduction in the renal histology score.  
There was however, some heterogeneity between the studies.  Four papers from one 
research group published between 2005 and 2009 all showed renoprotection of MSC (142, 
201-203).  This group uses a bilateral IRI method in Sprague Dawley and Fisher rats with 
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atraumatic vascular clamps over both renal pedicles for various duration from 35 minutes 
to 58 minutes.  MSC were applied immediately after reperfusion into the thoracic aorta via 
the left carotid artery at doses from 1-1.5 x 106 MSC per animal, with one study reporting 
some dose finding titration work (203).  In their work, serum creatinine and urea were 
improved from control IR results at 48 and 72 hours but not at 24 hours.  In the two studies 
reporting kidney injury scores, these were significantly improved at sacrifice.  Interestingly, 
one of their studies (203) looked at both syngeneic and allogeneic MSC administration and 
only found improvement in renal function with syngeneic MSC.  At the time this was the 
only rat study assessing allogeneic MSC in renal IRI.  Two other groups reported results in 
this area at this time.  One group found significant effect from administration of intravenous 
(IV) 2 x 105 MSC 6 hours after 60 minutes of bilateral renal IRI with reduction of serum 
creatinine and urea at 24 and 48 hours (204, 205). They did not assess histological 
damage.  Finally one paper modified mice to express human tissue kallikrein in an attempt 
to improve the resilience of MSC to the ischaemic environment (206).  Administration of 1 
x 106 MSC intra-arterial (IA) within 1 hour of 60 minutes of bilateral renal ischaemia led to 
a significant improvement in serum creatinine in urea, as early as 6 hours after injury in the 
kallikrein MSC group (TK MSC) and at 48 hours with standard MSC, although the overall 
improvement in renal function was consistently better in the TK MSC group.  Renal 
histology was unchanged with standard MSC but significantly improved with TK MSC. 
At the onset of the current work, murine studies were focused on the question of whether 
the injured tubular cells were repopulated by bone marrow cells or by intrarenal cells.  Two 
studies used models of renal IRI to look at this question.  Firstly, Duffield et al performed 
unilateral left renal ischaemia for 30 minutes (male recipients) and 45 minutes (female 
recipients). This was not a uraemic model.  0.5 x 106 MSC were administered IV through 
the tail vein 2 hours after IRI.  At 24 hours there was no effect on renal function if the MSC 
were cultured in the standard, plastic adherent manner.  However, MSC cultured on 
matrigel coated plates for several days prior to administration formed interconnecting 
tubes with branches. Perhaps because of this altered structure, a significant improvement 
was seen in serum creatinine at 24 hours.  Histology was not reviewed (27).  Lin et al were 
also looking at the source of the regenerating cells post IRI. They did not use MSC, but 
rather injected 1 x 106 “bone marrow cells” IV via tail vein 2 hours after reperfusion in a 
uraemic model of renal IRI (right nephrectomy, 45 minutes of ischaemia to the left renal 
pedicle) (28).  There was no improvement in serum urea and histology was not reported.  
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Since 2009, a further 8 murine studies of MSC and renal IRI have been published, with 
varying results. These will be presented further in the discussion chapter during analysis of 
the results of the current work. 
Interestingly, the two ovine studies published showed no effect on either renal function or 
histological damage of 50 x 106 autologous MSC (207) or 80 x 106 autologous MSC (208) 
administered IA at the time of reperfusion after bilateral renal artery occlusion using 
balloon catheters.  Since 2009 there have been two further non rodent papers, a porcine 
paper finding no effect of either autologous or allogeneic porcine MSC after 110 minutes of 
bilateral balloon catheter renal artery occlusion (210) and a feline paper showing no effect 
of IV allogeneic MSC after 60 minutes of unilateral IRI (210). While the negative larger 
animal studies are interesting, there is much to be gained from further investigation into 
the beneficial effect in rodent models to try and identify mechanism of effect, which could 
then be translated to a larger animal model including humans. 
In summary, at the time the current work was commenced, despite disparities among 
rodent models, MSC treatment appeared to consistently result in reduction in renal 
impairment on functional studies, and reduction in kidney injury score and tubular damage 
on immunohistochemistry.  Other consistent results include reduced apoptotic markers 
and increased cell proliferation markers.  However there are some interesting differences 
between studies which should be noted.  There may be a dose- dependent effect of MSC, 
as one study using dose titration and only showed benefit at high doses (211).  It is 
interesting that Duffield et al only showed benefit if MSC were cultured on matrigel, as it 
has been noted by others that MSC lose cell surface markers and possibly differentiation 
capacity in long term culture on plastic (27).  Studies using IA MSC administration may 
lead to a larger benefit than studies using IV administration, and Kunter et al repeated the 
same experiment with IA and IV MSC administration in two species of rats in a 
glomerulonephritis model of AKI and only found MSC efficacy in IA models (212).  This 
may be due to a dose effect, as IV administration generally leads to MSC trapping in lung 
capillaries, with a reduction in effective dose to injury site (213).  The only completely 
negative rodent study at the time of commencement of the current work in terms of renal 
impairment after injury infused 1 million “bone marrow cells” IV (28) and these cells may 
have contained only a small fraction of MSC.  It is important to note that Kunter et al 
looking at long term effects of MSC in their glomerulonephritis model showed 
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maldifferentiation of MSC into adipocytes within the glomeruli (214).  Long term this would 
be likely to be associated with reduced glomerular function and chronic kidney disease, 
and provides a warning against using MSC in AKI in the clinic until long term effects can 
be established. 
Given that the above evidence suggests that MSC are beneficial in AKI, the next 
experimental issue is to identify the mechanisms involved.  As alluded to above, there was 
debate for some time about whether the MSC accelerated recovery by differentiating into 
renal parenchymal cells.  However, as described in 2.1.2, the vast majority of the 
repopulating tubular epithelium originates as epithelial cells, with a very minor contribution 
from circulating bone marrow.  If the effect is then by soluble factors released by MSC, it 
would be interesting to understand whether these factors were acting in a paracrine 
fashion, in which case the MSC would be required to be in close contact with the injured 
tissue, or in an endocrine fashion.   
A number of researchers have localised MSC within tissue after experimental 
administration in kidney disease, using different methods including fluorescent labelling of 
MSC, bioluminescence imaging with luciferase transfected mice, in situ hybridisation for Y 
chromosome in gender mismatched MSC transplants and magnetic labelling of MSC for 
magnetic resonance imaging (MRI).  The method of MSC administration is very important 
in the distribution of cells.  Most studies using IA infusion insert a cannula in the carotid 
artery and deposit the MSC in the aorta.  With this mechanism, MSC have been detected 
in the kidney immediately after infusion but lost within 24 hours (142, 197, 213).  MSC are 
predominantly seen in the cortex rather than the medulla, regardless of the experimental 
model of AKI (202, 208, 215).  They are commonly demonstrated within glomerular 
capillaries (142, 201) or elsewhere in the glomeruli (212, 214).  Quantification of the 
detected cells demonstrates only a small percentage of injected cells within the kidney 
(0.03% (201) to 10% (208)), confirming that differentiation of MSC to renal cells is unlikely 
to play a significant role.  Studies with IV administration of MSC have more inconsistent 
results.  Although MSC have been found in the peritubular capillaries and more rarely in 
glomeruli and tubuli (140, 188, 200, 216), other studies detected MSC exclusively in the 
lungs after IV administration (212, 213, 217).  CD44, a cell surface marker that binds to 
hyaluron, has been shown to be required for effective MSC homing to injury site (140). 
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The significance of soluble factors in the mechanism of MSC renoprotection is supported 
by evidence that administration of MSC-CM twice daily after toxic AKI led to improved 
survival, renal function and tubular damage compared to medium alone (217).  Which 
soluble factors might be involved and how they might induce renoprotection had not been 
established at the commencement of this work.  A number of growth factors have been 
shown to be increased with MSC treatment, including VEGF, important in angiogenesis 
(197), and insulin like growth factor 1 (IGF1), a mediator of MSC renoprotection (188).  It 
appears that treatment with MSC reduces the inflammatory cytokine expression seen in 
AKI and may increase anti-inflammatory expression.  In particular, IL1β, IL1α, TNFα, IFNγ 
and IL6 have been shown to be reduced with treatment of MSC, while IL10 and IL4 may 
be increased (142, 204).  As discussed above, this correlates to decreased Th1 cytokine 
expression and increased Th2 cytokine expression, a situation which has been 
independently shown to be beneficial in AKI.  Although benefit in AKI was shown out to 48 
hours post-injury, alteration in cytokine concentration was only seen at 24 hours, and this 
may be a very early effect of MSC (204).   The immunomodulatory capability of MSC is 
well established and may well be important in renoprotection, but no studies to date have 
specifically examined the effect of MSC on the innate and adaptive immune systems in 
renal IRI.        
There are a number of conclusions which can be drawn from these studies.  Firstly, the 
evidence suggests that in the right conditions, MSC protect against renal IRI, with 
improved renal function, and reduction in histological damage.  Secondly, given that MSC 
are not the predominant cell type in the healing epithelium, it is likely that the majority of 
renoprotection is due to paracrine or endocrine effects.  Thirdly, delivery of the cells to the 
site of injury is important, as there is inconsistent migratory capability after ex vivo 
passage.  Finally, there may be long term adverse effects which have not yet been fully 
characterised. 
2.3 Summary 
In summary, at the time this work was commenced, there was some evidence that MSC 
were protective in renal IRI (particularly in a rat model) along with evidence that MSC were 
protective in other models of AKI.  There was a wealth of understanding about the effect of 
MSC on different components of the immune system and an increasing understanding of 
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the role of the immune system in renal IRI.  There were some clear intersections between 
the known pathways of damage in renal IRI and the potential ameliorating effect of MSC 
on those pathways. There was a clear understanding of the importance of soluble secreted 
factors in these effects, but only very early work published in MSC exosomes and 
microvesicles.  The hypotheses of this present work were that MSC would be 
renoprotective against IRI and that this effect would occur through inhibition of DC 
maturation thereby skewing the CD4+ T helper cell environment towards the anti-
inflammatory Th2 environment.  It was decided to study this in an in vitro and an in vivo 
model and to look at human and murine MSC.   
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Chapter 3 
Establishment of an in vitro model of renal proximal 
tubular ischaemia reperfusion injury 
3.1 Background and objectives 
This chapter describes the development of an in vitro model that will be used to study the 
effects of MSC on renal IRI at a cellular and a biochemical level.  In vivo renal IRI is a 
complex process involving glomerular epithelial and endothelial cells, proximal and distal 
tubular epithelial cells, the interstitium and the renal vasculature and capillary network.  IRI 
is modulated by the infiltration of large numbers of chemotactic and inflammatory cells, 
each of which have a myriad of effects.  While it is clearly of benefit to study renal IRI at a 
whole organ level, it can be difficult to provide important mechanistic insights into the 
molecular and cellular effects of individual treatments.  An in vitro model allows for the 
ability to study the effects of manipulating specific single variables, to determine their role 
in the propagation or attenuation of inflammatory injury in IRI.  The goal of this chapter was 
to establish a robust, replicable in vitro model of renal IRI. 
3.1.1 Origin of epithelial cells 
In preparing this in vitro model of ischaemia, it was important to consider the animal from 
which proximal tubular cells were isolated.  Of note, the second half of this thesis will be 
devoted to an in vivo rodent model.  Although a rat model of renal IRI had been well 
established in our laboratory, the decision was made to develop a mouse model to allow 
for future work involving genetically modified knock out mice.  The possibility of 
establishing a murine in vitro model of IRI was explored.  Given that there are no readily 
available immortalised cell lines derived from murine proximal tubular epithelial cells 
(PTEC), developing this model would involve fresh isolation of PTEC from mouse kidneys 
and then culturing them to a level where the experiments could be performed.  In 
discussion with experienced researchers who had attempted a similar model, it became 
clear that this was likely to be unsuccessful (Carol Pollock, personal communication).  
Therefore, the decision was made to develop the in vitro model using human PTEC.  Of 
note, no in vitro studies had been published using human PTEC or MSC in renal IRI, yet 
one human trial using MSC in renal IRI was already underway.  Human PTEC are readily 
available in an immortalised cell line (human kidney-2 (HK2) cells), and were available 
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within our laboratory.  In deciding which epithelial cells to study, it was also important to 
consider the source of other cells required to perform experiments in the in vitro model.  
The experimental design of aims 2 and 3 calls for MSC, CD4+ cells and DC as well as 
epithelial cells.  Human MSC are obtainable through donations of bone marrow or placenta 
from consented healthy volunteers.  Human peripheral blood is readily available from 
healthy volunteers, such that the isolation of CD4 cells and dendritic cells presents no 
difficulties.   
It is recognised that results obtained from a human in vitro model may be inconsistent with 
results obtained from a murine in vivo model, however, we believe that this design does 
not weaken the current project.  In fact, it may strengthen the validity and applicability of 
the findings. 
3.1.2 Choice of cell to study in the renal IRI model 
It is well known that renal IRI primarily leads to tubular damage and loss rather than 
glomerular injury, so it was decided to focus on studying primarily tubular cells in this 
model (13).  There has long been debate regarding the relative contribution of tubular 
segments in renal IRI (218) and this continues, with one review highlighting the differences 
between the distribution of tubular cell injury experimentally in the laboratory and 
physiologically in the human patient (219).  Most of the work in the area of in vitro renal IRI 
has been carried out with renal PTEC, based on widespread observations in different 
experimental systems that proximal tubules display more cellular injury and death than 
distal tubules (218).  The reasons behind this disparity are related to the reduction in 
glycolytic capacity in most segments of the proximal tubule as compared to the distal 
tubule (220), which markedly amplifies the effects of ATP depletion in IRI (221).  Briefly, 
ATP levels fall rapidly after ischaemia, particularly in the cortex where the bulk of the 
proximal tubules are situated.  This ATP depletion immediately interferes with a large 
number of critical cellular functions including membrane ion transporters, which further 
alters the electrochemical constituency of the cell, leading to the characteristic cellular 
depolarisation.  The ATP degradation caused by ischaemia results in an increase in the 
downstream metabolites adenosine, inosine and hypoxanthine, which can leak out of the 
cell, depleting the cell of purine substrate and driving the formation of ROS.  The loss of 
this purine substrate has critical implications for recovery of ATP after the ischaemic insult.  
In summary, the proximal tubular cells are rapidly affected by ATP depletion, with almost 
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immediate loss of normal cellular function, cellular damage and retardation of recovery 
potential.   
The distal tubules are somewhat protected from this by retaining their glycolytic capacity 
(220).  The distal tubules have also been shown to be less sensitive than proximal tubules 
in an in vitro study of oxidative stress, in which the distal tubules were found to have 
increased expression of the anti-apoptotic protein Bcl-xL and consequently reduced 
apoptosis (222).  Interestingly, the distal tubules are primarily located in the medulla which 
is known to be relatively hypoxic at rest potentially leading to increased susceptibility to IRI 
in vivo (223).  Within the medulla, there is also significant tubular obstruction, interstitial 
oedema due to tubular fluid backleak and cellular swelling in the setting of renal IRI.  
These may all potentiate the relative medullary hypoxia (221).  These haemodynamic 
factors are likely to be the reason that the S3 segment of the proximal tubule (usually 
found in the outer stripe of the outer medulla) is the most severely affected by 
experimental IRI, despite having the highest glycolytic capacity of any proximal tubular 
segment (224).   
Although both proximal and distal tubular cells are clearly important, the sheer volume of 
published data regarding ischaemic proximal tubular cells makes them an attractive 
experimental target.  Additionally, it is apparent that the pattern of injury seen in the warm 
IRI model used in the in vivo experiments is widespread proximal tubular injury (225).  
Given that the purpose of this model is to mimic renal IRI in an in vivo model of murine 
warm IRI, it would seem most appropriate to study the proximal tubular cells.   
3.1.3 The utility of an immortalised cell line in a model of regeneration and repair 
HK2 is a readily available immortalised PTEC cell line initially cultured from normal adult 
human kidney.  At the time of HK2 cell line development, most experiments used freshly 
isolated rat PTEC, which were difficult to maintain for more than 1-2 passages, and 
sustained a degree of damage during isolation that is likely to have interfered with 
regeneration and repair studies.  The HK2 cell line was established by isolating fresh 
human PTEC and transforming the culture with the human papilloma virus 16 E6/E7 genes 
(226).  This led to the development of a cell line which was stable in culture for more than 
one year.  Extensive characterisation experiments have been performed on this cell line, 
which was shown to express typical PTEC brush border membrane associated enzymes, 
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stain for typical PTEC cell surface markers (and not for endothelial or fibroblast cell 
surface markers) and retain functional characteristics of proximal tubules (including 
sodium transport and receptor activated hormonal responses).  Since that time, HK2 cells 
have been widely used to investigate in vitro features of PTEC function including 
regeneration and repair, and their validity under these experimental conditions is well 
established (227-230). 
There has been some criticism of the use of PTEC to study AKI, and this is derived from 
the fact that cells in culture have been shown to be phenotypically different from proximal 
tubule cells in vivo.  They are likely to become more proliferative in this setting, and studies 
have shown that their metabolism alters (231) and they undergo structural changes of the 
apical and basolateral membranes (232).  Clearly these changes are likely to affect the 
response to injury, and limit the physiological relevance of such studies.  However, studies 
of PTEC have certainly been able to make useful conclusions and have been consistent 
with in vivo studies (233).  The limitations described here apply to freshly isolated and to 
immortalised proximal tubular cell cultures.  Freshly isolated human PTEC tend to have 
small cell yields and can only be cultured for 4 passages, ideally being used at passage 2 
(234).  It is much more difficult to obtain freshly isolated human kidney tissue to use for 
these experiments, and for that reason most researchers have used the HK2 cell line or 
other established cell lines, of which there are now several. 
There is a valid argument that an immortalised cell line has been genetically engineered 
for unlimited passages in culture and this may result in different responses to damaging 
processes, compared with standard PTEC.  This would seem less important in a project 
designed to study, for example, electron transport channels, than a project designed to 
study the response to IRI.  However, there are many studies of IRI in HK2 cells, and for 
that reason, it was decided to use HK2 cells as a first approach in the current project.  
While it may be useful compare results using HK2 cells with results using freshly isolated 
human PTEC, but that is beyond the scope of the current study. 
3.1.4  Method of reproducing IRI 
There are many different in vitro models of PTEC damage, and it was important to select a 
model which would closely mimic the cellular effects of IRI.  Damage caused by ischaemia 
has been reproduced experimentally with models of hypoxia (235) or ATP depletion (236).  
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Although these models have attempted to reproduce both the ischaemic injury and the 
reperfusion injury, it is very difficult in vitro to mimic the cascade of inflammatory 
responses that occurs after reperfusion.  In particular, it is not feasible to try and mimic the 
tubular obstruction, interstitial oedema and endothelial vascular congestion that occurs in 
in vivo models of IRI (221).   
ROS have been implicated not only in the damage caused by ischaemia, but also in the 
injury that occurs as a consequence of reperfusion (237).  ROS (including O2-, H2O2, OH- 
and NO) are released by damaged endogenous kidney cells and also by infiltrating 
inflammatory cells, particularly leukocytes.  A number of studies have investigated the role 
of ROS in different models of IRI (238).  Taken together, these studies demonstrate that 
an in vitro model of ROS is likely to reproduce the effects of ischaemia and reperfusion 
more comprehensively than the above mentioned models of hypoxia and ATP depletion.  
Firstly, ROS themselves contribute to ATP depletion by impairing synthesis of ATP (239).  
ROS can lead to mitochondrial dysfunction by inhibiting the ATP-synthetase complex (240) 
and can also inhibit the regeneration of ATP by inactivating glyceraldehyde-3-phosphate 
dehydrogenase (241).  Secondly, ROS interfere with the cobblestone structure of the 
PTEC monolayer by interfering with the cytoskeleton, the function of the tight junction and 
may alter the distribution of integrin proteins which attach the cell to the basement 
membrane (238).  Thirdly, ROS increase membrane permeability and activate 
phospholipases, leading to impairment of both the structure and the function of the plasma 
membrane, which can ultimately lead to cell death (221). Oxidative stress occurs due to a 
cascade of reactions involving different molecules.   The first reaction converts O2 to O2-.  
The second reaction uses two O2- molecules and an H+ molecule to form H2O2 and O2.  
Hydrogen peroxide (H2O2) is then involved in a number of different reactions that form 
further reactive oxidants and are collectively labelled ROS (221).  Therefore, in using H2O2 
to cause damage to PTEC, the ROS cascade is being reproduced from a very early phase 
in the pathway, leading to a more physiologically relevant model.  Furthermore, the model 
of H2O2 induced injury is well established in our laboratory and has been validated to 
mimic renal IRI (222). 
3.1.5 Conclusion 
In summary, it was decided to develop an in vitro model of renal IRI using human proximal 
tubular cells from an immortalised cell line, and to induce damage by H2O2.  This H2O2 
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model has been used in our laboratory and in others, and it has relevance to the in vivo 
model used in subsequent experiments.  In the current study, it was important to gain a 
thorough understanding of the natural history of H2O2 induced cell damage in order to 
understand the potential effects of MSC.  The remainder of this chapter is devoted to 
developing this understanding. 
3.2 Materials and methods 
3.2.1 Ethical considerations 
All experiments using human cells and cell culture techniques were approved by the Mater 
Hospital Human Research Ethics Committee (HREC) (MMRI # 44 Mater #1262AM).   
3.2.2 Generic cell culture methods 
3.2.2.1  Retrieving cells from liquid nitrogen storage 
HK2 cells were originally sourced from ATCC (ATCC® CRL2190™) with early passage 
cultures stored in liquid nitrogen at our laboratory.  These cells are an immortalised 
proximal tubular epithelial cell line. Frozen ampoules were retrieved from liquid nitrogen 
storage and defrosted by body heat (aseptically holding them in a fist).  A water bath was 
not used, due to the potential risks of cell culture contamination. As soon as the cells were 
thawed sufficiently (approximately 2 minutes) they were placed in a 15ml Falcon tube 
which was filled with standard media (depending on the cell type) and centrifuged at 350g 
for 5 minutes at 4°C.  The supernatant was then discarded and cells were centrifuged a 
further two times in standard media to ensure removal of the preservative 
dimethylsulfoxide (DMSO) (Sigma-Aldrich-Aldrich).  Cells were then resuspended in 
standard media and seeded into a flask (Nunc). 
3.2.2.2  Culture media 
HK2 cells were cultured in Dulbecco’s modified Eagle’s media (DMEM) with Ham’s F-12 
supplementation including L glutamine (DMEM/F-12) (Invitrogen).  This is a 1:1 mixture of 
DMEM and F12 and has been shown in our laboratory to provide optimal conditions for 
growth of HK2 cells.  The DMEM/F-12 was supplemented with 10% fetal calf serum (FCS) 
(Invitrogen) and 1% 100U/ml penicillin, 100mg/ml streptomycin and 2mM L-glutamine 
(PSG) (Invitrogen).  
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3.2.2.3  Cell passaging 
Cells were passaged when appropriately confluent.  For HK2 cells, this was at 90-100% 
confluence once a characteristic cobblestone monolayer had been achieved.  Supernatant 
was discarded and replaced with TrypLE Select (Invitrogen) at approximately 1ml per 
25cm2 flask culture surface area.  The flask was incubated at 37°C for 5-7 minutes, until 
cells were seen to have detached from the flask.  The cell suspension was then 
transferred into a Falcon tube with PBS and the flask was thoroughly washed with 
phosphate buffered saline (PBS) to ensure collection of all cells.  Removal of cells was 
checked by direct visualisation of the flask with a light microscope.  A pellet was formed by 
centrifuging for 5 minutes at 350g, resuspended in 1ml standard media and then cells 
were counted.  After counting, cells were resuspended in an appropriate volume of media 
and re-seeded into a fresh cell culture flask, for example, 1x104 cells per ml. 
3.2.2.4 Cell counting 
Cells were incubated with 0.4% trypan blue (Sigma-Aldrich) at a 1:1 dilution for 1-3 
minutes.  10μl of the dilution was applied to a haematocytomer counting chamber 
(Neubauer Improved, Germany) and cells were visualised by light microscopy at 40x 
magnification.  Cells which had not taken up the trypan blue were counted as live, and 
cells which had taken up the trypan blue were counted as dead.  It was usual to find 70-
80% cell viability after the thaw.  Generally, cells in one square (1 x 1mm) were counted, 
multiplied by the dilution factor and by 104 to obtain concentration / ml.  If the cell 
suspension contained cells at a lower density such that less than 100 cells would be 
counted in a 1 x 1 mm square, then four 1 x 1 mm squares were counted, and the total 
number of cells divided by 4 prior to being multiplied by the dilution factor and by 104. 
3.2.2.5 Cryopreservation 
Cells were stored in liquid nitrogen for future use.  After passaging and counting as above, 
cells were resuspended in 90% standard media and 10% DMSO (Sigma-Aldrich) at a 
concentration of 1 x 106 cells per ml.  This suspension was then pipetted into 1.6ml 
cryovials (Nunc) at 1ml per vial, placed in a -80˚C freezer for 24 hours  in a Nalgene 
cryostorage container and then transferred to liquid nitrogen storage (-196°C).  
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3.2.3 Analysis of cell death and damage 
3.2.3.1  Morphologic studies 
HK2 cells were directly visualised under light microscopy.  Given the characteristic 
cobblestone appearance of the culture when healthy and confluent, it was easy to directly 
observe the changes of cell damage at a cell culture level.  However, examination of 
individual cells could not differentiate between cell damage or cell death.    
3.2.3.2 Cytotoxicity analysis by lactate dehydrogenase (LDH) 
Analysis of supernatant LDH levels at conclusion of the experiments was performed by 
spectrophotometry using a kit supplied by Promega (cytotox 96 non-radioactive 
cytotoxicity assay).  The assay was performed in a 96-well flat-bottomed plate (Greiner).  
The supernatant from each experimental well was removed at a pre-specified time point 
and put in 1.5ml tubes.  After vortexing, two 50μl aliquots of the supernatant were added to 
the 96-well plate.  In an initial test experiment, each experimental well was analysed in 
quadruplicate.  However, there was minimal variation between the four results (data not 
shown) and it was decided to perform the LDH analysis in duplicate for the remainder of 
the experiments. 
Controls included supernatant from untreated HK2 cells, media alone, the LDH positive 
control (supplied with the kit) and cells which had undergone 100% cell lysis by direct 
application of 30% H2O2. While the supernatant was being applied to the 96-well plate, the 
assay buffer was being thawed to room temperature.  12ml of the assay buffer were added 
to 1 bottle of substrate mix, and 50μl were added to each well.  The 96-well plate was then 
incubated for 30 minutes at room temperature, protected from light.  After the 30 minute 
incubation, 50 μl of Stop solution were added to each well.  Any bubbles were removed 
with a 14 gauge needle.  Absorbance was read at 490 nm within 1 hour of adding Stop 
solution, using Microplate Manager Software (Biorad). 
Results of the LDH analysis were presented as a percentage of cytotoxicity compared to 
control, as has been published (242).  Percentage cytotoxicity was calculated by the 
formula below: 
Experimental sample absorbance - Low control absorbance   x100%
High control absorbance – Low control absorbance
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In this model, low control is the mean of the absorbance of the untreated HK2 cells in the 
experiment, and high control is either the mean of the absorbance of the HK2 cells treated 
with 30% H2O2 or the LDH control supplied with the kit.   
Effect of different FCS concentration within media on cytotoxicity results 
It is known that FCS contains varying amounts of LDH in each lot number.  As all 
experiments in this project used the same lot number of FCS, it is unlikely that there was 
any variation from bottle to bottle of FCS.  However, it can be postulated that varying 
quantities of FCS within the media are likely to alter the absorbance recorded in this 
analysis.  Media with no added FCS, 10% FCS and 20% FCS were tested for LDH 
concentration.  
3.2.3.3 Cell viability analysis by annexin V and propidium iodide 
The purpose of flow cytometric analysis with AV and propidium iodide PI is to characterise 
dead and dying cells.  AV is a phospholipid binding protein which binds strongly to 
phosphatidylserine (PS), a phospholipid located in the intracellular plasma membrane of 
an intact, healthy cell, which is translocated from the intracellular to the extracellular 
membrane early in apoptosis (243).  Therefore cells may be characterised as either live 
(AV negative) or apoptotic (AV positive).  PI is a fluorescent dye that is widely held to be 
excluded from viable cells, but to enter necrotic cells and intercalate with double stranded 
deoxyribonucleic acid (dsDNA).  It was decided to exploit these features of dead and 
damaged cells to characterise the injury sustained by HK2 cells within this model.   
On completion of the H2O2 exposure, the supernatant was removed into an eppendorf tube 
and TrypLE Select was applied to the adherent cells and incubated for five minutes.  The 
supernatant was used to remove the adherent cells from the plastic after TrypLE Select 
incubation and the final cell suspension was collected into the same eppendorfs tube as 
the original culture supernatant.  This was to ensure that all non-adherent dead cells and 
debris were included for flow cytometric analysis.  The cell suspension was then spun for 
ten minutes at 1300 RPM at 4˚C.  The pellets were resuspended in 200µl of DMEM and 
then incubated with AV conjugated to fluorescein isothiocyanate (FITC) and PI for ten 
minutes at room temperature.  The resulting samples were then run through the BD LSR II 
Flow cytometer (BD Biosciences) and analysed with FlowJo flow cytometry analysis 
software (TreeStar Inc.).   
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PI is a fluorescent dye that can be detected by the red fluorescence channel, while AV-
FITC is detected by the green fluorescence channel.  There are four potential outcomes 
for cells stained with this protocol.  A cell may be AV negative and PI negative, indicating 
an intact plasma membrane, intracellular PS and intact DNA (labelled as “live” in this 
work).  A cell may be AV positive but PI negative, indicating external PS but an intact 
plasma membrane, characteristic of early apoptosis (labelled “apoptotic”).  A cell may be 
AV and PI positive, indicating damaged DNA and membrane disruption, characteristic of 
late apoptosis or necrosis (labelled “necrotic”).  Given that it is not possible for a cell to 
stain for PI but be unavailable for AV binding, it is likely that AV negative, PI positive 
staining indicates fragments of DNA bound to PI, or cellular debris.   
In all subsequent graphs of experiments with AV and PI, cell outcome is reported as a 
subset of 100%, where the 100% is made up of the three quadrants considered clinically 
significant (excluding the AV negative, PI positive quadrant).   
Gating strategy 
A consistent gating strategy was established to identify apoptotic and necrotic cells.  
Firstly, the population was gated by size.  In these experiments the population of cells 
identified as likely to be dead cells by size are included within the gate, as well as live 
cells.  Therefore, very small fragments of probable debris were excluded from further 
analysis.  The population gated for size was then further gated to remove cell doublets, 
leaving only a population of single cells.  This last population was displayed on FITC and 
phycoerythrin (PE), showing AV positivity on the X axis and PI positivity on the Y axis.  
Grouping into different quadrants was done on the basis of cell populations on the 
polychromatic dot plot and on the basis of known thresholds of positivity as defined by 
single staining in the set-up process and seen by histogram.         
Titration study of fluorochrome labelling concentration 
In the original protocol (obtained from the Apoptosis and Cytotoxicity Laboratory, MMRI), 
the labelling concentration of AV was 1:200 and PI 1:50.  This had been developed for use 
with HeLa cells in granzyme B experiments.  It was important to validate this protocol for 
use with HK2 cells.  A titration study was performed, where experimental wells were 
exposed to either 0.5mM H2O2 for 4 hours or 24 hours and then incubated with either AV 
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(FITC) at 1:200 (1μl) and PI at 1:50 (4μl) or with AV (FITC) at 1:100 (2 μl) and PI at 1:40 (5 
μl).  1 experiment was performed in triplicate. 
3.2.4 Experimental protocols 
All studies were performed on confluent HK2 cells in 24-well culture plates (Greiner).  Cells 
were seeded into 24-well culture plates from confluent 75 cm2 flasks, ensuring that any cell 
damage occurring as a result of the thaw from liquid nitrogen was no longer evident.  Cells 
were seeded at 1 x 104 cells / cm2 in standard media, which had been found in seeding 
density experiments to ensure confluence at 24 hours (data not shown).  They were 
incubated at 37˚C in standard tissue culture incubators with 5% CO2.   
At 24 hours, H2O2 containing media was prepared.  It was always prepared fresh 
immediately prior to applying to the cell culture, because of its tendency to instability.  30% 
H2O2 was purchased from Sigma-Aldrich and stored at 4˚C in the absence of light.  5% 
H2O2 was prepared for each experiment by adding 16.7 μl of 30% H2O2 to 83.3μl of milliQ 
water.  Aliquots of 5% H2O2 were added to standard media as listed in Table 3. to ensure 
specific millimolar concentrations of H2O2.  Prior to use in experiments, the H2O2 
containing media was mixed gently and protected from light.  Once the H2O2 media was 
prepared, the HK2 cells were removed from the incubator.  Standard media was removed 
and all wells were washed with PBS.  Media was replaced with either standard media 
(control wells) or with the specified concentration of H2O2.  Unless otherwise stated, all 
experiments were performed in triplicate.  The plates were then returned to the incubator 
for the duration of H2O2 exposure, before being analysed by either spectrophotometry 
(LDH levels) or flow cytometry (AV / PI staining).  Several experiments were performed 
with varying concentrations of H2O2 and varying durations of direct exposure as well as 
analysis time points.  The goal was to identify the optimum experimental conditions for 
further experiments with MSC.  It was also important to develop an understanding of the 
natural history of H2O2 induced HK2 damage.   
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   Table 3.1: Concentration of H2O2 for use in in vitro experiments 
mM H2O2 Volume of 5% H2O2 
Added to 15ml media 
mM H2O2 Volume of 5% H2O2 
Added to 15ml media 
0.1mM 1.02μl 0.6mM 6.12μl 
0.2mM 2.04μl 0.7mM 7.14μl 
0.3mM 3.06μl 0.8mM 8.16μl 
0.4mM 4.08μl 0.9mM 9.18μl 
0.5mM 5.10μl 1.0mM 10.2μl 
 
3.2.4.1 Pilot experiment of H2O2 induced cell damage 
This pilot experiment was designed to test the efficacy of the various methods used to 
analyse cell damage in the context of this model.  One experiment was performed in 
triplicate.  Experimental conditions included untreated cells (HK2 cells exposed to standard 
media), cells exposed to 0.6mM H2O2 for 24 hours, and cells exposed to 30% H2O2 for 24 
hours.  For the purposes of morphology, cells were photographed at 0, 4 and 24 hours.  
For the cytotoxicity analysis, the positive control used was the LDH sample that came with 
the kit.   
3.2.4.2 Effect of 4 hours exposure of varying concentrations of H2O2 on HK2 cells 
This experiment was designed to find the optimal H2O2 concentration to induce a moderate 
degree of cell damage.  Cells were exposed to 4 hours of H2O2 at different concentrations.  
Briefly, as described above, HK2 cells were seeded into 24 well plates in standard media 
at 1 x 105 cells per well.  24 hours later, the media was replaced with standard media or 
H2O2 containing media at 7 different concentrations ranging from 0.4mM to 1.0mM.  Each 
experiment was performed separately for analysis with both LDH and AV/PI.  4 hours after 
the H2O2 media was applied, cells and supernatant were examined for evidence of cell 
damage or death.  Two experiments were performed, each in duplicate.  For the LDH 
analysis, the low control was defined as untreated cells and the high control was defined 
as cells exposed to 30% H2O2.         
3.2.4.3 Effect of 24 hours exposure of varying concentrations of H2O2 on HK2 cells  
The effect of HK2 exposure to media with different H2O2 concentrations was then tested 
after 24 hours duration of exposure.  Firstly, for analysis of cytotoxicity by LDH, HK2 cells 
were seeded into 24 well plates in standard media at 1 x 105 cells per well. After 24 hours 
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of exposure to standard media, media was replaced with fresh standard media or H2O2 
containing media at concentrations of 0.4mM, 0.6mM, 0.8mM and 1.0mM H2O2.  After 24 
hours of exposure to this media, supernatant was removed and analysed for LDH content.  
Two experiments were performed, each in triplicate.  Secondly, an experiment was set up 
with slightly different H2O2 concentrations for analysis at 24 hours by AV/PI.  HK2 cells 
were seeded into 24 well plates as above, but at 24 hours the media was replaced with 
either standard media or H2O2 containing media at a concentration of 0.4mM, 0.5mM, 
0.6mM or 0.7mM H2O2.  At 24 hours, supernatant and cells were removed for analysis of 
cell viability by flow cytometry.  1 experiment was performed in quadruplicate.  
3.2.4.4 The delayed effect of a short exposure of H2O2 on HK2 cells  
Given that the half life of H2O2 is known to be very short, it was considered that H2O2 may 
induce a sequence of events that lead to ongoing cell damage over a period of time, even 
when the actual H2O2 is no longer present in solution.  To test this hypothesis, comparison 
was made between HK2 cells exposed to H2O2 for 4 hours and analysed immediately, 
HK2 cells exposed to H2O2 for 4 hours and analysed after exposure to standard media for 
a further 20 hours and HK2 cells exposed to H2O2 for 24 hours. This experiment was 
performed twice in duplicate and analysed with AV/PI. 
3.2.5 Statistical analysis 
Data reported in this model optimisation chapter are from two experiments performed in 
triplicate unless otherwise stated.  Each well in LDH experiments was analysed in 
duplicate.  Results are expressed as mean ± standard error of the mean (SEM).  Statistical 
differences between groups were assessed by one way analysis of variance (ANOVA) with 
multiple comparisons performed by Tukey’s test, unless otherwise specified.  Analyses 
were performed using the software package Graphpad Prism 6.  P values less than 0.05 
were considered significant. 
3.3 Results 
3.3.1 Analysis of H2O2 induced cell damage   
3.3.1.1 Morphologic studies 
Figure 3.1 shows representative photographs of the light microscopy appearance of HK2 
cells after varying degrees of cell damage.  These results are from the pilot study 
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described in 3.2.4.1.  As is seen in Figure 3.1 A, a healthy HK2 cell culture consists of 90-
100% confluent plastic adherent cells of similar size and morphology.  Of particular note is 
the cobblestone appearance indicating that the cells have formed a tight monolayer, 
essential to the function of proximal tubular cells.  Figures 3.1 B-D show increasing 
degrees of damage within the cell culture.  In Figure 3.1 B, cells have been exposed to 
0.6mM H2O2 media for 4 hours.  A proportion of cells has lifted from the surface, leading to 
multiple layers of cells in some areas, and patches devoid of cells in other areas.  
However, the remaining cell population still displays the cobblestone appearance, 
indicating that although the culture is damaged, some cells are likely to remain viable and 
functional.  Figure 3.1 C shows cells which have been exposed to 0.6mM H2O2 for 24 
hours.  More cells have detached from the surface, and although the underlying cells do 
still appear to form a cobblestone appearance, there appears to be damage to the 
cytoplasm, and there are some gaps beginning to form between cells, making it unclear 
whether these cells are functional or viable.  Finally, Figure 3.1 D is an example of very 
severe cell damage and death.  These cells have been exposed to 30% H2O2 for 24 hours.  
Very few cells are seen, none remain plastic adherent, and there is clear evidence of 
cellular debris in the growth media.  Light microscopy is therefore useful in that it can 
differentiate between a healthy cell culture population and a cell culture population that has 
experienced mild, moderate or severe damage.  However, these data cannot easily be 
quantified, and do not indicate the fate of individual cells.  
3.3.1.2 Cytotoxicity analysis by LDH  
Effect of different FCS concentration within media on cytotoxicity results 
Figure 3.2 shows the LDH concentrations of media containing FCS.  Minimal LDH was 
measured from media devoid of FCS.  There was an appreciable LDH content in media 
containing 10% FCS (standard HK2 cell media), which was significantly increased in 
media containing 20% FCS (standard MSC media) (p<0.001 when compared to media 
without LDH).  These data support the hypothesis that adding FCS to the media is likely to 
alter the results.  However, given that the formula presented in 3.2.3.2 takes the media into 
account on both sides of the equation, providing the FCS concentration is constant in the 
experimental sample, the low control and the high control samples, the percentage 
cytotoxicity will remain the same regardless of the FCS concentration.  For the remainder 
of the experiments, LDH analysis was conducted with media containing 10% FCS. 
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Figure 3.1: Representative photographs of light microscopy of HK2 cells in culture. A) Healthy HK2 cell 
culture in standard media.  B) HK2 cells exposed to 0.6mM H2O2 containing media for 4 hours. C) HK2 cells 
exposed to 0.6mM H2O2 containing media for 24 hours. D) HK2 cells exposed to 30% H2O2 for 24 hours 
(200x magnification).   
 
 
Figure 3.2:  LDH levels in media with varying concentrations of fetal calf serum, assessed by 
spectrophotometric absorbance, read at 490nm.  Data presented represent results from 1 experiment, 
performed in triplicate.  *** p<0.001 when compared to 0% FCS (1 way ANOVA test with a post test 
Bonferroni comparison performed using the Graphpad Prism 5 software).  
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Pilot experiment of H2O2 induced cell damage 
This pilot study was designed to test the validity of using LDH analysis in this model of 
H2O2 induced HK2 cell injury.  As is seen in Figure 3.3 A, the raw data (spectrophotometric 
absorbance) show a clear progression in LDH from the untreated cells (mean absorbance 
0.307) to the cells treated with 0.6mM H2O2 for 24 hours (mean absorbance 2.49, 
P<0.0001 when compared to untreated cells) to the LDH positive control (mean 
absorbance 3.1, P<0.0001 when compared to cells treated with 0.6mM H2O2).  Using the 
formula shown in 3.2.3.2, where the low control was the mean of the untreated cells and 
the high control was the LDH positive control, the percentage cytotoxicity compared to 
control was calculated for all three experimental conditions (Figure 3.3 B).  As is seen, the 
untreated cells approximate 0%, as they had been prespecified as the low control for 
cytotoxicity.  Likewise, the LDH positive control results approximate 100% as they had 
been prespecified as the high control.  The HK2 cells treated with 0.6mM H2O2 for 24 
hours showed a mean cytotoxicity compared to control of 78% (P<0.0001).  These data 
were reassuring in that it showed LDH was a reasonable measure of cytotoxicity and that 
the results were comparable in a way that could be quantified. 
 
Figure 3.3: Results from a pilot experiment comparing cytotoxicity as assessed by LDH in untreated cells 
and cells exposed to 0.6mM H2O2 for 24 hours.  Experiment performed in triplicate, error bars represent 
SEM.  A) absorbance as read at 490 nm by Microplate Manager Software (Biorad).  LDH positive control was 
supplied with kit (Promega).  B) Cytotoxicity expressed as a percentage compared to control when the low 
control used was the mean absorbance of the untreated cells and the high control was the mean 
absorbance of the LDH positive control.  *** P<0.0001 when compared to untreated cells, analysed by 1 
way ANOVA, multiple comparisons tested using Tukey’s test (GraphPad Prism 6). 
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3.3.1.3 Cell viability analysis by annexin V and propidium Iodide 
Gating strategy 
Figure 3.4 shows the gating strategy used in identifying apoptotic and necrotic cells.  
Firstly, the population was gated by size.  As seen in Figure 3.4 A, only a small proportion 
of the events are excluded.  These are the events with a low forward scatter area and a 
low side scatter area, likely reflecting debris rather than cells.  The population gated for 
size was then further gated as shown in Figure 3.4 B on the parameters forward scatter 
area and forward scatter height, to exclude cell doublets.  Finally this last population was 
displayed on FITC (AV) and PE (PI), and different quadrants are displayed (Figure 3.4 C).  
Live, apoptotic and necrotic cell populations are gated on the basis of evident cell 
populations on the polychromatic dot plot. 
A CB
Figure 3.4: Representative results showing gating strategies for Annexin V and Propidium Iodide (flow 
cytometric analysis performed by LSR II, software analysis by FlowJo (Treestar Inc.)).  A)  The first gate is 
labelled ‘size’ and includes essentially all cells, excluding only a small amount of cellular debris as defined 
by both low forward and side scatter area.  B) The second gate is labelled ‘singleton’ and excludes cell 
doublets.  C) The final gates are done with FITC AV in the X axis and PI in the Y axis.  Live cells are those 
which are double negative, Apoptotic cells are those which are AV positive but PI negative and Necrotic 
cells are those which are double positive.  Populations are determined based on histograms on single 
staining in the set up process, which gives a threshold for positivity, and also on visualisation of separate 
populations on either the polychromatic dot plot or the contour plot.    
 
Titration study of fluorochrome labelling concentration 
Figure 3.5 is a representative polychromatic dot plot of the results of the different 
fluorochrome labelling concentrations after 24 hours of H2O2 exposure.  Results were 
consistent across the duplicate wells.  In the wells which were stained with AV at 1:200 
and PI at 1:50, 38.9% of events fell in the quadrant which were PI positive but AV 
negative, indicating cellular debris (Figure 3.5 A).  Figure 3.5 B shows that with a higher 
concentration of AV and PI, the proportion of AV negative, PI positive cells dropped from 
38.9% to 7.26%.  There was also a small reduction in the percentage of live cells (from 
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14% to 11.5%), as some PI negative cells which were AV negative in the lower incubation 
concentration became AV positive in the higher incubation concentration. 
A B
 
Figure 3.5: Polychromatic dot plot of HK2 cells after exposure to 0.5mM H2O2 for 24 hours (flow 
cytometric analysis performed by LSR II, software analysis by FlowJo (Treestar Inc.)).  A) Cells incubated 
with AV (1:200) and PI (1:50).  B) Cells incubated with AV (1:100) and PI (1:40) (total volume of antibody 
incubation 200µl).  Representative plots shown. 
These changes were largely owing to the change in AV concentration and were only seen 
with more severe damage (Figure 3.6).  After 4 hours of exposure to H2O2, the mean 
proportion of AV positive cells per well was 19.1% (95% confidence interval (CI) 9.9-28.3) 
if diluted 1:200 and 21.8% (95% CI 10.4-33.2) if diluted 1:100 (p>0.05).  However, after 24 
hours of exposure to H2O2, the mean proportion of AV positive cells per well was 45.6% 
(95% CI 41.5-49.8) if diluted 1:200 and 74.6% (95% CI 63.6-85.5) if diluted 1:100 (p = 
0.0009).   After 4 hours of exposure to H2O2, the mean proportion of PI positive cells per 
well was 23.1% (95% CI -35-80.1) if diluted 1:50 and 18.3% (95% CI 10.35-26.2) if diluted 
1:40 (p>0.05).  After 24 hours of exposure to H2O2, the mean proportion of PI positive cells 
per well was 83.8% (95% CI 80.6-87) if diluted 1:50 and 83.4% (95% CI 80.8-85.9) if 
diluted 1:40 (p>0.05). It was therefore decided that for all subsequent experiments, the 
concentration of AV-FITC used would be 1:100 and PI 1:50.  
 
 
.  
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Figure 3.6:  Comparison of effect of different concentrations of AV and PI on proportion of AV and PI 
positive cells in different experimental conditions. A) Direct comparison of 1:200 dilution AV (1µl) and 
1:100 dilution AV (2µl) after short (4hr) or long (24 hr) exposure to H2O2. B) Direct comparison of 1:50 
dilution PI (4µl) and 1:40 dilution PI (5µl) after short (4hr) or long (24 hr) exposure to H2O2. ns = p>0.05, *** 
P 0.0009. 
 
Pilot experiment of H2O2 induced cell damage 
Figure 3.7 shows representative dot plots of the pilot experiment performed to test the 
sensitivity of the methods of analysis.  Figure 3.7 A shows the proportion of cells alive, 
apoptotic and necrotic after 24 hours of exposure to standard media.  In this example, 81% 
of cells were alive, 5.83% apoptotic and 10.9% necrotic.  Even with untreated cells, some 
degree of cell death will be noted, which is likely due to normal cell turnover.  Figures 3.7 B 
and 3.7 C show the changing cell proportion in cell populations as cell damage worsens.  
0.6mM H2O2 caused a significant degree of cell damage at 24 hours, with 39% cells live in 
this example, 21% cells apoptotic and 37.2% of cells necrotic.  The severity of the damage 
increased markedly when cells were exposed to 30% H2O2, with 80.9% of cells necrotic, 
15.6% cells apoptotic and only 2.34% cell alive at 24 hours.  It is not possible by this 
method to distinguish between primary and secondary necrosis, but it is reasonable to 
suggest that with very severe cellular insults, there is little apoptosis and the pathway to 
cell death is likely to be via primary necrosis.  For the purpose of the following 
experiments, it was important to induce a more moderate degree of damage in order to 
provide a window of opportunity for treatment, protection and/or recovery. 
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A B C
Figure 3.7: Examples of varying AV/PI staining with different degrees of cell damage.  A)  Untreated 
control HK2 cells. B) HK2 cells exposed to 0.6mM H2O2 for 24 hours. C) HK2 cells exposed to 30% H2O2 for 
24 hours.  The gate containing AV and PI negative cells represents live cells, the gate containing AV positive 
PI negative cells represents apoptotic cells and the gate containing AV and PI positive cells represents cells 
that have undergone necrosis. 
 
3.3.2 The natural history of H2O2 induced cell damage 
3.3.2.1 Effect of 4 hours exposure to varying concentrations of H2O2 on HK2 viability  
Cells were exposed to 4 hours of H2O2 at different concentrations.  At 4 hours, there were 
inconsistent results with different concentrations (Figure 3.8), suggesting that 4 hours may 
be too early for consistent effect and is unlikely to be a reliable time point to make any 
assessment of intervention.  
With cell viability analysis using AV and PI (Figure 3.8B), the percentage of live cells at 4 
hours in the untreated group was 76.3 ± 9.7% (95% CI 49.3-100).  All groups exposed to 
H2O2 had fewer live cells than the untreated group at 4 hours.  However, this was only 
statistically significant in groups exposed to 0.6mM H2O2 (35.6 ± 5.3%, 95% CI 18.8-52.4, 
p<0.01) and 1.0mM H2O2 (24 ± 1.2%, 95% CI 20.1-28.0, p<0.0001) when compared to 
untreated cells.  The difference was not statistically significant in groups exposed to 
0.4mM H2O2 (47.9 ± 4.4%, 95% CI 0-100), 0.5mM H2O2 (72.8 ± 5.1%, 95% CI 8-100), 
0.7mM H2O2 (61.1 ± 1.8%, 95% CI 55.3-66.8), 0.8mM H2O2 (70.8 ± 3.4%. 95% CI 60.1-
81.4) or 0.9mM H2O2 (71.0 ± 1.7%, 95% CI 65.7-76.3) when compared to untreated cells 
(p>0.05 for all comparisons).   
There was no significant change in the proportion of apoptotic cells with any concentration 
of H2O2, with untreated cells having 14.3 ± 7.6% apoptotic cells (95% CI 0-35.3) compared 
to 0.4mM H2O2 (9.9 ± 1.7%, 95% CI 0-31.5), 0.5mM H2O2 (12.1 ± 2.7%, 95% CI 0-46.4), 
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0.6mM H2O2 (22.3 ± 3.5, 95% CI 11-33.5), 0.7mM H2O2 (26.3 ± 1%, 95% CI 23.2-29.4), 
0.8mM H2O2 (19.1 ± 2.9%, 95% CI 9.8-28.4), 0.9mM H2O2 (17.7 ± 1.8%, 95% CI 11.8-
23.5) or 1.0mM H2O2 (1.7 ± 0.2%, 95% CI 1.1-2.4), p>0.05 for all comparisons (Figure 
3.8C).  However, an increase in necrotic cells was seen in some groups, with untreated 
cells having 8.8 ± 1.9% necrotic cells (95% CI 3.4-14), as compared to 0.4mM H2O2 (42 ± 
2.7%, 95% CI 7.7-76.3, p<0.0001), 0.6mM H2O2 (41 ±2.8%, 95% CI 32.1-50, p<0.0001) 
and 1.0mM H2O2 (74 ± 1.1%, 95% CI 70.4-77.5, p<0.001) (Figure 3.8D).  At other 
concentrations of H2O2 there was no change in percentage of necrotic cells, specifically 
0.5mM H2O2 (14.8 ± 2.5%, 95% CI 0-45.9), 0.7mM H2O2 (10.3 ± 1.1%, 95% CI 6.7-13.8), 
0.8mM H2O2 (7.7 ± 0.4%, 95% CI 6.4-9) and 0.9mM H2O2 (9.2 ± 0.7%, 95% CI 6.9-11.5) 
p>0.05 for all comparisons. It remains possible that the significant differences were due to 
chance. 
With LDH analysis (Figure 3.9), there was no significant increase in cytotoxicity of cells 
treated with varying concentrations of H2O2 for 4 hours when compared to control.  The 
low control value was drawn from the results for untreated cells (0.1 ± 6.2% cytotoxicity, 
95% CI -15 to 15) and the high control value from cells exposed to 30% H2O2 for 24 hours 
(100.1 ± 1.5%, 95% CI 96.5-103.7%, P<0.0001 compared to untreated cells).  There were 
no significant differences between untreated cells and 0.4mM H2O2 (11.8 ± 1.6%, 95% CI 
6.7-16.8) 0.6mM H2O2, (-9.1 ± 0.8%, 95% CI -11.6 to -6.6), 0.8mM H2O2 (-4.6 ± 0.2%, 95% 
CI -5.3 to -3.9) and 1.0mM H2O2 (1.6 ± 0.6%, 95% CI -0.5-3.6) (p>0.05 for all 
comparisons). 
This lack of a linear increase in damage with increasing concentrations of H2O2 led to the 
hypothesis that the duration of H2O2 exposure was too short to see consistent results.  The 
half-life of H2O2 is short and the direct physiological effect on the cells would be expected 
to happen within the first hour.  However, quantifiable cell death may not be apparent for 
some time after initiation of the cell death pathway.  Also, there is likely to be an indirect 
effect whereby dying cells cause damage to adjacent cells, stimulating further cell death.  
Therefore, it was decided to assess the same concentrations of H2O2 at a later time point.  
It is worth noting that even at this 4 hour time point, the highest concentration of H2O2 used 
(1.0mM H2O2) did lead to reduced live cells and increased necrotic cells, with very few 
apoptotic cells. 
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Figure 3.8:  Effect of varying concentrations of 4 hours of exposure H2O2 on HK2 cytotoxicity as measured 
by Annexin V and PI.  A) Total distribution of cell populations.  B) Percentage of live cells at 4 hrs. *** 
p<0.001 when compared to untreated cells.   C) Percentage of apoptotic cells at 4 hrs. P>0.05.  D) 
Percentage of necrotic cells at 4 hrs. **** p<0.0001 when compared to the untreated cells.  Results 
represent the mean ± standard error of the mean (SEM) of two experiments performed in triplicate, 
analysed by 1 way ANOVA with multiple comparisons by Tukey’s test (GraphPad Prism 6 software). 
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Figure 3.9: Effect of varying concentrations of H2O2 on cytotoxicity after 4 hours of exposure, as 
measured by LDH release.  Results from 2 experiments performed in duplicate show that adding H2O2 for 
4 hours caused no significant increase in cytotoxicity except for the group given 30% H2O2 (used as the 
high control in this experiment).   **** p<0.0001 vs untreated cells (1 way ANOVA analysis). 
3.3.2.2 Effect of 24 hours exposure to varying concentrations of H2O2 on HK2 viability  
Given that inconsistent results were obtained at 4 hours, it was decided to analyse the 
effect on cell viability 24 hours after adding H2O2 to the media.  When AV and PI were 
analysed, all concentrations of H2O2 led to a statistically significant reduction in live cells at 
24 hours (Figure 3.10 A, 3.10 B).  In this experiment, 0.4mM, 0.5mM, 0.6mM and 0.7mM 
H2O2 were tested.  The untreated control group were found to have 76.8 ± 3.7% live cells 
at 24 hours (95% CI 65.1-88.5).  This was reduced to 44.8 ± 10.6% in the 0.4mM group 
(95% CI 11.1-78.6, p<0.01), 5.7 ± 1.6% for cells exposed to 0.5mM H2O2 (95% CI 0.7-
10.7, p<0.0001), 3.1 ± 0.7% for cells exposed to 0.6mM H2O2 (95% CI 0.1-5.2, p<0.0001) 
and 2.7 ± 1.1% for cells exposed to 0.7mM H2O2 (95% CI 0-6.1, p<0.0001).  There was a 
statistically significant difference between 0.4mM and the higher concentrations (p < 0.001 
for all comparisons) but no difference in percentage of live cells between 0.5 and 0.7mM 
H2O2.  It is interesting that these experiments used very similar concentrations of H2O2 to 
the previous experiments, but by exposing the cells for 24 hours rather than 4 hours, it was 
possible to display significant effect, both in terms of cell damage and cell death.   
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Figure 3.10: Effect of varying concentrations of 24 hours of exposure H2O2 on HK2 cytotoxicity as 
measured by Annexin V and PI.  A) Total distribution of cell populations.  B) Percentage of live cells at 24 
hrs. **p <0.01, **** p < 0.0001 when compared to untreated cells.   C) Percentage of apoptotic cells at 24 
hrs. . **p <0.01 when compared to untreated cells.  D) Percentage of necrotic cells at 24 hrs. *p <0.05, 
****p <0.0001 when compared to the untreated cells.  Results represent the mean ± standard error of the 
mean (SEM) of two experiments performed in duplicate, analysed by 1 way ANOVA with multiple 
comparisons by Tukey’s test (GraphPad Prism 6 software). 
Percentage of apoptotic cells was analysed at 24 hours (Figure 3.10C).  It can be seen 
that with 0.4mM H2O2, which induced less cell death than the higher concentrations, the 
proportion of apoptotic cells was significantly increased from 7.9 ± 0.9% in the untreated 
cells (95% CI 4.9-10.8) to 22.7 ± 4.2% (95% CI 9.4-35.9, p<0.01).  There were no 
significant increases seen in apoptotic cells with exposure to 0.5mM H2O2 (15.5 ± 1.1%, 
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95% CI 12-19), 0.6mM H2O2 (12.5 ± 0.6%, 95% CI 10.7-14.3) or 0.7mM H2O2 (12.1 ± 
1.9%, 95% CI 6.2-18), p>0.05 for all comparisons. 
The proportion of cells that were necrotic was 13.2 ± 2.9% in the untreated control group 
(95% CI 3.9-22.5) (Figure 3.10D).  This was significantly increased in all groups exposed 
to H2O2.  Of cells exposed to 0.4mM H2O2, 31.2 ± 7.1% (95% CI 8.8-53.7, p<0.05) were 
necrotic at analysis.  The proportion of necrotic cells was larger with higher concentrations 
of H2O2, at 78 ± 2.5% (95% CI 70-86, p<0.0001) with 0.5mM H2O2, 83.3 ± 0.8% (95% CI 
80.7-86, p<0.0001) with 0.6mM H2O2 and 84.6 ± 2.9% (95% CI 75.4-93.7, p<0.0001) with 
0.7mM H2O2.   Overall these results suggest that with a smaller concentration of H2O2, 
dying cells may be more likely to proceed down the apoptotic pathway.  With higher 
concentrations and more severe cell damage, cells may be more likely to become necrotic, 
although it is possible that these cells were initially apoptotic and then developed 
secondary necrosis. 
Two experiments were conducted with H2O2 at concentrations of 0.4mM, 0.6mM, 0.8mM 
and 1.0mM, and LDH was measured to calculate cytotoxicity.  In comparison to the 4 hour 
results it was seen that at 24 hours all concentrations of H2O2 tested showed a statistically 
significant increase in cytotoxicity compared to untreated cells (Figure 3.11).  Untreated 
cells were used as the low control, and therefore exhibited cytotoxicity compared to control 
of -0.2 ± 4.3% (95% CI -9.7 to 9.2).  24 hours exposure to 0.4mM H2O2 led to 66.7 ± 7.4% 
cytotoxicity compared to control (95% CI 50.1-83.3), whereas exposure to 0.6mM H2O2 led 
to 93.2 ± 13.8% cytotoxicity (95% CI 62.5-123.8), 0.8mM H2O2 83.9 ± 11.5% cytotoxicity 
(95% CI 58.4-109.4) and 1.0mM H2O2 98.7 ± 12.1% cytotoxicity (95% CI 71.8-125.5) (each 
experimental condition p<0.0001 compared to untreated cells).  However, there was no 
statistically significant difference between the different concentrations of H2O2.  There was 
no significant difference between the cytotoxicity for the experimental groups and the 
group used for the high control (exposure to 30% H2O2: 100.0 ± 1.4% cytotoxicity, 95% CI 
96.8-103.2), suggesting a severe insult to the cell cultures. 
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Figure 3.11: Effect of varying concentrations of H2O2 on cytotoxicity after 24 hours of exposure, as 
measured by LDH release.  Results represent the mean ± standard error of the mean (SEM) of two 
experiments performed in triplicate, with the LDH assay of each well performed in duplicate. **** 
p<0.0001, vs untreated cells.  There was no statistical difference between the different concentrations of 
H2O2 and the high control (24 hours exposure to 30% H2O2). 
3.3.2.3 The effect of exposing HK2 cells to H2O2 for four hours with analysis at 24 hours 
It has been shown that after 4 hours of exposure to H2O2, there is some evidence of cell 
damage, but this is not consistent.  However, after 24 hours, there is significant cell death.  
It is unclear from this data whether H2O2 is required to be present for the entire duration.    
It is possible that H2O2 induces a sequence of events that leads to cell death over a period 
of time, best appreciated at 24 hours.  To test this hypothesis, comparison was made 
between HK2 cells exposed to H2O2 for 24 hours, HK2 cells exposed to 0.5mM H2O2 for 4 
hours and analysed immediately, and HK2 cells exposed to 0.5mM H2O2 for 4 hours and 
standard media for a further 20 hours (Figure 3.12 A).  There was no difference in the 
proportion of live cells between untreated cells (70.9 ± 3.1%, 95% CI 57.5-84.4) and cells 
exposed to H2O2 for 4 hours (66.6 ±  5.4%, 95% CI 53.8-79.3, p>0.05) (Figure 3.12B).  
There was a significant reduction in live cells in the group exposed to H2O2 for 4 hours and 
then standard media for 20 hours (13.8 ± 0.7%, 95% CI 11.7-16, p<0.0001 compared to 
untreated cells).  There was also a significant reduction in the percentage of live cells in 
the group exposed to H2O2 for a full 24 hours (5.7 ± 1.6%, 95% CI 0.7-10.7, p<0.0001 
compared to untreated cells).  Although there was a trend to a worsened outcome in the 
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group exposed to H2O2 for 24 hours compared to the group exposed for 4 hours and 
analysed at 24 hours, this was not statistically significant.  It is possible that the media 
removed at 4 hours contained some dead cells which would lead to an underestimation of 
cell death in the group receiving 4 hours of H2O2 and 20 hours of standard media and 
could account for this difference.  These results are consistent with the hypothesis that 
H2O2 sets in motion a train of events which take some time to occur and may eventually 
lead to cell death.   
Figure 3.12 C shows the proportions of apoptotic cells seen at analysis.  Changes were 
inconsistent.  8 ± 2.2% (95% CI 0-17.7) of untreated cells were found to be apoptotic.  
There was a statistically non-significant increase in apoptotic cells after exposure to 4 
hours of H2O2 in the group analysed immediately (17.8 ± 3.4% apoptotic cells, 95% CI 9.6-
25.9, p>0.05 when compared to untreated cells).  The difference between the group 
exposed to H2O2 for 4 hours but analysed immediately and the group exposed to H2O2 for 
4 hours and analysed after 20 hours of standard media was statistically significant, with 
only 5.6 ± 0.3% of the latter group developing apoptotic cells (95% CI 4.5-6.6, p<0.05). 
There may have been some apoptotic cells in the supernatant removed at 4 hours when 
the media was changed in this group, but this was not assessed.  The group exposed to 
H2O2 for the full 24 hours resulted in 15.5 ± 1.1% apoptotic cells (95% CI 12.1-19, p>0.05 
compared to untreated cells. 
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Figure 3.12: Effect of varying duration of exposure of H2O2  on cytotoxicity after 24 hours of exposure, as 
measured by AV and PI. A) The proportion of live, apoptotic and necrotic cells after 0.5mM exposure H2O2 
for either no time (untreated cells), 4 hours (analysed at 4 hours (T4) or 24 hours (T24)) and 24 hours.  B) 
The percentage of live cells drops significantly only after 24 hours (**** p<0.0001). C) Changes in apoptotic 
cells are inconsistent. (*p <0.05 ).   D) There is a significantly increased proportion of necrotic cells in the 
groups analysed at 24 hours (**** p<0.0001) but not when analysed at 4 hours. Data shown represents two 
experiments, performed in duplicate.  All data analysed by 1 way ANOVA with Tukey’s multiple comparison 
test using Graphpad Prism 6 software. 
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3.4 Discussion  
The goal of this chapter was to develop a robust, replicable model of H2O2 induced cell 
injury in HK2 cells, an immortalised cell line of proximal tubular cells.  At the same time, it 
was important to develop an understanding of the natural history of such injury, in order to 
appropriately plan experiments aimed at modifying this outcome.  The experiments 
showed that cell cytotoxicity as determined by LDH content of the supernatant, and cell 
viability as determined by AV/PI staining were both useful and replicable methods of 
analysing cell outcome after damage.  With regard to the AV/PI methodology, the protocol 
has been validated for use with the current model.  Using this methodology, the outcome 
of cells after damage by H2O2 can be assessed.  A damaged cell may remain viable, 
become apoptotic or become necrotic.  In the case of either primary or secondary 
necrosis, the plasma membrane loses its integrity and may become fragmented, in which 
case AV may bind to PS even if the PS has remained on the intracellular membrane.  
Therefore, it is not possible to differentiate between apoptotic and necrotic cells on the 
basis of AV alone.  In the experiments described above, the most useful marker was the 
proportion of live cells remaining at the end of the experimental period.  The percentage of 
cells made up by apoptotic and necrotic cells appeared to be more variable, and there was 
no clear linear pathway of damage on reviewing these results.  The results have been 
included in these and future experiments as they are interesting and hypothesis 
generating.   
Regarding the natural history of H2O2 induced damage, the experiments show that H2O2 
led to cellular changes early after exposure, which, if not addressed, were likely to induce 
significant cell damage and cell death in 24 hours.  The replacement of standard media 
within the first 3 hours appeared to ameliorate these effects (data not shown).  However, 
with 4 hours of exposure to media containing H2O2, a number of molecular pathways are 
stimulated which lead to significant cell death despite replacement of standard media.  
H2O2 was used to replicate the ROS which are released during IRI.  It is expected that this 
initial damage causes injured HK2 cells to release a cascade of pro-inflammatory 
molecules which further potentiate cell damage.  There is therefore a window of 
opportunity to intervene in this system and reduce overall cell death.  It is likely that the 
earlier this intervention occurs, the more protection will occur, but given that events are 
happening over a period of 24 hours, intervention at any stage may still have an effect.   
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For the purposes of further experimentation, it has been demonstrated that the 
concentration of H2O2 is less important than the time point for analysis.  Given that there 
was little difference between exposing the cells to H2O2 for 24 hours and exposing them 
for 4 hours and analysing at 24 hours, further experiments will analyse cell viability after 24 
hours without replacing media during this time.  This will reduce the likelihood of removing 
dead cells and, perhaps more importantly, inflammatory supernatant due to release of 
molecules by damaged cells.  Overall the results suggested that 0.4mM H2O2 led to a 
more moderate degree of cell damage.  There was no significant difference between 
0.5mM and 1.0mM H2O2 and it was decided to use 0.6mM H2O2 for all future experiments.  
This concentration would be expected to cause significant cell death at 24 hours, with an 
increase in necrotic cells, LDH and possibly apoptotic cells.  Using this more severe model 
of cell death would be expected to increase the chances of seeing a significant effect of an 
intervention.  
Having developed a robust model replicating IRI, the next step was to investigate any 
effects of MSC in this model.  The following chapter examined the effect of MSC using this 
established in vitro model. 
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Chapter 4 
Investigation into the efficacy of mesenchymal stromal 
cells in protecting HK2 cells from H2O2 induced damage 
in vitro 
4.1 Background and objectives 
Having developed a validated model of renal IRI in vitro, the next objective was to test the 
efficacy of human MSC in protecting against IRI in this model.  It was important to ensure 
a robust and reproducible method of isolating and culturing MSC for use in these 
experiments.  There are different methods of isolating human MSC and different ways of 
treating MSC to attain effect, so it was decided to test a number of these methods to find 
an effective and convenient source of human MSC.  In this chapter, the literature behind 
the use of different populations of MSC will be reviewed and the methods used to isolate 
and culture these populations will be described.  Results are presented on the effect of 
different human MSC under different conditions on HK2 cell damage, using the model 
defined in Chapter 3. 
4.1.1 Bone marrow derived MSC vs placental derived MSC 
Adult MSC have been isolated from a large number of tissues.  In our laboratory, isolation 
of MSC from bone marrow and from placenta is standard practice.  Most studies of MSC in 
renal IRI have used bone marrow derived MSC (BM MSC) (196).   However, BM MSC 
must be obtained from healthy volunteers undergoing a bone marrow aspiration, an 
intrusive procedure.  Relatively few MSC are isolated from a single donation, although 
these can be cultured ex vivo.  No studies have used placental derived MSC (Plac MSC) 
in renal IRI.  In contrast to bone marrow, placental tissue was readily obtainable from the 
maternity unit in the hospital attached to the Mater Medical Research Institute (MMRI) 
laboratory.  This tissue would generally be discarded.  It contains plentiful numbers of 
MSC, which are easy to expand ex vivo.  The ASC team at MMRI has previously found 
that Plac MSC have the same morphologic and cell surface marker phenotypes as BM 
MSC (244).  However, they were shown to proliferate more rapidly in culture and to be a 
more robust cell population.  Plac MSC were readily able to differentiate into osteogenic 
and chondrogenic lineages but were less able to differentiate into adipocytes than BM 
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MSC.  It is likely that MSC from different tissues may behave differently, even if they 
display the same cell surface markers and characteristic features of MSC.  One paper 
examined the functional differences between BM MSC and MSC from the umbilical cord 
and the amniotic membrane (245).    They found that although MSC from all three sources 
displayed similar morphology and cell surface markers, perinatal MSC were likely to have 
a higher potential for immunomodulation than BM MSC, based on gene expression 
profiling.  There were also some differences in growth factors secreted by different 
populations of MSC.  Another study looked at differences in T cell suppression by MLR 
between different populations of MSC, including Plac MSC and BM MSC.  There was no 
statistical difference between the two populations (246).  In the current work, it was 
decided to first test both populations, to identify any potential functional differences in their 
immunomodulatory capacity. 
4.1.2 MSC vs MSC-CM 
As reviewed in Chapter 2, it is very likely that MSC exert their effects in a paracrine 
manner by the secretion of specific growth factors and immunomodulatory molecules.  At 
the time this work was commenced, early reports suggested that MSC effects could be 
replicated by the use of MSC-CM, implying that direct exposure to MSC may not be 
required for beneficial effect.  One group showed that MSC-CM led to a reduction in cell 
death and apoptosis and an increase in angiogenesis in ischaemic endothelial cells (247).  
Another group found that MSC-CM reduced the size and extent of myocardial infarction in 
a porcine model (248).  It was decided to examine the differences between MSC and 
MSC-CM in the current model.    
4.1.3 MSC from standard culture vs MSC stimulated by exposure to inflammatory 
cytokines 
Ischaemic preconditioning has been shown to be beneficial in a number of experimental 
settings (249).  In a rat heart transplant model, MSC pretreated with pro-inflammatory 
cytokines suppressed T cell proliferation more than MSC pretreated with anti-inflammatory 
cytokines (250).  The authors suggested that this differential effect of MSC depending on 
pretreatment and the immune environment may explain some of the conflicting results 
seen in the MSC literature. The beneficial effect of MSC pre-treated with pro-inflammatory 
cytokines (IL1β and TGFβ) was confirmed in a rat myocardial IRI model (251).  In the 
current work, it was decided to test MSC with and without pre-treatment.   
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4.1.4 Conclusion 
Given that there are so many uncertainties within the literature regarding the use of MSC, 
for the purposes of this study it was decided to test multiple different experimental 
conditions using both BM MSC and Plac MSC.  The effects of MSC were analysed directly 
and indirectly, and media conditioned by MSC were studied.  The effect of pre-treatment 
with pro-inflammatory cytokines was compared to standard MSC culture.  The goal of this 
chapter was to establish the effects of MSC alone on injured proximal tubular cells, 
independent of the effects of immune cells. 
4.2 Materials and methods 
4.2.1 Ethical considerations 
All experiments involving human cells were approved by the Mater Health Services HREC 
(Reference number MMRI # 44 Mater # 1262AM).  Bone marrow was donated by healthy 
volunteers, and retrieved by medical staff in the Haematology Department, Mater Hospital, 
Brisbane, in line with standard clinical practice. Given the variation between human donors 
and therefore the need for multiple donors to achieve scientifically valid results, throughout 
the course of this project a strong collaboration existed with the Adult Stem Cell (ASC) 
Team at MMRI.  Some BM MSC and Plac MSC to be used in this project were therefore 
obtained from the ASC team to be used in this project.  This practice was also approved 
by the Mater Health Services HREC.  The Plac MSC sourced by the ASC team were 
sourced from consented healthy donors undergoing caesarean section at Mater Hospital.   
4.2.2 Model of H2O2 induced HK2 injury 
As described in Chapter 3, HK2 cells were cultured in DMEM F12 with 10% FCS and 1% 
PSG and when 90% confluent, seeded into experimental plates at 1x104 cells/cm2. 
Experiments were performed 24 hours after seeding, when HK2 cells were shown to have 
formed a confluent monolayer.  Standard media was replaced with 0.6mM H2O2 media or 
standard media (control) according to the experimental protocol.  Analysis occurred 24 
hours after exposure to H2O2 in all experiments.  
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4.2.3 Isolation and culture of human MSC 
4.2.3.1 Isolation of MSC from healthy bone marrow  
15-20ml bone marrow was obtained from healthy donors and delivered to the laboratory in 
EDTA tubes.  Up to 10ml each was then transferred into 50ml Falcon tubes and the EDTA 
tube was washed twice with 3ml PBS and added to the Falcon tube, ensuring collection of 
all cells in the specimen.  All falcon tubes were topped up to 35ml with PBS.  Each tube 
was then underlaid with 15ml Ficoll (GE Healthcare) and centrifuged at 535g (1600rpm) at 
20°C for twenty minutes, ensuring that no brake was applied.  This resulted in formation of 
a buffy layer, or interface cells.  These cells were carefully removed with a 5ml pipette and 
transferred to a 50ml Falcon tube, centrifuged in PBS and spun at 535g for 10 minutes 
with brake.  A second wash then occurred followed by 5 minutes centrifugation with brake, 
discarding the supernatant on both occasions.  The pellet was resuspended in 10ml 
DMEM (low glucose) (DMEMLG) (Invitrogen) with 20% FCS and 1% PSG and incubated in 
a T75 culture flask (Nunc) at 37°C in 5% carbon dioxide (CO2).  It was usual to have 
several million cells at this point, although variation between donors was noted.  The 
media was discarded and washed with PBS at 72 hours and then replaced with standard 
media.  Media was replaced every 3-4 days until cell cultures were 70-80% confluent. 
4.2.3.2 Isolation of MSC from human placenta 
MSC isolated from human placenta were kindly donated to this project by the ASC Team, 
MMRI.  The placenta had been retrieved from consented healthy donors after caesarean 
section.  In the laboratory the placenta was dissected, washed to remove excess cord 
blood and then incubated with DMEMLG, 100U/ml Collagenase type I (Worthington 
Biochemical Corporation) and 5μg/ml DNase I (Roche) on a shaker (220rpm, 37°C) for 2 
hours.  Tubes were then centrifuged at 540g for 5 minutes and filtered through 70μm 
filters.  The cell suspension was then resuspended in PBS and washed before being 
resuspended in 30ml PBS and underlaid with 15ml Ficoll as described above.  The 
interface was removed and cells were cultured in standard MSC media (DMEMLG, 20% 
FCS and 1% PSG). Cells were donated from the ASC Team at the point of initial 
incubation in a T75 flask, or from liquid nitrogen storage at low passage. 
63 
 
4.2.3.3 MSC cell culture 
Once cells reached approximately 70-80% confluence, they were passaged and expanded 
using standard cell culture techniques (see Chapter 3.2.2).  Standard media for human 
MSC (bone marrow and placenta) was DMEMLG with 20% FCS, 1% PSG.  Given that 
experiments in this chapter required co-culture of HK2 and MSC and it was important for 
analysis that the media was consistent, MSC were tested for viability after 24 hours of 
culture in DMEM/F12 with 10% FCS and 1% PSG (HK2 standard media).  Viability was 
assessed by trypan blue counting and also by flow cytometry with AV and PI.  It was found 
that 24 hours in HK2 cell standard media did not adversely affect cell survival (data not 
shown).  Therefore during the pre-experiment phase of cell culture, MSC were grown in 
DMEMLG with 20% FCS.  However all experiments were performed in HK2 standard media 
from the application of H2O2 to analysis.  
4.2.3.4 Culture of MSC stimulated by inflammatory cytokines 
BM MSC were cultured in standard MSC media as described.  24 hours prior to the 
experiments, they were seeded into 24 well plates or the inserts of a 12 well transwell 
plate (Corning) at a concentration of 1 x 104 cells per well.  For the experimental condition 
of stimulated MSC, TNFα and IFNγ were added to each well at the time of cell seeding at 
a concentration of 10ng/ml (TNFα and IFNγ were kindly donated by Cancer 
Immunotherapies Team, MMRI).  Thus by the time the MSC were applied in the 
experiment, they had been exposed to TNFα and IFNγ for 24 hours.  
4.2.3.5 Preparation of MSC-CM 
Some experiments used MSC-CM instead of direct application of MSC.  24 hours prior to 
experiments, MSC had been seeded into 24 well plates and transwell plates.  At 24 hours, 
this media was removed to be replaced with H2O2 containing media.  The media removed 
from the MSC was not discarded, but combined into a 50ml Falcon tube and centrifuged at 
350g for 5 minutes at 4°C to ensure that any cells within the media were not collected.  
The supernatant was then filtered through a 40μm cell strainer.  To ensure that cells were 
still exposed to the nutrients of fresh media, the resultant product was diluted with fresh 
standard media so that the final conditioned media product was 2/3 media previously 
exposed to MSC and 1/3 standard media.  This media was then used in experiments with 
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0.6mM H2O2 instead of standard media where appropriate. For control purposes, 
experimental wells were also exposed to MSC-CM without H2O2. 
4.2.3.6 Characterisation of human MSC 
MSC were characterised according to the minimal criteria for MSC, as defined by the 
International Society of Cellular Therapies (14).  Three criteria were utilised: firstly the 
ability to be isolated by plastic adherence in culture, with a characteristic fibroblastic type 
appearance on light microscopy; secondly the expression of a specific pattern of cell 
surface markers and thirdly, multipotentiality with the ability to be differentiated into 
adipocytes, osteocytes and chondrocytes with appropriate stimulation.     
Morphology 
By definition due to the cell culture techniques used, the cell population identified was 
plastic adherent.  Light microscopy was routinely used to assess morphology, confirming 
the fibroblastic type morphology of MSC. 
Immunophenotyping 
MSC were further defined by the expression of characteristic cell surface markers, which 
can be examined by incubating the cells with specific anti-human antibodies conjugated to 
fluorescent markers and analysed by flow cytometry.  In detail, dilutions of 1-5μg/ml of 
antibody or matched isotype controls were prepared in antibody staining buffer (0.5% 
bovine serum albumin (BSA, Invitrogen) and 2mM ethylenediaminetetracetic acid (EDTA, 
Sigma-Aldrich-Aldrich) in PBS).  Pellets of 1 x 107 MSC were then resuspended in 100μl of 
the antibody dilution and incubated for 30 minutes at 4°C while protected from light.  
Excess antibody was removed by washing with the antibody staining buffer and then 
centrifuged, with the supernatant being discarded.  The pellet was resuspended in 
appropriate volume of the antibody staining buffer for analysis.  Cell viability was 
determined by adding 1μg/ml of 7-Amino Actinomycin ten minutes prior to analysis.  Table 
4.1 shows the antibodies used for analysis of cell surface expression of human MSC.  All 
anti-human antibodies were raised in mice and sourced from BD Biosciences (except 
CD105 and CD29, sourced from eBiosciences).   
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Table 4.1: Human antibodies used for the immunophenotyping of human MSC.  (FITC = Fluorescin 
Isothiocyanate, PE = Phycoerythrin, PE Cy7 = PE cyanine-7 dye, APC = Allophycocyanin, APC Cy7= APC 
cyanine-7 dye) 
Antibody to:  Otherwise known as: Label / Fluorophore* Isotype 
CD55 Complement Decay Accelerating Factor (DAF) FITC IgG2a 
CD29 Integrin beta 1  FITC IgG1 
CD146 Melanoma Cell Adhesion Molecule (MCAM) FITC IgG1 
CD106 Vascular Cell Adhesion Molecule 1 (VCAM1) PE IgG1 
CD73 Lymphocyte maturation marker PE IgG1 
CD166 Activated leukocyte Cell Adhesion Molecule (ALCAM) PE IgG1 
CD44 Cell surface glycoprotein PE Cy7 IgG2b 
CD90 Thymus Cell Antigen (Thy-1) APC IgG1 
CD105 Endoglin (component of TGFβ receptor 1 complex) APC IgG1 
CD117 c-kit (glycoprotein receptor for stem cell factor) APC IgG1 
CD45 Leukocyte common antigen  APC Cy7 IgG1 
 
After cell staining, cell analysis was undertaken by fluorescence-activated cell sorting 
(FACS) on an LSR II flow cytometer (BD).  BDTM CompBeads (BD) were used according to 
the manufacturer’s instructions to minimise the effect of spectral overlap.  Once 
compensation had been performed, samples were individually run through the LSR II, with 
a minimum of 5 x 104 events collected for each sample.  Compensation was then checked 
and collected data analysed using the software programme FlowJo (Tree Star, 
Incorporated). 
Functional Capacity 
To test the functional capacity of MSC, the cells were induced to differentiate into 
osteocytes, adipocytes and chondrocytes using standard protocols (141). Observation of 
this differentiation confirmed MSC multipotency.  All experiments for differentiation 
included negative controls, where cells were seeded in the same way but maintained with 
standard media rather than differentiation media.  They were then stained in an identical 
manner to the test group, to confirm the lack of background uptake. 
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Osteocyte Differentiation 
To induce differentiation into osteocytes, MSC were plated at 1 x 104 per well into a 24 
well plate with DMEMLG, 20% FCS and 1% PSG.  When the cells were 100% confluent, 
the media was replaced by osteocyte differentiation media (Table 4.2).  The plate was 
incubated at 37°C in 5% CO2.  Media was replaced by fresh ‘osteocyte media’ twice 
weekly for three weeks, at which time the plates were fixed with 4% paraformaldehyde 
(PFA) and stained with Alizarin red.  Alizarin red is used to identify calcium in tissue 
sections, as calcium forms an Alizarin red S-calcium complex.  To stain the cells with 
Alizarin red, a fresh solution was made up of 0.5g Alizarin red-S, 50ml water and 0.5% 
ammonium hydroxide.  Once the solution was mixed, the pH was adjusted to 4.1-4.3 using 
0.5% ammonium hydroxide.  All wells in the plate were covered with the solution for 1-3 
minutes and then excess stain was removed from the slide and the wells were washed 
with distilled water.  Plates were photographed immediately to prevent drying and ensure 
valid results. 
     Table 4.2:  Osteocyte Differentiation Media 
Reagent for Osteocyte Differentiation Reagent Source Final Concentration 
DMEM Invitrogen  
Dexamethasone  
(8mM stock, held in laboratory at 0.8mM) 
Sigma-Aldrich 0.1μM 
β-Glycerol Phosphate (1M) Sigma-Aldrich 10mM 
L-Ascorbate-2-phosphate (200mM) Sigma-Aldrich 200μM 
FCS Invitrogen 10% 
PSG Invitrogen 1% 
Calcium chloride (1M) Sigma-Aldrich 4mM 
 
Adipocyte Differentiation 
To induce differentiation into adipocytes, cells were seeded as described above.  When 
cells were 70% confluent, the standard media was replaced with ‘adipocyte differentiation 
media’ (Table 4.3).  Cells were incubated at 37°C in 5% CO2 and media was changed 
twice weekly, with fresh ‘adipocyte media’ being applied each time.  Between 2 and 3 
weeks the media was discarded and the cells were fixed with 4% PFA and stained with 
Oil-red-O (0.7g in 100ml) as per protocol.    After the PFA was removed and cells were 
rinsed in distilled water they were further rinsed with 60% isopropanol, covered with Oil-
red-O solution for 30 minutes and washed again with 60% isopropanol and then distilled 
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water.  They were then washed in gently running water and left to air dry.  Plates were 
photographed within 30 minutes to prevent drying. 
        Table 4.3: Adipocyte Differentiation Media 
Reagent for Adipocyte Differentiation Reagent Source Final Concentration 
DMEM Invitrogen  
IBMX 500mM 
(3-isobutyl-1-methylxanthine) 
Sigma-Aldrich 0.5mM 
Indomethacin (25mM) Sigma-Aldrich 60μM 
Dexamethasone  
(8mM stock, held in laboratory at 0.8mM) 
Sigma-Aldrich 1μM 
Insulin (10mg/ml) Sigma-Aldrich 5μg/ml 
FCS Invitrogen 10% 
PSG Invitrogen 1% 
 
Chondrocyte differentiation 
For chondrocyte differentiation, MSC were seeded at 1 x 105 cells in 100μl of standard 
media per well into a 96 well V-bottom plate.  The plate was then centrifuged for 3 minutes 
at 300g.  The supernatant was carefully removed so as not to disturb the pellets and 100μl 
of ‘chondrocyte differentiation media’ (Table 4.4) was added to each well without 
resuspending the pellets.  The plate was then transferred to an incubator and the media 
was changed twice weekly without resuspension of pellets.  After three weeks, the pellets 
were snap frozen in optimum cutting tissue compound (OCT) on dry ice and sectioned 
using a cryostat at -20°C.  The sections were then fixed with 4% PFA and Alcian blue 
staining was used to confirm presence of acid muco-substances and acetic mucins, seen 
in cartilage.  Firstly, slides were covered in fresh filtered 1% Alcian blue 8 in 3% acetic acid 
(pH 2.5) for 10 minutes, before being rinsed in running water.  Slides were then 
counterstained with 0.1% nuclear fast red solution (0.1g nuclear fast red and 5g 
ammonium sulphate in 100ml distilled water) for 1-2 minutes.   
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     Table 4.4: Chondrocyte Differentiation Media 
Reagent for Chondrocyte 
Differentiation (stock concentration) 
Reagent Source Final Concentration 
DMEM Invitrogen  
L-Ascorbate-2-phosphate (200mM) Sigma-Aldrich 200μM 
Sodium Pyruvate (100mM) Sigma-Aldrich 1mM 
Dexamethasone  
(8mM stock, held in laboratory at 0.8mM) 
Sigma-Aldrich 0.1μM 
Proline (40mg/ml) Sigma-Aldrich 40μg/ml 
TGFβ3 (10μml) R & D 10ng/ml 
ITS (insulin, transferrin, selenium, 50mg/ml) BD Biosciences 5μg/ml 
PSG Invitrogen 1% 
 
4.2.4 Experimental protocols 
4.2.4.1 Co-culture of HK2 cells and MSC 
To test the direct effect of MSC a co-culture system was used.  In this system 24 well 
plates were used.  1 x 105 HK2 cells per well were seeded at the same time as 1 x 104 
MSC per well and co-cultured for 24 hours prior to the onset of the experiment and H2O2 
exposure.  Experiments were analysed by LDH cytotoxicity as described in Chapter 3.  
4.2.4.2 Indirect exposure of HK2 cells to MSC: A transwell model 
A model of indirect exposure to MSC was developed using a transwell plate (Costar® 
Transwell® Inserts, Corning) (Figure 4.1).  For most experiments, a 12 well transwell plate 
was used.  The porous inserts for this plate are the same size as a 24 well plate and were 
seeded with the cell density and media volume used in a 24 well plate.  Transwell 
membranes used were polyester, with a membrane thickness of 10μm and pore sizes of 
0.4 μm.  The small pore sizes were chosen to inhibit cell migration but to allow diffusion of 
media, cytokines and other released factors between the two wells.  Preliminary 
experiments found that HK2 cells did not consistently form a tight monolayer with the 
characteristic cobblestone appearance when seeded into the insert (data not shown).  It 
was therefore decided to seed the HK2 cells into the lower layer of the transwell plate and 
MSC to the upper plate.     
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Figure 4.1: Graphic of a transwell system, with a standard lower well seeded with HK2 cells and an insert 
insert polyester membrane seeded with MSC.  As is seen, media can freely travel between wells but the 
cells cannot migrate. 
Each experiment was set up in the same way. 24 hours prior to administration of H2O2, 2 x 
105 HK2 cells / well were seeded into a 12 well plate in 1ml standard media (Figure 4.2) . 
At the same time, 1 x 104 MSC / well were seeded into the upper inserts of a 12 well 
transwell plate in 0.5ml media (with 1ml MSC standard media alone in the lower wells).  All 
plates were returned to incubate for 24 hours.  At that time, the transwell inserts containing 
MSC were transferred to the HK2 12 well plate and all media was replaced with either HK2 
standard media (controls) or 0.6mM H2O2.  It is acknowledged that this model allows the 
MSC to be exposed to H2O2, leading to a risk of MSC damage.  However, it was shown in 
Chapter 3 that early intervention was necessary to protect the HK2 cells from injury, so 
early exposure to MSC was important.   
 
Figure 4.2: At the time of H2O2 application, the insert containing the MSC is transferred to the plate 
containing the HK2 cells, giving a standard transwell indirect system for the remainder of the experiment. 
4.2.4.3 Experimental conditions 
Each experiment was set up with untreated controls, and the untreated controls were 
tested in a separate plate to ensure separation from H2O2.  All experimental conditions 
were tested in triplicate.  For the purposes of this chapter, experimental conditions 
included: HK2 cells alone; HK2 cells with BM MSC; HK2 cells with Plac MSC; HK2 cells 
with BM MSC stimulated with IFNγ and TNFα (4.2.3.4); HK2 cells with BM MSC-CM; HK2 
cells with Plac MSC-CM and HK2 cells with MSC-CM taken from BM MSC stimulated with 
IFNγ and TNFα (4.2.3.5).  The experiments were predesigned to test these experimental 
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conditions in parallel and analyse the data separately.  Multiple donors of BM MSC and 
Plac MSC were used to allow for the heterogeneity between humans.  MSC were used 
between passage (P) 1 and P5 for BM MSC and between P1 and P8 for Plac MSC.  
Preliminary experiments found that the growth in culture of BM MSC slowed considerably 
after P5, although Plac MSC continued to grow well in culture until higher passages.  
Direct experiments comparing P1 and P8 Plac MSC found no difference between the two 
conditions (data not shown).  Each experiment was performed between 3 and 6 times over 
a period of months.  Some experimental conditions were only reported as pooled data for 
two experiments. 
4.2.4.4 Analysis of H2O2 induced cell damage 
Experiments performed in the transwell model were analysed using AV and PI according 
to the methods described in Chapter 3 (3.2.3.3).  24 hours after the H2O2 was applied, the 
upper well inserts containing the MSC were discarded.  The media was removed from the 
HK2 cells and reserved in labelled eppendorfs.  The adherent cells were detached with 
TryPLE Select and resuspended with the media from the original well.  This ensured 
collection of detached dead cells as well as adherent live and damaged cells.  This cell 
suspension was centrifuged to form a pellet and resuspended in DMEM and incubated 
with AV and PI before being analysed by the LSR II.  Results are presented in four parts.  
Firstly, the total contribution of live, apoptotic and necrotic cells for each condition are 
presented in one graph as an overview.  Then each possible outcome is shown separately 
with statistical analysis. 
Experiments performed in the co-culture model were assessed for cell damage by LDH 
content, analysed by spectrophotometry as described in Chapter 3 (3.2.3.2).  Results are 
presented as the percentage of cytotoxicity compared to control.  In these experiments, 
HK2 cells exposed to H2O2 media have been set as the control and using the formula 
presented in Chapter 3 will approximate 100%.  Therefore it is possible for the ‘percentage 
of cytotoxicity compared to control’ to be either above or below the control of HK2 alone.   
4.2.5 Statistical analysis 
All statistical analysis was performed using the software program GraphPad Prism, version 
6 (Graphpad Software Inc., La Jolla, USA).  Data were analysed by 1 way ANOVA in all 
circumstances and multiple comparison tests were then done using Tukey’s post-hoc test.  
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Unless otherwise stated, results are reported as mean ± SEM.  95% confidence intervals 
are presented to show the reliability of the results. With respect to the flow cytometry data, 
where results represent a percentage of the total cell population, if the confidence interval 
was below 0%, it was reported as 0%.  Conversely, if the confidence interval was above 
100%, it was reported as 100%.  Results were considered statistically significant if p<0.05, 
and are visually represented as * p<0.05, ** p<0.01 and *** p<0.0001.      
4.3 Results 
4.3.1 Isolation and characterisation of human BM MSC and Plac MSC 
4.3.1.1 Morphology of BM MSC and Plac MSC 
BM MSC and Plac MSC were indistinguishable on light microscopy, as shown in Figure 
4.3.  The characteristic fibroblastic type morphology was clearly evident at all levels of 
confluence and all passages. 
 
Figure 4.3: Representative photographs of MSC morphology (Light Microscopy: 100x magnification).  (A) 
Human bone marrow derived MSC (B) Human placenta derived MSC. 
4.3.1.2 Immunophenotyping of BM MSC and Plac MSC 
Immunophenotyping was remarkably consistent between BM MSC and Plac MSC, and 
consistent with results reported in the literature.  Both BM MSC and Plac MSC were 100% 
positive for CD29, CD44, CD73 and CD166.  They were more than 95% positive for CD55, 
CD90, CD105 and CD106.  Both BM MSC and Plac MSC were 100% negative for CD117 
(c-kit) and CD45.  The only cell surface marker which exhibited differences between the 
two MSC populations was CD146, where Plac MSC tended to have a smaller population of 
cells positive for CD146 (approximately 80%) than BM MSC (approximately 90%).  Figure 
4.4 shows representative images of this data. No significant changes were seen in cell 
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surface marker expression from passage 1 to 5 (BM MSC) and passage 1 to 8 (Plac MSC) 
(data not shown). 
 
Figure 4.4: Representative data from immunophenotyping of MSC in BM MSC and Plac MSC.  Negative 
isotype controls are seen in black, BM MSC in blue and Plac MSC in red.   Both cell populations are positive 
for CD 44 (A), CD73 (B), CD 105 (C) and CD90 (D).  Although both cell populations are positive for CD146, a 
difference is seen between the two groups (E).  Cells are negative for CD117 (F). 
4.3.1.3 Functional capacity of BM MSC and Plac MSC 
Both BM MSC and Plac MSC, under the appropriate stimulating media, were able to 
differentiate into osteocytes and adipocytes.  This was confirmed at all passages from P1-
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P5 (BM MSC) and P1-P8 (Plac MSC) by cell staining as described in 4.2.3.6  
Representative photographs are shown in Figures 4.5 and 4.6.  It was consistently noted 
that Plac MSC did not take up the stain for adipocytes as avidly as BM MSC and the 
significance of this is unclear.  Chondrocyte differentiation in these cell populations was 
confirmed using the methods described in 4.2.3.6 (Heazlewood, ASC team, MMRI, data 
not shown).   
 
Figure 4.5: MSC differentiation into Adipocytes.  Stained with Oil-red-O after three weeks of culture in 
‘Adipocyte differentiation media’. Light microscopy (100 x magnification) (A) BM MSC, negative control (B) 
BM MSC showing adipocyte staining.  (C) Plac MSC, negative control (D) Plac MSC showing adipocyte 
staining. 
4.3.2 Transwell and co-culture experimental models  
As discussed in 4.2.4, experiments were performed in a transwell model and in a co-
culture model.  Figure 4.7 A shows the HK2 cells in the lower well of the transwell system, 
where they have formed a tight cobblestone monolayer suggesting healthy proximal tubule 
cells.  Figure 4.7 B shows the MSC after seeding into the insert of the transwell membrane 
plate.  In figure 4.7 C, the co-culture model is pictured, and on light microscopy, the normal 
phenotype of HK2 cells can be seen mixed with the larger fibroblastic spindle-shaped 
MSC. 
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Figure 4.6: MSC differentiation into Osteocytes.  Stained with Alizarin red after three weeks of culture in 
‘Osteocyte differentiation media’. Light microscopy (100 x magnification) (A) BM MSC, negative control (B) 
BM MSC showing osteocyte staining.  (C) Plac MSC, negative control (D) Plac MSC showing osteocyte 
staining. 
   
Figure 4.7: Examples of the models used in the study:  (A) HK2 cells in the lower well of a transmembrane 
plate (B) MSC in the upper well/insert of a transmembrane plate (C) Co-culture of HK2 cells and MSC.  All 
images from light microscopy, 100 x magnification. 
4.3.2.1 BM MSC vs Plac MSC in model of H2O2 induced HK2 cell damage 
BM MSC were directly compared with Plac MSC in a transwell model and analysed by flow 
cytometry (Figure 4.8 A).  After 24 hours of exposure to H2O2, 41.8 ± 10.81% of HK2 cells 
remained alive (95% confidence interval (CI) 8.7-75%).  Although there was a trend to an 
increase in live cells in the HK2 groups indirectly exposed to BM MSC (53.8 ± 3.9%, 95% 
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CI 36.9-70.7%), this was not statistically significant (p>0.05).  No change in the proportion 
of live cells was seen in the HK2 groups exposed to Plac MSC (41.4 ± 9.2%, 95% CI 1.8-
81%, p>0.05) when compared to HK2 cells alone.  Importantly, there was no statistically 
significant difference between the BM MSC and the Plac MSC (Figure 4.8 B). 
Damaged cells in this model were analysed as being apoptotic (AV positive, PI negative) 
or necrotic (AV positive, PI positive).  Note that the population labelled as “necrotic” 
included cells which had undergone primary necrosis as well as late apoptotic cells, or 
cells that began with apoptosis and then developed secondary necrosis.  In this model, it 
was not possible to differentiate these two groups.  Concomitantly to the results seen in 
the live cell population in this experiment, there was a trend to a reduction in apoptotic 
cells in the BM MSC group (23.7 ± 4.7%, 95% CI 3.6-43.9%) when compared to HK2 cells 
alone (32 ± 2.7%, 95% CI 23.5-40%) (p>0.05).  There was no difference found in the 
proportion of apoptotic cells at 24 hours in HK2 cells exposed to Plac MSC (35.0 ± 12%, 
95% CI 0-86.6%) when compared to HK2 cells alone (p >0.05) (Figure 4.8 C).   
There was no difference seen in the proportion of necrotic cells in any of the three groups.  
BM MSC exposed HK2 cells were 22.5 ± 7.7% necrotic (95% CI 0-55.5%) compared to 
23.7 ± 2.8% (95% CI 11.5-35.8%) in the Plac MSC exposed HK2 cells.  HK2 cells alone 
had a mean proportion of necrotic cells of 26.2 ± 11.1% (95% CI 0-61.5%), p>0.05 for all 
comparisons (Figure 4.8 D).   Again, importantly, there was no significant difference 
between BM MSC and Plac MSC.  Note that data presented here represent pooled data 
from 4 experiments, with multiple MSC donors. 
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Figure 4.8: Proportion of live, apoptotic and necrotic HK2 cells after culture with media containing 
0.6mM H2O2 for 24 hours.  Analysis by AV and PI staining with flow cytometry.  Comparative data 
presented from three experimental conditions:  HK2 cells alone (HK2); HK2 cells exposed indirectly to BM 
MSC (HK2/BM MSC) and HK2 cells exposed indirectly to Plac MSC in a transwell model (HK2/Plac MSC). (A) 
Total distribution of cell populations (B) Percentage of live cells, (C) Percentage of apoptotic cells, (D) 
Percentage of necrotic cells,  Results reflect pooled data from 4 experiments, data presented as mean ± 
SEM, analysed by 1 way ANOVA with multiple comparisons (Tukey’s post-hoc test) using GraphPad Prism 6 
software.  P >0.05 for all graphs. 
The effect of BM MSC and Plac MSC on HK2 cells was also examined in a co-culture 
system.  Results from 4 experiments have been pooled and are shown in Figure 4.9.  As 
can be seen, co-culture with either BM MSC or Plac MSC did not significantly alter the 
cytotoxicity.  HK2 cells co-cultured with BM MSC developed 91.8 ± 13.2% (95% CI 49.8-
133.8%) cytotoxicity compared to control and HK2 cells co-cultured with Plac MSC 
developed 88 ± 6.5% (95% CI 60-116%) cytotoxicity compared to control (p>0.05).  There 
was no significant difference between the two groups of MSC in the effect on cell 
cytotoxicity. 
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Figure 4.9: HK2 cytotoxicity after exposure to 24 hours 0.6mM H2O2 with or without BM MSC and Plac 
MSC.  Percentage of cytotoxicity compared to control (HK2 cells alone) assessed by supernatant content of 
LDH measured by spectrophotometry after 24 hours of cell culture in media containing 0.6mM H2O2 with 
or without different MSC populations.  Results shown are pooled data from 4 experiments and analysed by 
1 way ANOVA with multiple comparisons (Tukey’s post-hoc test) using GraphPad Prism 6 software.  Data 
presented as mean ± SEM. p>0.05. 
4.3.2.2 Effect of MSC-CM on H2O2 induced HK2 cell damage 
The next goal was to assess the effect of media which had previously been exposed to 
healthy MSC on HK2 cells exposed to H2O2.  Given that no difference was found between 
BM MSC and Plac MSC as shown in 4.3.2.1, for the purposes of this experiment both BM 
MSC and Plac MSC were used in media preparation.  Results for these experiments 
reflect pooled data from 3 experiments and are presented as the mean ± SEM.  There was 
no appreciable difference in the proportion of live, apoptotic and necrotic cells in HK2 cells 
alone, HK2 cells exposed to MSC indirectly and HK2 cells exposed to MSC-CM (Figure 
4.10A) 
Figure 4.10 B specifically shows the results for live cells.  After 24 hours exposure to 
0.6mM H2O2, the wells of HK2 cells alone were found to contain 41.8 ± 10.4% live cells 
(95% CI 0-75%), compared to 47.4 ± 13% (95% CI 0-100%) for HK2 cells exposed to MSC 
and 48.1 ± 18.2% (95% CI 0-100%) for HK2 cells exposed to MSC-CM (p>0.05).  The 
wide confidence intervals reflect significant variation between experiments. 
Figure 4.10 C shows the results for apoptotic cells in this model in more detail.  Again the 
error bars are wide, more so in the MSCCM group, which makes interpretation difficult, but 
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no significant difference was found among the three groups.  Wells containing HK2 cells 
alone resulted in 32 ± 2.7% (95% CI 23.5-40.4) apoptotic cells, whereas wells containing 
HK2 cells exposed to MSC led to  30.4 ± 14.3% (95% CI 0-91.8)  apoptotic cells and wells 
containing HK2 cells exposed to MSC-CM 36.6 ± 17.3% (95% CI 0-100) (p>0.05).    
There was a reduction in necrotic cells in the MSC-CM group (15 ± 1.1%, 95% CI 10.3-
19.8%) compared to the control group (26.2 ± 11.1%, 95% CI 0-61.5%) but this was not 
statistically significant due to the wide variation between experiments in the control group 
(p>0.05, Figure 4.10 D).  Necrotic cells in the HK2/MSC group made up 22.2 ± 5.6% (95% 
CI 0-46.4%) of the total cell population (p>0.05 compared to the HK2 group). 
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Figure 4.10: Proportion of HK2 cell population alive, apoptotic or necrotic after exposure to 0.6mM H2O2 
for 24 hours with and without exposure to MSC or MSC-CM.  Analysis by AV and PI with flow cytometry. 
(A) Total distribution of cell populations. (B) Percentage of live cells at 24 hours (C) Percentage of apoptotic 
cells at 24 hours (D) Percentage of necrotic cells at 24 hours.  Results reflect pooled data from three 
experiments and are expressed as mean ± SEM.  Analysis performed using 1 way ANOVA and multiple 
comparisons (Tukey’s post-hoc test), p>0.05 for all graphs (GraphPad Prism 6).   
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The effect of MSC-CM on HK2 cell damage was also analysed by LDH and compared to 
direct exposure of HK2 cells to MSC in a co-culture model as well as HK2 cells alone.  As 
in the previous experiment, data are presented as “percentage cytotoxicity compared to 
control” where the control used was HK2 cells alone.  Results presented in Figure 4.11 
reflect pooled data from 5 experiments and also reflect data from both BM MSC and Plac 
MSC.  There was no difference in cytotoxicity between the HK2 alone group and the 
HK2/MSC group (HK2 alone: 97.6 ± 2.4% (95% CI 90-105%) vs HK2/MSC: 96.9 ± 6.8% 
(95 CI 78-115%), p>0.05).  However, there was a significant reduction in cytotoxicity in the 
MSC-CM group when compared with the control group (mean 47.6 ±10.9% (95% CI 17.5-
77.7%) (p < 0.01 when compared with HK2 alone).       
 
Figure 4.11: HK2 cytotoxicity after exposure to 24 hours 0.6mM H2O2 with or without MSC and MSC-CM.  
Percentage cytotoxicity compared to control (HK2 cells alone) after 24 hours exposure to 0.6mM H2O2 for 
24 hours, with or without MSC and MSC-CM, assessed by LDH release analysed on spectrophotometry.  
Results reflect pooled data from 5 experiments, presented as mean ± SEM.  1 way ANOVA, P=0.0013.  
Multiple comparisons performed by Tukey’s post-hoc test, p>0.05 for MSC compared to HK2 cells, p<0.01 
for MSC-CM compared to HK2 cells (GraphPad Prism 6 software). 
4.3.2.3 Effect of IFNγ and TNFα stimulated MSC on H2O2 induced HK2 damage  
Given the published literature suggesting the beneficial effect of ischaemic 
preconditioning, it was important to assess the effect of stimulating MSC with inflammatory 
mediators prior to exposing them to H2O2.  IFNγ and TNFα are known proinflammatory 
mediators and stimulators of MSC and were used in this experiment.  BM MSC were 
exposed to TNFα and IFNγ 24 hours prior to the onset of the experiment.  The media was 
then replaced with standard media containing H2O2.   
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There was no significant difference between the groups, although there was a trend to an 
increase in live cells and a reduction in apoptotic cells in the HK2 cells exposed to 
stimulated MSC (Stim MSC) (Figure 4.12 A).  Data presented represent pooled data from 
three experiments.  HK2 cells alone were found to have 55.0 ± 8.3% (95% CI 28.5 – 
81.6%) live cells after 24 hours exposure to H2O2 containing media.  This can be 
compared to 53.8 ± 3.9% (95% CI 36.9-70.7%) in the HK2/MSC group (p>0.05) and 67.36 
± 4.0 (95% CI 50-84.8%) in the HK2/Stim MSC group (p>0.05) (Figure 4.12 B).   
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Figure 4.12: Proportion of HK2 cell population alive, apoptotic or necrotic after exposure to 0.6mM H2O2 
for 24 hours with and without exposure to MSC or Stim MSC.  Analysis by Annexin V and PI with flow 
cytometry.  Results reflect pooled data from 3 experiments and are presented as mean ± SEM.  (A) Total 
distribution of cell populations in each experimental condition (HK2 cells alone, HK2 cells in indirect culture 
with MSC and HK2 cells in indirect culture with MSC that had previously been stimulated with 
proinflammatory mediators).  (B) Percentage of cells alive after 24 hours (p>0.05).  (C)  Percentage of cells 
apoptotic at 24 hours (p>0.05).  (D) Percentage of cells necrotic at 24 hours (p>0.05).  Statistical analysis 1 
way ANOVA with multiple comparisons by Tukey’s post-hoc test (GraphPad prism 6). 
With respect to apoptotic cells, 28.9 ± 3.6% (95% CI 17.6-40.3%) of cells from the HK2 
alone group were found to be apoptotic, versus 23.7 ± 4.7% (95% CI 3.6-43.9%) in the 
HK2/MSC group (p>0.05) and 17.4 ± 2.4% (95% CI 6.7-27.9%) in the HK2/Stim MSC 
group (p>0.05) (Figure 4.12 C).  There was no difference in the proportion of cells which 
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were necrotic, as 16 ± 4.9% (95% CI 0.5-31.5%) of cells from the HK2 group were necrotic 
compared to 22.5 ± 7.7 (95% CI 0-55.5%) in the HK2 MSC group (p>0.05) and 15.2 ± 1.6 
(95% CI 0-22.3%) in the HK2/Stim MSC group (p>0.05) (Figure 4.12 D). 
Stimulated BM MSC were also used in the direct co-culture model.  In this model, the MSC 
were stimulated at the time of seeding into plates, and therefore the HK2 cells in those 
wells would also have been exposed to IFNγ and TNFα for 24 hours.  IFNγ and TNFα 
containing media were removed at the time of addition of H2O2.  With respect to 
cytotoxicity as measured by LDH, there was no significant difference found between HK2 
alone (99.4 ± 2.9%, 95% CI 62-137%) and HK2/MSC (80.6 ± 15.2%, 95% CI 38.6-122.7%) 
or HK2/Stim MSC (88.6 ± 1.0%, 95% CI 76.4-100.9%) (p>0.05) (Figure 4.13).  Results 
reflect pooled data from 2 experiments. 
.
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Figure 4.13: HK2 cytotoxicity after exposure to 24 hours 0.6mM H2O2 with or without MSC and Stim 
MSC.  Analysis by LDH assessment with spectrophotometry. Results reflect pooled data from 2 
experiments, analysed by 1 way ANOVA, p>0.05. 
4.3.2.4 Effect of IFNγ and TNFα stimulated MSC-CM on H2O2 induced HK2 damage  
For the final experiment for this chapter, it was decided to look at the effect of MSC-CM 
from MSC that had been exposed to IFNγ and TNFα.  CM used for experiments was 
sourced from wells of MSC that had been exposed to IFNγ and TNFα for 24 hours and 
then prepared as described in 4.2.3.5.  Data shown in Figure 4.14 A were pooled from 3 
experiments.  There was no difference in the proportion of live HK2 cells after 24 hours 
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(Figure 4.14 B).  In the control group, 55 ± 8.3% (95% CI 28.5-81.6%) of cells were alive, 
compared with 51.7 ± 7.6% (95% CI 19.1-84.4%) in the HK2/stimulated MSC conditioned 
media (Stim MSC-CM) group (p>0.05).  There was a significant reduction in apoptotic cells 
in the HK2/Stim MSC-CM group (15 ± 1.9% (95% CI 7.0-23%) compared to 28.9 ± 3.6% 
(95% CI 17.6-40.3%), (p 0.02, Figure 4.14 C), but as this appears to be due to a non 
significant increase in necrotic cells (33.3 ± 6.2% (95% CI -6.7-60%) compared to 16.0 ± 
4.9% (95% CI 0.5-31.5%) p>0.05) (Figure 4.14 D) it is likely that it does not reflect true 
protection by Stim MSC-CM.   
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Figure 4.14: Proportion of HK2 cell population alive, apoptotic or necrotic after exposure to 0.6mM H2O2 
for 24 hours with and without exposure to Stim MSC or Stim MSC-CM.  Analysis by Annexin V and PI with 
flow cytometry.  Results reflect pooled data from 3 experiments and are presented as mean ± SEM.  (A) 
Total distribution of cell populations in each experimental condition (HK2 cells alone, HK2 cells in indirect 
culture with MSC previously stimulated with proinflammatory mediators and HK2 cells in direct culture 
with media that had been preconditioned by MSC stimulated with proinflammatory mediators).  (B) 
Percentage of live cells after 24 hours (p>0.05).  (C)  Percentage of apoptotic cells at 24 hours (p = 0.02).  (D) 
Percentage of necrotic cells at 24 hours (p>0.05).  Statistical analysis 1 way ANOVA with multiple 
comparisons by Tukey’s post-hoc test (GraphPad prism 6). 
The same model was used to examine cell cytotoxicity with LDH release.  Results reflect 
pooled data from 2 experiments only.   There is no difference between the three groups 
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examined (Figure 4.15).  HK2 cells alone were used as the high control and that is 
reflected in the cytotoxicity of 99.9 ± 3.1% (95% CI 92.2-107.5%).  The mean cytotoxicity 
found in the HK2/Stim MSC-CM group was 79.7 ± 25.7% (95% CI 15.9-143.5%) which 
was no different from that found in the group exposed to Stim MSC (90.1 ± 2.7%, 95% CI 
83.4-96.8%) or from the control group (p>0.05). 
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Figure 4.15: HK2 cytotoxicity after exposure to 24 hours 0.6mM H2O2 with or without Stim MSC and Stim 
MSC-CM.  Data pooled from 2 experiments, expressed as mean ± SEM.  Results analysed by 1 way ANOVA 
and multiple comparisons (Tukey’s post-hoc test), P>0.05. 
4.4 Discussion 
The objectives of this study were to culture and characterise MSC, compare BM MSC with 
Plac MSC and to assess the efficacy of MSC in an in vitro model of proximal tubule cell 
IRI.  Firstly, MSC were characterised using standard techniques.  MSC displayed a typical 
morphology on light microscopy.  They expressed characteristic cell surface markers and 
importantly, did not express cell surface markers of other lineages, which might have 
indicated cell population contamination.  They were able to differentiate into adipocytes, 
osteocytes and chondrocytes. 
 Comparison was made between BM and Plac MSC.  ASC team, MMRI, has published on 
the characterisation of Plac MSC and BM MSC and found that both display 
immunosuppressive properties and are therefore suitable for use in this type of research 
(244). Previous published results (244) are consistent with the results of this study, in that 
BM MSC and Plac MSC were indistinguishable by light microscopy, but that Plac MSC 
consistently proliferated more rapidly and were able to be maintained in cell culture at 
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higher passages without alteration of their phenotype, thereby making them very suitable 
for research use.  However, there were some differences in differentiation ability and it was 
clearly shown in this study that Plac MSC do not take up adipocyte staining as avidly as 
BM MSC.  This is consistent with previous published work from our laboratory which found 
that using the same assay Plac MSC appeared less able to differentiate into adipocytes.  
However, when further analysed, mRNA expression of PLIN (an adipocyte lineage specific 
marker) was clearly observed in both BM MSC and Plac MSC (244). Therefore it was 
concluded that the cell populations derived from both bone marrow and placenta 
expressed characteristic properties of MSC and would be suitable for use in further 
experiments.  This was desirable, as placentae are readily available in our institution, 
donated to research by healthy mothers giving birth by caesarean section.  Acquiring bone 
marrow is obviously a more invasive procedure, particularly when obtained from healthy 
donors who would not otherwise require a bone marrow aspirate. 
 The efficacy of BM MSC and Plac MSC in protection against H2O2 induced HK2 damage 
in the model developed in Chapter 3 was explored.  The original hypothesis was that MSC 
in vivo act by altering the response of the immune system to the ischaemic injury, inhibiting 
DC maturation and skewing the Th phenotype towards an anti-inflammatory Th2 
phenotype.  It could therefore not be expected to find a protective effect in a system 
containing only proximal tubule cells and MSC.  However, MSC themselves do release 
inflammatory mediators which may also have a direct effect on the HK2 cells, so it was 
important to assess the response independently.  Neither BM MSC nor Plac MSC 
increased the proportion of viable HK2 cells 24 hours after exposure to 0.6 mM H2O2.  
These results were seen with HK2 cells directly exposed to MSC in a co-culture model and 
with HK2 cells indirectly exposed to MSC in a transwell model.   Although there were small 
alterations in the populations of dead cells, wide variation was seen between experiments 
and no conclusion could be drawn.  Using a different model and a different method of 
analysis, it was shown that there was no significant difference in cytotoxicity as assessed 
by LDH release in HK2 cells exposed to BM MSC or Plac MSC.  Because of the lack of 
difference between the two cell populations, in further experiments results from both 
groups of MSC have been pooled.  In all experiments, multiple MSC donors were used. 
The next goal of this chapter was to assess the effect of MSC-CM on HK2 cell damage.   
Given that MSC are known to release growth factors and cytokines, it was considered 
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possible that merely exposing the HK2 cells to the supernatant from an MSC cell culture 
might protect them from damage.  There was no significant difference in the proportion of 
HK2 cells alive, apoptotic or necrotic with exposure to MSC-CM.  However, when 
cytotoxicity was analysed by LDH, there was a significant reduction in LDH release in HK2 
cells exposed to MSC-CM when compared to HK2 cells alone or HK2 cells exposed to 
MSC.  This is an interesting observation, as it could be assumed that HK2 cells co-cultured 
with MSC would, by definition, also be exposed to MSC-CM.  In considering the reason for 
the difference in the results, it should be noted that the seeding density of the HK2 cells 
was identical in all three experimental conditions (1 x 105) but the group with HK2 and 
MSC also contained 1 x 104 MSC in a co-culture, and it is known that MSC themselves 
have the potential to release LDH.  The MSC were also exposed to H2O2 due to the 
experimental protocol and it is possible that the MSC themselves were damaged and 
therefore released LDH.  Preliminary experiments did show LDH release in control wells of 
MSC alone (data not shown).  Therefore, it is possible that the significant improvement in 
HK2 cells exposed to MSC-CM alone may be a feature of the study design rather than a 
true effect of MSC-CM.  However, the result certainly requires consideration.   
MSC were then stimulated with IFNγ and TNFα to provide a ‘preconditioned’ environment.  
There appeared to be an increase in live cells and a reduction in apoptotic cells in the 
group exposed to Stim MSC, although this was not statistically significant and large 
confidence intervals suggest significant heterogeneity.  Wide confidence intervals are are 
seen consistently in the results presented in this chapter, despite the use of 2-3 MSC 
donors in each experiment, the fact that each experimental condition was tested in 
triplicate and the fact that each experiment was performed between three and six times.  
The most likely explanation for the large confidence intervals is that this study involves 
cells from human donors.  Although multiple donors were used, the total number of human 
MSC donors for this work was 10-15.  Individual variation in humans is well documented, 
and it was clearly seen throughout the course of this study that MSC from some donors 
proliferated well in culture and maintained high viability on thawing frozen stock, whereas 
MSC from other donors did not perform so well.  It is reasonable to postulate, therefore, 
that these MSC may also differ in their immunosuppressive or anti-inflammatory functions.   
Given the positive results found with MSC-CM on cytotoxicity, it was decided to further test 
the effect on HK2 cell damage by exposure to the supernatant of MSC stimulated by IFNγ 
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and TNFα (Stim MSC-CM).  There was no difference in the proportion of live cells after 
H2O2 exposure.  There was a substantial reduction in apoptotic cells in the group exposed 
to Stim MSC-CM but this was mitigated by an increase in necrotic cells suggesting an 
increase in overall damage to HK2 cells, which was unexpected.  In contrast to the 
cytotoxicity results seen with regular MSC-CM, there was no difference in cytotoxicity 
between HK2 exposed to Stim MSC and HK2 exposed to Stim MSC-CM.   
In conclusion, neither direct nor indirect exposure to MSC was found to be protective of 
HK2 in these models of ischaemic injury, although MSC-CM may have had a beneficial 
effect.  The next step in the inquiry into the role of MSC in an in vitro model of renal IRI 
was to examine the effect of both MSC and MSC-CM in the presence of dendritic cells and 
CD4 cells, and this was explored in Chapter 5.  
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Chapter 5 
Effect of mesenchymal stromal cells in an in vitro model 
of H2O2 induced HK2 damage in the presence of 
dendritic cells and CD4+ T cells 
5.1 Background and objectives 
As described in Chapter 2, there is good biological plausibility and background data to 
suggest that in vivo MSC interact with cells of the immune system, particularly dendritic 
cells.  It was the hypothesis of this work that by interacting with dendritic cells, MSC skew 
T helper cells (CD4+ cells) from a Th1 phenotype to a Th2 phenotype thereby altering the 
inflammatory milieu and protecting renal cells from damage.  It is not a straightforward 
proposition to examine this in vitro, as clearly complex processes are involved.  For the 
purposes of this study it was decided to expand the models described in Chapters 3 and 4 
to include specific cells of the immune system, namely DC and CD4+ cells, and assess the 
potentially modulating impact of these cells on the effect of MSC in the previously 
described models.  Given the suggestion of benefit of MSC-CM shown in the previous 
chapter, it was also decided to assess the effect of MSC-CM on HK2 damage in the 
presence of DC and CD4+ cells. 
With respect to the DC and CD4+ cells, there are a number of different possible methods 
for isolating relevant cells, each probably leading to a slightly different cell population.  In 
the literature reviewed in Chapter 2 studies certainly suggested DC play an important role 
in regulating the inflammatory milieu (136, 157-160).  However, it is likely that the DC 
taking on this role in renal IRI are resident within the kidney under normal circumstances.  
It is probable that there is movement between circulating mature DC and resident DC 
populations, but how and when this occurs is unclear.  In this work, DC were derived from 
PBMC by culturing monocytes in a specific media known to skew development into DC.  
Clearly these are not the same cells as renal resident DC and as they are immature cells 
they also do not reflect the population of circulating DC. However, they are easy to obtain, 
more plentiful and stable in cell culture for several days.  Mature DC can be isolated from 
peripheral blood but are very rare cells and so it was decided for this study to use 
monocyte derived DC for convenience. Therefore the objectives of the next phase of study 
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were as follows:  firstly to isolate and characterise monocyte derived DC and CD4+ cells; 
secondly to test the effect of DC and CD4+ cells without MSC exposure in the models 
previously developed; thirdly to test the effect of MSC co-culture with DC and CD4+ cells 
on H2O2 induced HK2 injury; and finally to assess the effect of MSC-CM on H2O2 induced 
HK2 injury in the presence of DC and CD4+ cells. 
5.2 Materials and methods 
5.2.1 Ethical considerations 
All experiments involving human cells were approved by the Mater Health Services HREC 
(Reference number MMRI # 44 Mater # 1262AM).  Both DC and CD4+ cells were sourced 
from PBMC isolated from peripheral blood donated by healthy volunteers.    
5.2.2 Model of HK2 injury 
The model of H2O2 induced injury developed in Chapter 3 and used to evaluate efficacy of 
MSC in Chapter 4 was used to assess the effect of cell exposure to DC and CD4+ cells.  
As in the previous chapter, a transwell model of indirect MSC exposure was used in 
addition to a co-culture model.  HK2 and MSC were seeded 24 hours prior to H2O2 injury, 
whereas DC and CD4+ cells were added to both models at the time of exposure to H2O2.  
24 hours after the H2O2 was applied analysis was performed for cell viability using the 
AV/PI flow cytometry method and cytotoxicity as assessed by LDH release 
(spectrophotometry).      
5.2.3 Isolation and culture of human MSC 
MSC used were both BM MSC and Plac MSC.  These cells were isolated, characterised 
and cultured as outlined in Chapter 4.  Multiple donors were used.  MSC-CM was prepared 
as described in 4.2.3.5.  
5.2.4 Isolation of human peripheral blood mononuclear cells 
Peripheral blood was donated by healthy individuals for research purposes.  The blood 
was received in the laboratory in standard blood donation bags of approximately 400ml 
and PBMC were isolated using aseptic techniques.  17.5ml of blood were added to 17.5ml 
of PBS (room temperature) in as many 50ml Falcon tubes required.  Each Falcon tube 
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was then mixed with a mixing cannula and gently underlaid with 15ml Ficoll.  Once all 
Falcon tubes had been underlaid with Ficoll they were centrifuged at 535g for 20 minutes 
at room temperature with the brake off to produce an interface of PBMC, with plasma 
above and granulocytes below.  The PBMC layer was then collected from each interface 
and transferred into fresh Falcon tubes up to a volume of 25ml.  Each Falcon tube was 
then topped up to 50ml with room temperature PBS and centrifuged at 300g for 10 
minutes at room temperature with the brake on.  At this point the supernatant was 
discarded and the pellets were resuspended in PBS and pooled into one Falcon tube 
which was then topped up to 50ml with PBS.  This tube was centrifuged for 10 minutes at 
300g at room temperature with the brake on, resuspended in PBS and re-centrifuged at 
300g for 5 minutes.  Cells were then counted at 1:50 dilution due to the high number of 
cells, and resuspended in cold magnetic activated cell sorting buffer (MACS buffer:  PBS + 
0.5% BSA and 2mM EDTA at pH 7.2).  At this point PBMC were aliquoted into eppendorfs 
at 50 x 106 cells per aliquot and frozen in DMSO if not required immediately, using 
standard cell culture techniques (Chapter 3, 3.3.2).    
5.2.5 Isolation and culture of dendritic cells 
To generate monocyte derived DC, monocytes must be first isolated from PBMC.  This 
protocol takes advantage of the monocyte cell surface marker CD14, and isolates CD14+ 
cells by positive selection using magnetic labelling.  PBMC were resuspended in cold 
MACS buffer (Miltenyi) at a concentration of 80μl per 1 x 107 cells.  CD14 Microbeads 
(Miltenyi) were added at a concentration of 5μl per 1 x 107 cells and incubated in the fridge 
for 15-20 minutes, before being topped up with MACS buffer to 50ml and centrifuged at 
300g for 10 minutes at 4°C.  The pellet was resuspended in 500μl MACS buffer.  CD14+ 
cells were then isolated with the auto MACS separator using the POSSELd program.  The 
positive fraction was centrifuged at 535g for 5 minutes at 4°C and resuspended in 10% 
complete AB medium (Table 5.1) at a concentration of 3.33 x 105 cells/ml. 
Aliquots of both the positive fraction (at least 1 x 103 cells) and the negative fraction (50μl) 
were then retrieved for flow cytometry analysis, to confirm purity of population.  For flow 
cytometry, three tubes of each were set up:  unstained cells; cells stained with 1.5μl IgG 
FITC Isotype control; and cells stained with 1.5μl antibody to CD14 on FITC.  Cells were 
incubated for 20 minutes in the fridge and then centrifuged for 5 minutes before being 
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resuspended in 200μl MACS buffer and run through the LSR II flow cytometer to analyse 
fraction of CD14+ cells in each group. 
Table 5.1: 10% complete AB medium  
Medium component Company of Origin 
Roswell Park Memorial Institute (RPMI) medium Invitrogen 
10% heat inactivated AB serum Invitrogen 
1% PSG Invitrogen 
1mM sodium pyruvate Invitrogen 
0.1mM non essential amino acids (NEAA) Invitrogen 
10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer solution Invitrogen 
50μM 2-mercaptoethanol Sigma-Aldrich 
 
Once confirmation was obtained of a pure CD14+ cell population, the cells were induced 
to differentiate into DC by the protocol in use by the Dendritic Cell Team at MMRI.  
granulocyte-macrophage colony-stimulating factor (GMCSF) was added to the culture in 
complete AB medium at a concentration of 800U/ml and IL4 was added at a concentration 
of 1000U/ml.  Both GMCSF and IL4 were obtained in aliquots from MMRI stock (GMCSF 
aliquot 5000U/μl, IL4 aliquot 444U/μl).  This culture was then seeded into a 6 well plate 
(3ml per well) at a seeding density of 1 x 106 cells per 3ml for 5-7 days 
After 5-7 days cells were counted and stained to confirm conversion to monocyte derived 
DC in culture.  Monocyte DC are negative for CD14 and CD3, but positive for HLA DR and 
CD11c.  Table 5.2 describes the antibody staining protocol for assessment of monocyte 
derived DC.  Phenotype was assessed by flow cytometry using the LSR II machine.  Note 
that monocyte derived DC were not found to store well in liquid nitrogen and were used 
fresh in every experiment. 
5.2.6 Isolation of naïve CD4+ T cells 
Naive CD4+ T cells were isolated by lineage depletion, or negative selection.  Briefly, the 
concept is that PBMC are incubated with mouse anti-human monoclonal antibodies which 
are expressed on cells that are not required.  These antibodies then bind to cells 
expressing those cell surface markers.  This mixture is then incubated with goat anti-
mouse IgG microbeads, which bind to the monoclonal antibodies and can be magnetically 
sorted by the autoMACS.  This mixture is then run through the autoMACS and the positive 
fraction is discarded, whereas the negative fraction is assumed to contain the cells of 
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interest.  To confirm the validity of this approach, the fraction prior to separation as well as 
the negative and positive fractions were characterised by cell surface marker staining 
using flow cytometry. 
Table 5.2: Template of antibody staining for confirmation of monocyte derived DC generation after 5-7 
days of monocyte culture with GMCSF and IL4. 
Tube type Cell 
No. 
Antibody Antibody 
concentration 
Antibody 
volume 
Unstained 1 x 103 None - - 
Isotype controls 1 x 103 Immunoglobulin G (IgG) FITC, IgG 
PE, IgG APC, IgG APC Cy7 
1:30 1.5μl each 
Test 1 x 103 
–  
1 x 105 
CD3 FITC 
CD14 PE 
HLA DR APC Cy7 
CD11c APC 
1:30 
1:30 
1:30 
1:50 
1.5μl 
1.5μl 
1.5μl 
1.0μl 
FITC Compensation 1 x 103 HLA DR FITC or CD11c FITC 1:30 1.5μl 
PE Compensation 1 x 103 HLA DR PE or 
CD11c PE 
1:30 1.5μl 
APC Compensation 1 x 103 CD11c APC 1:50 1.0μl 
APC CY7   Compensation 1 x 103 HLA DR APC Cy7 1:30 1.5μl 
 
It was decided to use a lineage depletion selection process because CD4+ cells do not 
maintain viability well either in culture or on thawing.  It was therefore important to use 
freshly isolated cells in the experiments.  A positive selection process with microbeads 
would lead to cells being used in experiments with IgG microbeads attached to them, 
which may potentially interfere with the function of the cell.  This was not an issue with the 
DC, as they had been in culture for 5-7 days after the beads were applied, giving them 
time to detach.  As described above, the CD4+ cells were not bound to either mouse anti-
human antibodies or to the IgG goat anti-mouse secondary antibody and therefore their 
function should have been normal.  
Specifically, to isolate naive CD4+ cells by lineage depletion, PBMC were resuspended in 
1ml cold MACS buffer per 1 x 108 cells.  The lineage depletion monoclonal antibodies 
were added in the concentration and volume shown in Table 5.3, and the volume was 
adjusted to the actual cell count (all monoclonal antibodies sourced from MMRI stock).  
Cells to be excluded from the final negative fraction included cells expressing CD8 
(cytotoxic T cells), CD11c (mature DC), CD14 (monocytes), CD19 (B cells), CD20 (B 
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cells), CD56 (NK cells), CD34 (haematopoietic cells), CD45RO (memory T cells), human 
leukocyte antigen – antigen D related (HLA DR) (antigen presenting cells) and CD235a 
(erythrocytes).  Once mixed, this suspension of cells and monoclonal antibodies was 
incubated on ice for 20 minutes and then washed in cold MACS buffer and resuspended in 
900μl of MACS buffer per 1 x 108 cells.  Prior to separation, 1μl was reserved for flow 
cytometry analysis. 
Table 5.3: Monoclonal antibody mixture required to isolate naïve CD4+ T cells by lineage 
depletion. All antibodies sourced from MMRI laboratory stock.  Note that volumes must be 
adjusted depending on cell count. 
Lineage depletion monoclonal antibodies Concentration Volume (if 1x 108 cells) 
CD8 0.81 μg/μl 2.5μl 
CD11c 0.2 μg/μl 10μl 
CD14 0.2 μg/μl 10μl 
CD19 0.2 μg/μl 10μl 
CD20 0.2 μg/μl 10μl 
CD56 5 μl/test 5μl 
CD34 0.05 μg/μl 40μl 
CD4+5RO 1.15 μg/μl 2μl 
HLA DR 0.29 μg/μl 5μl 
CD235a 0.5 μg/μl 4μl 
 
Goat anti-mouse IgG microbeads (Miltenyi) were then added at a concentration of 100μl 
per 1 x 108 cells and incubated on ice for 15 minutes.  Cells were then washed well with 
cold MACS buffer and resuspended at 1ml per 1 x 108 cells, mixing well to ensure a single 
cell suspension.  Naïve CD4+ T cells were then isolated with the autoMACS separator 
using the DEPL025 program.  Small aliquots of the negative and positive fractions were 
reserved for flow cytometry.  The negative fraction was then centrifuged at 535g for 5 
minutes at 4°C and resuspended in complete AB medium.  To test population purity, each 
of the three cell fractions (‘before purification’, negative fraction and positive fraction) were 
incubated with CD4+ FITC and CD45-RA PE, and run through the LSR II flow cytometer 
with their isotype controls and unstained cells.  Note that CD45-RA is a marker of naïve T 
cells.   
In early experiments, CD14+ cells were isolated by positive selection and put in culture to 
generate monocyte derived DC.  Then the negative fraction from this separation was used 
as the cell population to undergo lineage depletion to isolate naïve CD4+ T cells.  This 
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method was successful, but given that the T cells were used fresh and the DC required 5-7 
days in culture, this system only worked when experiments were planned 1 week apart.  It 
was also found that CD4+ cell yield was improved when isolated straight from PBMC, 
rather than after an earlier separation (data not shown), so in most experiments these cell 
types were isolated from different aliquots of PBMC.  However, to ensure that there was 
no immunological activation between DC and CD4+ cells, the PBMC used in each 
experiment were always from the same donor.  Multiple PBMC donors were used in this 
study, but each experiment only used one donor to ensure consistency.   
5.2.7  Experimental protocols 
Experiments were performed using the same models described in Chapters 3 and 4.  
Briefly, HK2 cells and MSC were seeded to 12 well transwell plates in an indirect model 
and to 24 well plates as a co-culture model.  Seeding densities remained unchanged from 
4.2.4.1 and 4.2.4.2.  After 24 hours, media was removed and replaced with media 
containing H2O2.  MSC-CM was prepared as outlined in 4.2.3.5 at this stage.  Immediately 
after the H2O2 media was applied, CD4+ cells and DC were added to wells at 4 x 103 cells 
per well.  In the transwell model, they were seeded into the insert, thereby being in direct 
contact with MSC but not with HK2 cells.  In the co-culture model they were seeded into 
the well of MSC and HK2 cells.  Experimental conditions included HK2 cells alone, MSC 
alone, HK2/CD4+, HK2/DC, HK2/CD4+/DC, HK2/MSC/CD4+, HK2/MSC/DC and 
HK2/MSC/CD4+/DC.  The effect of MSC-CM was also tested with CD4+ cells, DC and 
CD4+/DC.  All experiments were analysed 24 hours after exposure to H2O2 looking at cell 
viability outcome and cytotoxicity using methods previously described (Chapter 3). 
5.2.8 Statistical analysis 
All statistical analysis was performed using the software program GraphPad Prism, version 
6 (Graphpad Software Inc., La Jolla, USA).  Data were analysed by 1 way ANOVA in all 
circumstances, as results reflected three or more groups, assessing the response to one 
factor.  Multiple comparison tests were then done using Tukey’s test, as recommended by 
GraphPad Prism.  Unless otherwise stated, results are reported as mean ± SEM.  95% 
confidence intervals are presented to show the reliability of the results presented.  Results 
were considered statistically significant if p<0.05,and are visually represented as * if 
p<0.05, ** if p<0.01 and *** if p<0.0001.      
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5.3 Results 
5.3.1 Isolation and Characterisation of Monocyte derived Dendritic Cells 
5.3.1.1 Isolation of CD14+ monocytes from PBMC 
CD14+ cells were isolated from PBMC.  Purity was assessed by staining cells for the cell 
surface marker CD14 in both the ‘positive’ and the ‘negative’ fraction after positive 
selection by the autoMACS.  Results of a representative isolation are shown in Figure 5.1, 
where the negative fraction contained only 0.052% CD14+ cells and the positive fraction 
contained 95.1% CD14+ cells, showing excellent separation between the two groups and 
high cell purity.  Regarding cell yield, as an example, in one separation, 1.25 x 107 PBMC 
yielded 9.6 x 105 CD14+ cells.   
 
Figure 5.1: Assessment of cell population purity after positive selection for CD14+ cells using microbeads 
(Miltenyi).  (A) CD14+ cells in negative fraction (purple) compared to isotype control (green) (B) CD14+ cells 
in positive fraction (purple) compared to isotype control (green). The isotype control consistently had a 
dual peak of unknown origin. (C) Direct comparison of CD14 positivity in negative fraction (red) and 
positive fraction (blue) showing excellent purity. (D) Dot plot image of negative fraction showing 0.052% of 
cells in the positive range. (E) Dot plot image of positive fraction showing 95.1% of cells in the positive 
range. 
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5.3.1.2 Generation of monocyte derived DC from CD14+ cells 
The CD14+ cells were then put in culture for 5-7 days in complete AB medium with 
GMCSF and IL4.  When required for the experiment cells were harvested and phenotyped. 
Approximately 27% of cells were found to be dead on FACS analysis.  By gating for live 
cells by size, 99.2% of cells were negative for CD3 and CD14 (Figure 5.2 A) and 83.9% of 
cells were positive for CD11c and HLA DR (Figure 5.2 B) in a representative plot, 
suggesting good conversion to the DC phenotype.  No significant population was found 
expressing CD11c or HLA DR alone.  It was thought that the double negative population of 
approximately 16% represented dead cells as 32% of cells in the total population (before 
gating for live cells) were negative for CD11c and HLA DR. 
 
Figure 5.2: Phenotyping of monocyte derived DC after 7 days in culture with complete AB media, GMCSF 
and IL4, (A) Dot plot of CD14-PE (Y axis) and CD3-FITC (X axis) showing 99.2% of cells are negative for the 
monocyte and T cell markers.  (B) Dot plot of HLA DR-APC Cy7 (Y axis) and CD11c-APC (X axis) showing that 
83.9% of cells are positive for DC markers. 
5.3.2 Isolation and characterisation of CD4+ cells 
CD4+ cells were isolated by lineage depletion as outlined above.  Figure 5.3 shows 
representative dot plots of the phenotype in three cell populations analysed.  The first cell 
population analysed was the pre-purification fraction, which in this example was the 
negative fraction after a positive selection for CD14 purification.  Therefore, none of these 
populations would be expected to contain CD14+ cells, which alters the total proportion of 
the PBMC.  The second cell population analysed was the positive fraction for lineage 
markers, which is therefore the fraction expected to be CD4 negative, and hereafter will be 
called the ‘CD4 negative’ fraction.  The third cell population analysed was the negative 
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fraction for lineage markers, which is therefore the fraction expected to be CD4 positive 
and hereafter will be referred to as the ‘CD4 positive’ fraction.   
As shown in figure 5.3 A-C, the proportion of cells which were CD4 positive was 49.8% in 
the pre-purification fraction, 37.3% in the ‘CD4 negative’ fraction and 76.8% in the ‘CD4 
positive fraction’.  The significant proportion of CD4+ cells in the ‘CD4 negative’ fraction is 
explained by the presence of double positive cells (eg CD4/CD8 cells).  There was also a 
reasonable proportion of cells in the ‘CD4 positive fraction’ which were not CD4+.  These 
cells have not been further identified, and it is possible that some of these are dead cells.  
  
Figure 5.3 D-F shows representative results for CD45 RA labelling in each of the three 
fractions tested.  CD45 RA is an immature T cell marker, and it was found on 64.3% of the 
cells prior to purification, 55.8% of the ‘CD4+ negative’ fraction and 92.1% of the ‘CD4+ 
positive’ fraction.  There are many cells that co-express CD45 RA and other markers at 
times, for example cytotoxic CD8 T cells, memory T cells and also some CD56 cells.  The 
key reason for testing CD45 RA in this population was to ensure that the CD4+ cells 
isolated were not mature or activated T cells, but were immature, inactivated T cells.  Of 
the 76.8% CD4+ cells in the ‘CD4 positive’ fraction, 97.7% were also CD45 RA positive 
(data not shown). 
As shown in figure 5.3 G-I, where CD4 is on the X axis and CD45RA on the Y axis, 26.2% 
of the pre-purification fraction co-expressed CD4 and CD45RA.  This went down to 8.16% 
in the ‘CD4 negative’ fraction, suggesting that most of these cells, which were the cells of 
interest, had been collected.  72.8% of the ‘CD4 positive’ fraction co-expressed CD4 and 
CD45RA, indicating reasonable purity. 
Purity of the population and cell yield was further assessed using cell numbers. There 
were 39 x 106 cells in the original CD14 negative fraction that were incubated with the 
monoclonal antibodies.  If 26.2% of those were double positive for CD4 and CD45RA, then 
approximately 10.2 x 106 cells in the pre-purification fraction would be expected to be the 
cells of interest.  After separation there were 13.1 x 106 cells in the ‘CD4+ negative 
fraction’ and 8.16% of these cells were double positive, which implies 1 x 106 cells.  In the 
‘CD4+ positive’ fraction there were 8.5 x 106 cells, of which 72.8% co-expressed CD4+ 
and CD4+5RA, which can be estimated at approximately 6.2 x 106 cells.  This is 
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approximately 60% of the number of double positive cells found in the pre-purification 
sample.  Given that some of those cells would have been positive for other cell markers, 
this represented a good cell yield.        
rPre-purification fraction ion fraction ‘CD4+ negative’ fraction ‘CD4+ positive’ fraction 
 
 
Figure 5.3: Phenotype of a population of CD14 negative PBMC before and after lineage depletion to 
isolate naïve T cells.  (A) CD4+ positivity of the pre-purification fraction (B) Proportion of cells CD4 positive 
in the ‘CD4 negative’ fraction (C) Proportion of cells CD4 positive in the ‘CD4 positive’ fraction (D) 
Proportion of cells positive for CD45RA in the pre-purification fraction (E)  Proportion of cells positive for 
CD45RA in the ‘CD4 negative’ fraction (F) Proportion of cells positive for CD45RA in the ‘CD4 positive’ 
fraction  (G) Cells double positive for CD4 and CD45RA in the pre-purification fraction (H) Cells double 
positive for CD4 and CD45RA in the ‘CD4+ negative’ fraction (I) Cells double positive for CD4 and CD45RA in 
the ‘CD4 positive’ fraction. 
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5.3.3   Effect of DC and/or CD4+ cells on H2O2 induced HK2 cell damage without the 
presence of MSC 
The first thing to test was the independent effect of DC and CD4+ cells on damaged HK2 
cells.  Given that both types of cells would be expected to be activated by the H2O2 
induced HK2 cell damage, it is plausible that they may change the inflammatory milieu in 
and of themselves.  Data on cell viability presented in 5.3.3, 5.3.4 and 5.3.5 represent 
pooled data from 2 experiments, each performed in quadruplicate.  The cell cytotoxicity 
data from the co-culture experiments is presented from 4 experiments, in triplicate.   
There were no significant differences in cell outcome 24 hours after exposure to H2O2, 
regardless of the immune cells that the HK2 cells were exposed to (Figure 5.4).  There 
was significant variability within duplicate wells, leading to broad confidence intervals and 
large error bars.  Of the HK2 cells exposed to naïve CD4+ cells when damaged, 21 ± 
13.8% (95% CI -154-196%) were live at 24 hours compared to 32.9 ± 22.1% (95% CI -
248-314%) for HK2 (p>0.05).  The HK2/DC group also had a non-significant slight 
reduction in mean percentage of live cells compared to HK2 cells alone (24.9 ± 14.6% 
(95% CI -161-221%, p>0.05).  The results for the HK2/DC/CD4 groups were almost 
identical to that for HK2 alone (figure 5.4 B).   
No statistically significant difference in the proportion of apoptotic cells after 24 hours 
exposure to H2O2 was found in any group (Figure 5.4 C).  The HK2/CD4 group had 33.3 ± 
3.5% apoptotic cells at 24 hours (95% CI -11.6-78.2%), the HK2/DC group had 41.0 ± 
3.4% apoptotic cells (95% CI -2-83.8%) and the HK2/DC/CD4 group had 35.7 ± 5.2% 
apoptotic cells (95% CI -30.1-101.7%) compared to 30.0 ± 1.0% (95% CI 16.8-43.2%) for 
the HK2 alone group (p>0.05 for all comparisons).  
There was no difference found in the proportion of necrotic cells in any group (Figure 5.4 
D).  In the HK2 alone group, 37.1 ± 21.1% of cells were necrotic after 24 hours (95% CI -
231-305%).  In the HK2/CD4 group, 45.7 ± 17.3% of cells were necrotic (95% CI (-174-
265%) and in the HK2/DC group, this figure was 34.2 ± 11.3% (95% CI -109-177%).  In 
the group exposed to both CD4+ cells and DC, 32.4 ± 14.7% of cells were necrotic (95% 
CI -155-220%) (p>0.05 for all comparisons).     
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 A
D
B
C
Figure 5.4: HK2 cell outcome 24 hours after exposure to H2O2 with or without the presence of DC and 
CD4+ cells.  (A)  Overview of all outcomes in all conditions showing no significant differences between the 
groups.  (B) Proportion of live HK2 cells (P>0.05).  (C)  Proportion of apoptotic HK2 cells (P>0.05). (D) 
Proportion of necrotic HK2 cells (P>0.05).  All experiments analysed by 1 way ANOVA with multiple 
comparisons (Tukey’s test) using data pooled from 2 experiments (GraphPad Prism 6 software). 
The same experiments were performed in a co-culture and in this model the results were 
convincing, with small error bars and confidence intervals (Figure 5.5).  As in Chapter 4, 
the HK2 cells alone were used as the high control for cytotoxicity analysis.  Pooling of the 
data from a number of experiments meant that the value of cytotoxicity in this group was 
not quite 100% but was consistently close to that (in this case, 97.62 ± 2.4% (95% CI 90-
105.2%).  In all other groups, the mean ± SEM was close to 100% and there was clearly 
no significant difference between the groups.   
Specifically, HK2 cells exposed to CD4+ cells were found to have 98.4 ± 4.4% cytotoxicity 
(95% CI 84.4-112.4%), HK2 cells exposed to DC were found to have 95.8 ± 3.2% 
cytotoxicity (95% CI 85.6-105.9%) and HK2 cells exposed to both CD4+ cells and DC to 
have 99.9 ± 1.3% cytotoxicity (95% CI 96-104%) (p>0.05 for all comparisons).  These 
results are consistent with the results from the transwell experiment, confirming that there 
is unlikely to be an independent effect of CD4+ cells and/or DC on H2O2 induced HK2 cell 
damage.    
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Figure 5.5: Effect of the presence of CD4+ and DC on cell cytotoxicity compared to the percentage 
cytotoxicity seen with HK2 cells exposed to H2O2. Results represent pooled data from 4 experiments, 
analysed with 1 way ANOVA with multiple comparisons (Tukey’s test), P>0.05. 
 
5.3.4 Effect of MSC on H2O2 induced HK2 cell damage in the presence of DC and 
CD4+ cells 
These experiments were next performed in the presence of MSC (Figure 5.6).  Pooled 
data from two experiments showed no effect of the MSC in this system, regardless of the 
presence of CD4+ cells and DC (Figure 5.6 A).  There was a statistically non-significant 
increase in live cells in all groups exposed to MSC, with the highest proportion of live cells 
seen in the HK2/MSC/CD4+ group (figure 5.6 B). After 24 hours of H2O2 exposure, the 
proportion of live HK2 cells was 41.8 ± 10.4% (95% CI 8.7-75%).  This seemed to increase 
slightly with exposure to MSC (47.6 ± 5.3% (95% CI 34-61.1%) but more particularly with 
exposure to MSC and CD4+ cells (56.3 ± 6.5% (95% CI 35.8-76.8%).  There was a slight 
increase in the HK2/MSC/DC group with a mean of 52.0 ± 9.4% live cells (95% CI 22-
82%), and addition of CD4+ to the HK2/MSC/DC approached that seen with 
HK2/MSC/CD4 at 54.7 ± 7.1% (95% CI 32.2-77.2%) (p>0.05 for all comparisons).   
There were no statistically significant differences in the proportion of apoptotic cells with 
exposure to MSC, regardless of the presence of CD4+ cells and DC (Figure 5.6 C).  
Apoptotic cells represented 25.5 ± 7.9% of the population in the HK2/MSC/CD4 group 
(95% CI 0.5-50.5%) whereas they represent 32 ± 2.7% of the HK2 group (95% CI 25.5-
40.4%).  The other three experimental condition groups fell between these two groups, 
with the HK2/MSC group found to have 29.4 ± 6.3% apoptotic cells (95% CI 13.2-45.5%), 
the HK2/MSC/DC group to have 28 ± 9.5% apoptotic cells (95% CI -2.4-58.3%), and the  
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HK2/MSC/CD4/DC group to have 27 ± 8.2% apoptotic cells (95% CI 31.1-53.5%) (p>0.05 
for all comparisons). 
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Figure 5.6: Proportion of HK2 cells alive, apoptotic or necrotic 24 hours after exposure to H2O2 with and 
without MSC, CD4+ cells and DC.  (A) Total distribution of cell populations  (B) Proportion of live HK2 cells 
(p>0.05). (C) Proportion of apoptotic HK2 cells (p>0.05). (D) Proportion of necrotic HK2 cells (p>0.05).  
Results represent pooled data from 2 experiments, analysed with 1 way ANOVA (multiple comparisons by 
Tukey’s test) (GraphPad Prism 6 software). 
There was a trend to reduction in necrotic cells in HK2 cells exposed to both MSC and 
cells of the immune system, with particular improvement continuing to be seen in any 
group containing CD4+ cells.  However, these changes were not statistically significant, 
possibly due to significant variability within duplicate wells (Figure 5.6 D).  In this 
experiment, the proportion of HK2 cells which were necrotic 24 hours after exposure to 
H2O2 was 26.2 ± 11.1 (95% CI -9.1-61.5%), and there was no real difference if the HK2 
cells were exposed to MSC (23.1 ± 3.7%, 95% CI 13.7-32.5%).  There was a non- 
significant reduction in the proportion of necrotic cells if the HK2 cells were exposed to 
MSC and DC (20.1 ± 2.0%, 95% CI 13.7-26.4%) and an even larger reduction in the 
proportion of necrotic cells if they were exposed to MSC and CD4+ cells (18.2 ± 1.8%, 
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95% CI 12.4-24.1%).  There was no additive effect of exposing the cells to MSC, CD4+ 
cells and DC, but the trend to a protective effect of CD4+ cells persisted (18 ± 2.8%, 95% 
CI 9.1-27%) (p>0.05 for all comparisons). 
The same experimental conditions were analysed in a co-culture model and assessed for 
cytotoxicity.  Again there were no statistically significant differences between the groups 
(Figure 5.7).  The HK2 alone group was used as the high control and showed 96.2 ± 2.3% 
cytotoxicity (95% CI 89.7-102%).  There was little change in the HK2/MSC group (90.2 ± 
6.5%, 95% CI 74.8-105.6%) but a relatively small reduction in cytotoxicity in the 
HK2/MSC/CD4 group that was not significant (82.2 ± 7.5%, 95% CI 63.8-100.6%).  The 
HK2/MSC/DC group developed 85.3 ± 5.5% cytotoxicity (95% CI 72.2-98.4%) and the 
HK2/MSC/CD4/DC group 87.6 ± 7.4% (95% CI 69.4-105.8%) (p>0.05 for all comparisons).  
These results are consistent with those found in the transwell experiments. 
HK2          HK2 HK2 HK2 HK2
MSC           MSC MSC MSC
CD4          DC           CD4/DC
 
Figure 5.7: Cytotoxicity after 24 hours H2O2 exposure in a co-culture model of HK2 cells with and without 
MSC, CD4+ cells and DC.  Cytotoxicity assessed by LDH release and compared to the control group of HK2 
cells alone.  Results represent pooled data from 4 experiments, analysed by 1 way ANOVA with multiple 
comparisons (Tukey’s test).  P>0.05 
 
5.3.5 Effect of MSC-CM on H2O2 induced damage to HK2 cells in the presence of DC 
and CD4+ cells 
Given the reduction in cytotoxicity in HK2 cells exposed to MSC-CM (4.3.2.2), the effect of 
CD4+ cells and DC on MSC-CM was tested in the models established (Figure 5.8).  Figure 
5.8 A shows the overview of the results in the transwell experiment, which showed no 
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significant effect of MSC-CM with or without CD4+ cells and DC.  There was no significant 
change in the proportion of viable HK2 cells at 24 hours (Figure 5.8 B).  Specifically, 38.4 ± 
7.8% of HK2 cells were viable at 24 hours (95% CI 16.6-60.2%) compared to 48.1 ± 18.2% 
if the HK2 cells were exposed to MSC-CM (95% CI -30-126%).  The addition of DC did not 
confer any additional protection to HK2 cells (46.8 ± 15.3% viable at 24 hours, 95% CI -19-
112.5%). A small, non significant increase in live cells was seen in the HK2/MSC-CM/CD4 
group (52.3 ± 14.7% live cells, 95% CI -11-116%) but the results with HK2/MSC-CM/CD4 
and DC were indistinguishable from HK2/MSC-CM alone (49.8 ± 11.4%, 95% CI 13.5-
86.2%) (p>0.05 for all comparisons). 
There was no difference in the proportion of apoptotic cells in any experimental condition 
and wide variation within groups was seen (figure 5.8 C).  Mean percentage of apoptotic 
cells 33.0 ± 1.8% in the HK2 alone group (95% CI 28-37.8%), 33.6 ± 17.3% in the 
HK2/MSC-CM group (95% CI -37.6-111%), 34.5 ± 15.3% in the HK2/MSC-CM/CD4 group 
(95% CI -31.4-100.3%), 40.1 ± 15.3% in the HK2/MSC-CM/DC group (95% CI -35.9-
106%) and 37.1 ± 12% in the HK2/MSC-CM/CD4/DC group (95% CI -1.1-75%) (p>0.05 for 
all comparisons). 
Interestingly, necrosis was reduced in all groups exposed to MSC-CM There was no 
difference, however, between any of the groups exposed to MSC-CM, suggesting that if 
the apparent reduction in necrotic cells was true, there was unlikely to be any additional 
protection afforded by exposing the HK2 cells to CD4+ cells or DC (figure 5.8 D).  The 
mean percentage of necrotic cells was 28.6 ± 7.7% in the HK2 alone group (95% CI 7.3-
50%); 15.0 ± 1.1% (95% CI 10.3-19.8%) in the HK2/MSC-CM group; 13.2 ± 0.8% (95% CI 
9.6-16.8%) in the HK2/MSC-CM/CD4 group; and 13.2 ± 0.1% (95% CI -12.7-13.6%) in the 
HK2/MSC-CM/CD4/DC group  (p>0.05 for all comparisons).          
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Figure 5.8: Effect of MSC-CM on HK2 injury with and without CD4+ cells and DC.  (A) Overview of 
experimental results.  (B)  Proportion of live cells after exposure of HK2 cells to H2O2 (p>0.05).  (C)  
Proportion of apoptotic cells after exposure of HK2 cells to H2O2 (p>0.05).  (D) Proportion of necrotic cells 
after exposure of HK2 cells to H2O2 (p>0.05).  Data represents pooled data from 2 experiments, analysed by 
1 way ANOVA and the Tukey’s multiple comparison test (GaphPad Prism 6 software). 
 
The same experimental conditions were applied in the co-culture model (figure 5.9).  As 
was seen in 4.3.2.2, a significant reduction in cytotoxicity was seen in HK2 cells exposed 
to MSC-CM (53.0 ± 10.4%, 95% CI 26.4-79.5%) compared to HK2 alone (96.8 ± 2.0%, 
95% CI 91.7-102%), p<0.05.  This reduction was maintained with exposure to MSC-CM 
and CD4+ cells (49 ± 7.8% cytotoxicity, 95% CI 29-69%, p<0.01 when compared to HK2 
cells alone), exposure to MSC-CM and DC (53.3 ± 8.9% cytotoxicity, 95% CI -30.5-76.1%, 
p<0.05 when compared to HK2 cells alone) and exposure to MSC-CM with CD4+ cells and 
DC (57.3 ±11.6% cytotoxicity, 95% CI 27.6-87%, p<0.05 when compared to HK2 cells 
alone).  However, using Tukey’s test for multiple comparisons (GraphPad Prism 6), it was 
clear that there was no difference between any of the groups exposed to MSC-CM.  
Therefore it does not seem that the presence of CD4+ or DC alter the effect of MSC-CM. 
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Figure 5.9: Cytotoxicity after 24 hours H2O2 exposure in a co-culture model of HK2 cells with and without 
MSC-CM, CD4+ cells and DC.  Results represent pooled data from 4 experiments and have been analysed 
using 1 way ANOVA with Tukey’s test for multiple comparisons (GraphPad Prism 6 software).  * P<0.05, ** 
P<0.01 when compared to HK2 cells alone. 
 
5.4 Discussion  
The first objective of this phase of the study was to isolate and characterise DC and CD4+ 
cells.  By using a positive selection method of magnetic sorting, a very pure population of 
monocytes could be isolated from PBMC and, after several days in culture, over 80% of 
the cells exhibited DC markers.  Therefore, a reliable and reproducible population of 
monocyte-derived DC could be easily obtained and used in experiments. By using a 
lineage depletion method, a population of cells was able to be isolated that contained over 
70% naïve CD4+ T cells.   
In the next phase of study, the response of HK2 cells to these immune cells was 
investigated.  Although multiple different PBMC donors were used in the study overall, in 
each replicate of the experiment, HK2 cells were only exposed to one donor, in order to 
minimise unwanted allogeneic activation.  The PBMC were not HLA typed and therefore 
the possibility existed of HLA mismatches with the HK2 cells, an immortalised cell line 
arising from one donor.  It is not clear to what extent cells from this immortalised cell line 
will respond to allogeneic cell exposure.  Interestingly, because of the different models 
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used in these experiments, immune cells were only directly in contact with HK2 cells in the 
co-culture experiments.  In the transwell experiments, DC and CD4+ cells were deposited 
in the insert, in direct contact with MSC but separated from the HK2 cells.  Direct contact 
between HK2 cells and MSC was considered to be less likely to cause allogeneic 
activation due to the immunosuppressive properties of MSC.   
A firm conclusion regarding the independent response of HK2 cells to CD4+ cells and DC 
in a transwell model was not able to be drawn due to the wide variation between 
experimental results.  However, the cytotoxicity tests were more consistent, with a much 
smaller degree of variation, showing no change in cytotoxicity with exposure to CD4+ cells 
and DC.  No evidence was seen that CD4+ cells and DC mitigated HK2 injury either in the 
absence or the presence of MSC.   
MSC-CM was examined with CD4+ cells and DC, due to the protection of MSC-CM 
against HK2 cytotoxicity previously found (Chapter 4).  In the transwell model, which 
assessed cell viability, there was no significant difference among any of the groups, 
although there appeared to be a reduction in necrotic cells in all groups exposed to MSC-
CM.  There was a statistically significant reduction in cytotoxicity seen in all groups 
exposed to MSC-CM.  There did not appear to be any additional benefit in adding CD4+ or 
DC to the culture.   
There were some limitations to the work presented in this chapter and the preceding 
chapter.  There was a significant degree of variability within each experiment, between 
duplicate wells.  This was unable to be removed despite extensive altering of the design 
protocol and I believe is likely due to the variability between different immune cells, 
including MSC, particularly in human studies.  The experiments may have benefited from 
using more donors and pooling data from more replicates. But based on the multiple 
experiments performed (some data not shown) the variability is likely to have been 
persistent and may not have resulted in a decrease in heterogeneity.  These experiments 
also do not control for potential allogeneic responses between HK2 cells, PBMC derived 
cells and MSC and a logical next step would have been to perform the same experiments 
on fresh PTEC from donors who also contributed MSC and PBMC.  Also, in the current 
experiment, the MSC, CD4+ cells and DC are necessarily exposed to H2O2, which is likely 
to alter their functionality.  Using MSC-CM means that media is derived from cells not 
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exposed to H2O2, however it removes the ability for direct contact between the CD4+ cells 
and DC, possibly removing any potential beneficial interaction between these cells.  
Finally, it is well recognised that there is significant inter- and intra-variability in humans, 
which may require a much larger number of experiments to draw definitive conclusions. 
In summary, there was no evidence of improved cell viability to H2O2 induced HK2 damage 
with exposure to MSC.  This did not change with the addition of monocyte-derived DC or 
naïve CD4+ T cells.  There was some reduction in cytotoxicity with MSC-CM, but no 
additional benefit from the PBMC derived immune cells.  It was considered important to go 
on and develop a whole organism model to study these processes in vivo.  
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Chapter 6 
Development of a murine in vivo model of renal 
ischaemia reperfusion injury 
6.1 Background and objectives 
Given that MSC have such a wide ranging spectrum of immunological effects (described in 
Chapter 2), it is possible that the outcomes of MSC administration in renal IRI may not be 
best demonstrated in an in vitro model.  It may be that the primary effect of MSC is 
mediated in a manner not exposed by these particular experiments.  The remainder of this 
thesis will be devoted to an in vivo murine model of renal IRI.     
6.1.1 Selection of the appropriate animal for the in vivo model 
The most relevant animal to study renal IRI in would clearly be the human.  However, at 
the time of experimental development, there were no published papers on MSC 
administration in humans with AKI.  A rodent study suggesting that MSC can mal-
differentiate into adipose cells in the glomeruli when administered intra-arterially (214) is 
concerning.  Safety in humans had not been established.  A clinical trial to appropriately 
study this would be required to be a multi-centre, probably multi-national trial to ensure 
adequate power. It was decided to use a non-human model.  Our laboratory was not 
equipped to study either non-human primates or large animal models such as sheep or 
pigs.  Therefore, it was decided to use a rodent model to study the in vivo effects of MSC 
on renal IRI.  Rodent models are well established in medical science.  Both rat and murine 
models display a significant genetic homogeneity with humans (252), which increases their 
relevance in this field of work.  Our laboratory did have a well established rat model of 
renal IRI, but it was decided at the outset of this study to use a murine model to enable 
future work with genetically modified knock-out mice, not feasible with rat models.  It is 
acknowledged that different strains of mice tolerate renal IRI differently (253).  C57 Bl/6 
mice were chosen as they experience a more severe phenotype of renal IRI and many 
relevant genetically modified strains are from a C57/Bl 6 background.  Male mice were 
chosen as there is also a gender differential in the response to renal IRI, with males 
showing a more severe phenotype (254).   
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6.1.2 Surgical technique 
There are a number of possible surgical techniques to access murine kidneys and to 
temporarily inhibit renal blood flow.  Initially both midline and flank incisions were trialled.  
The flank incision approach was chosen as it was convenient, less likely to induce large 
intra-operative fluid losses and led to relatively quick post-operative recovery.  As 
discussed in Kennedy et al (255) even very small variations in the surgical environment or 
technique alter the response to renal IRI.  Therefore, each laboratory must develop and 
titrate their renal IRI models carefully, and it is important that each surgery within an 
experiment is performed consistently with respect to every minor detail.   
6.1.3 Titration of duration of renal ischaemia 
A number of different renal IRI protocols have been described in the literature.  In 
particular, using C57Bl/6 mice, the duration of renal ischaemia reported has differed from 
18 minutes (256) to 30 minutes (257).  Some groups clamp both renal arteries, some do a 
unilateral nephrectomy and clamp the remaining renal artery and others clamp one renal 
artery, leaving the other untouched.  Many factors are involved in the development of an 
ideal model, including the species and gender of mouse as discussed previously, the age 
of the mouse, the temperature during surgery and the availability of oxygen during surgery.  
The goal of this study was to develop a protocol relevant to human IRI and a consistent 
model. 
6.2 Materials and methods 
6.2.1 Ethical considerations 
All animal experiments were approved by the University of Queensland Animal Ethics 
Committee (AEC) (UQ AEC MMRI/518/08/MMRI).  Prior to undertaking any animal work, 
the University of Queensland Research Animal Workshop was completed by the principal 
researcher.  Male 6-7 week old C57Bl/6 mice were sourced from the Animal Resources 
Centre (Murdoch, Western Australia).  Mice were acclimatised to the MMRI animal house 
for 1-2 weeks prior to experimentation.  They were fed standard rodent chow and provided 
with environmental enrichment. 
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6.2.2 Anaesthetic 
Mice were anaesthetised with an intraperitoneal injection of ketamine and xylazine, at a 
dose of 75mg/kg Ketamine and 10mg/kg Xylazine prior to the renal IRI surgery.  This dose 
was chosen after reviewing available literature and on-line resources (258, 259).  The 
solution used to attain this dose was 0.075ml Ketamine (100mg/ml) / 0.05ml Xylazine 
(20mg/ml) in 0.825 ml normal saline.  This was mixed by inverting the syringe several 
times and aliquoting into an eppendorf.  Prior to surgery, the mouse was weighed, and 
anaesthetic solution was drawn up at 0.1ml per 10g body weight.  The anaesthetic was 
administered via intra-peritoneal (IP) injection, with the mouse stabilised in a head down 
position.  The mouse was then placed into a single cage until it was unresponsive.  
Sedation was checked by manipulation of the paw and once full anaesthesia was 
confirmed, the surgery proceeded.   
Animals were anaesthetised for a second time at 48 hours after the initial surgery.  The 
duration of anaesthesia required was much shorter, as these animals were euthanised 
while under anaesthetic after the terminal cardiac bleed was taken.  The dose required for 
anaesthesia 2 days post-operatively was much reduced, and this was considered likely to 
be due to the presence of renal failure.  Animals were effectively anaesthetised with two 
thirds of the initial dose (50mg/kg Ketamine with 6.6 mg/kg Xylazine). 
6.2.3 Surgical technique 
Prior to surgery, a mouse was selected from the cage, weighed and placed in an isolation 
cage.  The appropriate dose of anaesthetic was administered IP.  The animal was placed 
back in the single cage for a period of approximately 5 minutes for maximal anaesthetic 
effect.  When sedation had been confirmed, the animal was shaved over both flanks using 
an electric clipper, and the shaved area was cleaned with 70% ethanol (Figure 6.2 A).  A 
lubricant eye gel (GenTeal Eye Gel, Amcal Pharmacy) was applied and the eyes were 
then wrapped in saline soaked gauze.   
The animal was placed on the right flank on a temperature controlled heat pad which was 
set at 35 degrees and under a heat lamp.  The setting of 35 degrees of the heat pad was 
chosen as that had been used in previous experiments in the laboratory.  A 1.5 cm 
horizontal skin incision was made caudally, ending at the hindlegs, approximately 1 cm 
ventral to the spine (Figure 6.1).  A small incision was then made in the muscle layer 
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beneath the skin incision, and blunt dissection was applied to expose the kidney (Figure 
6.2 B).  A cotton swab was used to gently dissect the fat away from the kidney and the 
hilum and the kidney were lifted out of the intra-peritoneal cavity.  Forceps were then used 
to expose the renal pedicle and an atraumatic vascular clamp was applied (Fine Science 
Tools, North Vancouver, Canada).  As soon as the clamp was securely in place, the timer 
was activated.  Ischaemia was confirmed by visual inspection of the change in colour of 
the kidney (Figure 6.2 C).  Once ischaemia was confirmed, the kidney was gently lifted 
back into the intraperitoneal space.  A saline soaked piece of gauze was placed over the 
wound and the mouse was turned onto the other flank.  The process was repeated on the 
second side and the animal was turned back to the initial flank for completion of the 
ischaemic time.  During this time the animal was maintained on the temperature controlled 
heat pad and under the heat lamp.  The first atraumatic clamp was removed promptly at 
the required time (time depending on the experimental condition) (Figure 6.2 D), and the 
kidney was observed through reperfusion.  The muscle layer and skin were then closed 
with 3.0 vicryl sutures.  The mouse was turned over and the second clamp was removed 
exactly on the timer.  The second flank incisions were then sutured and 0.5ml warmed 
normal saline was injected IP.  The mouse was wrapped in gauze and placed in an 
isolation cage on a warming mat under a heat lamp until full recovery from the anaesthetic.  
Full recovery was assessed by visualisation of the animal walking freely around the cage, 
and usually took 0.5-1.5 hours.       
 
Figure 6.1: Location of left flank incision with reference to kidney position (figure kindly drawn by 
Professor L Hall) 
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Figure 6.2: Photographic examples of surgical technique.  A)  After shaving small area on left flank. B) 
Exposing the right kidney, prior to applying clamp.  Note bright pink / red colour of kidney. C) Immediately 
after applying a clamp to the hilum of the right kidney. Note dusky colour change indicating ischaemic 
onset.  D) After 25 minutes of ischaemia, prior to removing clamp from left kidney. Note very dark 
burgundy colour indicating full ischaemia. 
The mouse was monitored twice daily and scored with a scoring system approved by the 
UQ AEC (Appendix 1).  A score was given between 0 and 4+ with 0 indicating no physical 
effects of surgery whatsoever, 1-2 considered normal in the post-operative period, 3 
indicating severe illness and consideration for euthanasia and 4 or greater an indication for 
immediate euthanasia.  The planned sacrifice for analysis was at 24 or 48 hours 
depending on the study.  Rarely did an animal require euthanasia prior to the planned 
sacrifice.  Most animals recovered well from the procedure on day 0, were healthy and 
active on day 1 and beginning to show evidence of illness consistent with renal failure on 
day 2. 
The animal was sacrificed 24 or 48 hours after unclamping of the renal pedicles.  It was 
first anaesthetised with Ketamine and Xylazine IP as described.  When fully sedated, a 
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terminal cardiac bleed was taken by direct puncture.  Approximately 1 ml of blood was 
obtained this way, then decanted into capiject tubes (Terumo, Australia) and placed on ice.  
After obtaining the cardiac bleed, the animal was euthanised by cervical dislocation.  A 
rapid midline incision was then made, and the kidneys were removed from the intra-
peritoneal cavity.  Each kidney was dissected in two by cross section, and a 2-3 mm slice 
was taken from each exposed surface – one placed in formalin (Sigma-Aldrich) for 
histological analysis and the other snap frozen in an eppendorf in liquid nitrogen or dry ice 
(laboratory stores) for PCR analysis.  In some experiments, other organs including the 
lungs, liver, heart, spleen, bones and brain were collected and snap frozen as above.  The 
remainder of the animal was disposed of according to animal house protocol. 
6.2.4  Appropriate duration of renal ischaemia  
To ascertain the appropriate duration of renal ischaemia in this model, a pilot study was 
performed.  Bilateral renal IRI was induced for 0, 20, 22.5, 25, 27.5 and 30 minutes in male 
8 week old B57 Bl/6 mice.  Each group represents 1-3 mice.  Serum was analysed at 48 
hours for creatinine and urea and kidneys were retrieved for histopathological analysis. 
6.2.5 Effect of renal IRI at 8 weeks and 20 weeks of age 
As part of the titration pilot experiment, renal IRI was also performed on 20 week old male 
mice and the results compared with the 8 week old mice.   
6.2.6 Analysis of renal function 
As described above, blood was collected in a 1ml syringe with a 27 gauge needle and then 
transferred into serum separating capiject tubes.  The tubes were then placed on ice until 
removal to the laboratory.  They were centrifuged for 10 minutes at 1300rpm at 4 degrees.  
On removal from the centrifuge, the serum was carefully aliquoted out of the capiject tube 
and placed in a labelled eppendorf.  The serum was then stored at -80 degrees Celsius 
(°C) until required for analysis.  Plasma creatinine, blood urea nitrogen and lactate 
dehydrogenase were measured using a modular blood analyser (Hitachi Australia, Milton, 
Australia) at the Queensland Health Pathology Services Unit, Royal Brisbane and 
Women’s Hospital (RBWH), Australia.  
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6.2.7 Histopathology 
Tissue samples were retrieved and placed in formalin overnight at 4°C.  After 24 hours in 
formalin, the formalin was drained and replaced by 70% ethanol.  At this stage, the 
specimens were delivered to Queensland Institute of Medical Research (QIMR) Histology 
Facility (Herston, Brisbane, Australia), where they were processed into paraffin blocks and 
slides and stained with either haematoxylin and eosin (H and E) or Periodic acid-Schiff 
(PAS) stain.  
Slides were scored for renal tubular and interstitial damage using an Olympus BX 50 
microscope.  The scoring system used was adapted from the Goujon method (cited in 
260).  Specifically, each slide was analysed in 10 high power fields (light microscopy, 200 
x magnification) with each field being examined for the proportion of the section showing 
damage (table 6.1).  Each field had a minimum possible score of 6 and a maximum 
possible score of 30, and the average score of 10 fields was used for each kidney.  The 
outer medulla was preferentially assessed, as this is known to receive the most significant 
damage, being relatively hypoxic even in the normal state.   
   Table 6.1: Histopathology scoring system used for all experiments (adapted from the Goujon method) 
Experiment 
Mouse 
Field 
Normal 
 
10% or 
less of 
section 
20% of 
section 
50% of 
section 
75% or 
more of 
section 
 1 2 3 4 5 
Apical cytoplasm vacuolisation      
Tubular necrosis      
Tubular dilatation      
Cell detachment and cast formation      
Loss of Brush Border Integrity      
Denuded Basement Membrane      
 
For the quantitative analysis of the pilot study and the experiment described in 6.2.4, the 
histopathology was independently scored by two researchers.  The principal researcher 
had previous experience assessing human kidney biopsies but not murine kidneys.  
Associate Professor Gobe (School of Medicine, University of Queensland) provided 
training in mouse kidney assessment prior to scoring the experiments.  Both studies were 
independently scored by both researchers and then the results were compared (data not 
shown).  There was clear evidence of consistency of scoring in both experiments, 
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therefore, for the remainder of the experiments in this work, scoring was undertaken by the 
principal researcher. Figure 6.3 shows representative slides of relevant histopathological 
observations.   
 
Figure 6.3: Representative slides of relevant histological observations used in histological scoring 
system. A) Control (200x magnification) B) Apical cytoplasmic vacuolisation (400x magnification) C) 
Tubular necrosis (400x magnification) D) Tubular dilatation (200x magnification) E) Cell detachment 
and cast formation (400x magnification) F) Loss of brush border integrity and denudement of 
basement membrane (400x magnification).   All photographs taken through Olympus BX 50 light 
microscope. 
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In all histological scoring, investigators were blinded as to the experimental condition.  
Slides were labelled with a re-identifiable code and information regarding 
experimental condition was not accessed until analysis of the results, after all scoring 
had taken place. 
6.2.8 Statistics 
Results are presented as mean ± standard deviation, where n >1.  All statistics were 
calculated using Graphpad Prism 6.  It is acknowledged that this was a pilot study which 
was not designed to be statistically significant, but to show a direction for future studies.  
However, it was considered most appropriate to present all data and standard deviations 
where available, in this Chapter.  
6.3  Results 
6.3.1 Appropriate duration of renal ischaemia 
Animals underwent bilateral renal IRI for either: 0, 20, 22.5, 25, 27.5 or 30 minutes.  As 
shown in Figure 6.4, neither 20 minutes of ischaemia nor 22.5 minutes were sufficient to 
induce acute renal failure at 48 hours (mean serum creatinine 16 ± 1μmol/l and 35μmol/l 
respectively, compared to control 17 ± 6μmol/l).  However, 30 minutes of ischaemia 
induced such severe renal failure that the animal did not survive 24 hours.  25 minutes of 
ischaemia produced a mean serum creatinine of 133 ± 55μmol/l at 48 hours compared to 
238μmol/l for 27.5 minutes.  With respect to serum urea, the mean control value was 9.5 ± 
1mmol/l.  This was essentially unchanged with 20 and 22.5 minutes of ischaemia 
(11mmol/l and 13mmol/l respectively) but was increased to a mean value of 51 ± 22mmol/l 
with 25 minutes ischaemia.  Serum urea was unavailable for the 27.5 minute time point.    
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Figure 6.4: Effect of differing duration of induced renal ischaemia on renal function at 48 hours.  There is 
little difference in renal function from control if ischaemia is less than 25 minutes in duration as measured 
by serum creatinine in figure 8.3A and serum urea in figure 8.3B.  27.5 minutes induced a very severe lesion 
with a serum creatinine of 238 μmol/l compared to the control serum creatinine of 22 μmol/l.  Control 
values reflect the serum levels of a healthy animal sacrificed without surgery. N=1-3 in each group. 
Histopathology of kidney tissue after renal IRI was analysed as described in 6.2.7.  For the 
purposes of establishing the model, individual components of the scoring system are 
displayed in Figure 6.5.  The minimum possible score for each component was 1, with a 
maximum possible score of 5.  Each feature was only rarely seen on the control kidney 
with only apical cytoplasmic vacuolation and cell detachment / cast formation scoring 
above 1.  A clear linear association with duration of ischaemia and markers of damage 
was seen with tubular necrosis, tubular dilatation, loss of brush border integrity and 
denuded basement membrane.  Cell detachment and cast formation were severe at any 
degree of injury.  Figure 6.6 shows the composite scores of each marker of injury 
(minimum score was 5, with a maximum possible score of 30).  Any degree of ischaemia 
led to a score above 15, and a stepwise increase was shown with every 2.5 minutes 
additional ischaemic time (score 17.4, 19.5 and 23.8 for 22.5, 25 and 27.5 minutes of 
ischaemia respectively).  Histology was not available for 30 minutes ischaemia as the 
animal did not survive 24 hours.  Representative photographs of slides from each time 
point are shown in Figure 6.7.  All slides were photographed at 200 x magnification.  The 
control condition was stained with PAS rather than H and E (the stain used for the 
experimental conditions).  With 27.5 minutes of ischaemia, the normal tubular structures 
were completely disrupted. 
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Figure 6.5: Results of the histological scoring system in this pilot study of different ischaemic duration.  
Note that for all features assessed, the degree of damage noted was increased with IRI as compared to 
control.  In most cases, this was in a linear fashion with increased duration of ischaemia. N=1 for each 
condition in this analysis.  Each feature of injury was assessed on 10 high powered fields, and the average 
of all ten fields is presented. Minimum attainable score was 1, with a maximum possible score of 5. 
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Total Histopathological Score
 
Figure 6.6: Total histopathological score after bilateral renal IRI.   Score calculated from adding the mean 
results of assessing 10 high power fields for each of the six features of ischaemic damage.  The minimum 
score is 6 and the maximum is 30. 
 
Figure 6.7: Representative slides from each time point showing the increase in damage as the duration of 
ischaemia increased.  A)  Control (0 minutes ischaemia) stained with PAS.  B) 22.5 minutes ischaemia, C) 25 
minutes ischaemia, D: 27.5 minutes ischaemia, all stained with H and E.   All photographs taken at 200 x 
magnification through an Olymnpus BX 50 Light Microscope. 
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6.3.2 Effect of renal IRI at 8 weeks and 20 weeks of age 
Renal function tests were only available for 1 of the 20 week old mice, at the 22.5 minute 
time point.  When comparing renal function results between the 8 week old mouse and the 
20 week old mouse a large difference was seen in both serum creatinine (35 vs 110μmol/l, 
respectively) and serum urea (13 vs 33mmol/l respectively) (Figure 6.8).  Of note, the 20 
week old animals were surgically more challenging, due to large amounts of peri-renal fat.  
The changes seen in the renal function analysis with older animals were not replicated in 
the histopathology.  Representative slides from the 22.5 minute time point are shown in 
Figure 6.9.  There was no clinically relevant difference in the composite histological scores 
of animals of differering ages (Figure 6.10).  However, only one mouse was tested in each 
group and this study was not powered to show statistical differences. 
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Figure 6.8:  Animal age is important in a renal IRI model. With the same duration of renal ischaemia (22.5 
minutes), an older mouse displays a more severe injury than a young mouse, analysed by serum creatinine 
(A) and serum urea (B).  
 
Figure 6.9: Representative slides of murine kidneys after 22.5 minutes ischaemia. A)  8 week old mouse.  
B)  20 week old mouse.  200 x magnification, H and E staining.   
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Figure 6.10: Comparison of histopathology scoring after renal IRI in two different age groups of mice.  The 
increase in severity seen in the renal function analysis was not mirrored in the histopathology in this small 
pilot study. Mice of 8 weeks of age are compared to 20 week old mice (n=1 each group) at different 
durations of ischaemia.  Maximum possible score 30. 
6.4 Discussion  
In the literature, ischaemic times for renal IRI vary from 18 minutes to 30 minutes 
depending on other experimental conditions.  The goal of developing the present model 
was to establish a consistent animal model of renal IRI for use in further experiments, 
which would be clinically relevant to human renal IRI.   
Temperature appears to be critical in determining the level of injury achieved after a 
specific insult.  Unfortunately we did not have access to a rectal probe for constant 
temperature monitoring, but the temperature controlled heat pad and heat lamp ensured 
that there was uniform exposure to heat across all procedures.  In a laboratory visit, 
constant temperature monitoring with rectal probes was observed.  No significant variation 
in temperature throughout the renal IRI procedure was found with the use of a temperature 
controlled heat pad set at 37°C (Laboratory of Professor Ben Humphreys, Harvard Institute 
of Medicine, Boston, USA).  The results presented in this thesis were achieved with the 
heat pad set at 35°C, which was consistent with previous experiments in our laboratory.   
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Analysis of renal function was performed by the Queensland Health Pathology Services 
Uint, ensuring validity of results.  The histological scoring system developed was based on 
a published scoring system widely used in the literature (260).  Apoptotic and mitotic cells 
were counted also, but there were no trends with regards to absolute numbers of these 
cells and severity of injury (data not shown).  All histopathology was scored in a blinded 
fashion and the principal researcher was trained in assessment of IRI.  All scores 
presented here were validated by two separate researchers with very consistent results 
(data not shown).  10 high power fields of each kidney were assessed, which at this 
microscopic power (400x magnification) ensures that most of the outer medulla of the 
kidney was directly visualised and scored.  Kidney sections assessed were perihilar.  
Therefore the medulla of an appropriate section of the kidney was analysed in its entirety, 
scored by a trained and validated blinded researcher and a composite score achieved 
from an aggregate of several different markers of injury over multiple fields.  This was 
considered to be a robust and replicable model. 
Based on the results from this pilot study, 25 minutes of ischaemia in 8-9 week old male 
mice was selected for future work, ensuring a significant injury without the risk of necrosis 
or infarction and without compromising the safety of the animal during the 48 hour follow 
up time frame.  In summary, the surgical techniques were consistent and replicable and 
the methods of analysis of renal injury were robust.  Unless otherwise stated, all future in 
vivo experiments used these surgical and analytic methods. 
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Chapter 7 
Investigation of mesenchymal stromal cells in a murine 
model of renal ischaemia reperfusion injury 
7.1 Background and objectives 
Having established a murine model of renal IRI, the next step was to test the efficacy of 
MSC using this model.  As described in Chapter 2, there are varying reports in the 
literature regarding the efficacy of MSC in renal IRI, depending on the methods of isolation 
of the cells, the animal model used and the mode of administration of MSC.  The aim of 
the work described in this chapter was to isolate and culture cells which fit current 
definitions of MSC and to investigate their utility in providing renoprotection in a 
standardised model of IRI. 
7.2 Materials and methods 
7.2.1 Culture and characterisation of murine MSC 
The methods used to isolate and culture murine MSC in this study are similar to those 
used in 4.2.3 to isolate and culture human MSC, with a few important differences. 
7.2.1.1 Isolation of Murine MSC 
Murine MSC were isolated using a standard operating protocol developed by the ASC 
Team at the MMRI, following ethical approval by the University of Queensland AEC.  
Donor mice were inbred 8-10 week old male C57 Bl/6 mice which were transgenic for 
green fluorescent protein (GFP) under the ubiquitin promoter (sourced from MMRI Animal 
house).  GFP+ mice were chosen so that the MSC could be tracked after administration 
into wild-type mice.    Mice were sacrificed by carbon dioxide asphyxiation and cervical 
dislocation.  The pelvis, tibia and femur were removed and cleaned of muscle with a 
scalpel blade.  A sterile ceramic mortar and pestle were used to crush the bones into very 
small bone fragments.  These fragments were then incubated on a shaker at 220rpm 
(37°C) for 20 minutes in a 50ml tube containing 10ml alpha modified Eagle’s media 
(αMEM, Invitrogen) with 3mg/ml of type I Collagenase (Worthington) and 10μg/ml of 
deoxyribonuclease (DNase) I (Roche).  After incubation, the tube contents were mixed 
thoroughly in αMEM with reservation of the supernatant.  The supernatant was then 
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centrifuged at 1200 rpm for 5 minutes and the pellet resuspended in PBS, which was 
filtered through a 40m cell strainer to remove bone fragments, and then re-centrifuged for 
5 minutes.  The pellet was resuspended in 30ml PBS and underlaid with 15ml of sterile 
Ficoll Density Gradient.  This was centrifuged at 1600 rpm for 20 minutes at room 
temperature without a brake, ensuring a clear segregation of the interface layer, which was 
then removed with a 10ml serological pipette and washed in PBS.  The cells were plated 
into T75 tissue culture flasks (cells from 3 mice seeded into 1 T75 plate) in a 5% CO2 
incubator at 37 degrees in αMEM supplemented with 20% FCS and 1% PSG, replaced 
twice weekly until confluence was reached.  At the end of the first passage, the adherent 
cells were harvested and stained with mAb to mouse Sca-1 (PE) (BD Pharmingen) and to 
mouse CD45 (APC) (BD Pharmingen) at a concentration of 2.5 g/ml in PBS with 1% 
BSA.  Harvested cells were then sorted for Sca-1+ (found on murine HSC and MSC) and 
CD45- (found on HSC but not on MSC) using the BD FACS-ARIA flow cytometer (Figure 
7.1). These cells were then returned to culture and further passaged and expanded.  
 
Figure 7.1: Flow cytometry isolation strategy for murine MSC.  Mononuclear cells were isolated after leg 
bones of C57Bl/6 mice had been crushed and enzymatically digested, and were placed in tissue culture 
medium in an incubator.  After the cells achieved confluence, they were sorted by FACS-ARIA (BD) such that 
Sca-1 positive, CD45 negative cells were retained in culture. FSC: forward scatter, SSC: side scatter 
7.2.1.2 Murine MSC cell culture 
Standard murine MSC tissue culture medium consisted of αMEM, 20% FCS and 1% PSG.  
As with human MSC, our laboratory has previously found optimum culture growth with 
20% FCS.  Cells were passaged, expanded, frozen and thawed using standard tissue 
culture techniques (3.2.2).  It was noted that by about passage 8 the cells were behaving 
like an immortalised cell line, in that expansion was rapid and predictable and could 
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continue easily to very high passages without significant alteration of characteristics.  
Experiments from the Bone Marrow Transplant Team laboratory (MMRI) have shown that 
even at high passage, murine MSC retained their ability to suppress T Cells (Dr Melinda 
Christensen, personal communication).  Cells were used at high passage in the initial 
experiments described (>P8).  
7.2.1.3 Characterisation of murine MSC 
As with human MSC, characterisation of murine MSC involves three general phenotypic 
requirements.  Firstly, the cells must have a characteristic appearance on light microscopy 
and they must be plastic adherent.  Secondly, they must express a specific pattern of cell 
surface markers (Sca-1 and CD90 positive, CD45 negative). Thirdly, they must be able to 
be induced to differentiate into adipocytes, osteocytes and chondrocytes.   
Morphology 
By definition, the cell population identified was plastic adherent.  All MSC cultures were 
directly visualised using light microscopy during the culture process to assess 
characteristic appearances, confluence and any suggestion of bacterial contamination.  
The typical appearances expected were that of a large branching fibroblastic type cell, 
very similar to that seen with human MSC and described in 4.3.1.1.    
Immunophenotyping 
Immunophenotype analysis was performed using methods similar to those described in 
4.2.3.6.  Flow cytometry was performed using fluorochrome labeled rat-anti mouse mAb as 
follows: Sca-1PE (IgG2a), CD45APC (IgG2b), CD31PE (IgG2a), CD44PE (IgG2b), CD11bPE 
(IgG2b). All antibodies, including isotype controls, were purchased from BD Biosciences. 
1x106 cells were incubated with mAb in PBS with 0.5% BSA and 2mM EDTA for 30 
minutes at 4°C and washed in PBS to remove excess mAb. Fluorescence was detected on 
the BD LSRII and analysed using FlowJo (Treestar, Incorporated). 
Functional Capacity 
MSC were induced into adipocyte, osteocyte and chondrocyte lineages using the standard 
operating protocols developed by the ASC Team at MMRI and described in 4.2.3.6.     
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7.2.1.4 MSC injection preparation 
MSC were resuspended in injection media immediately prior to administration, at a dose 
specific to the experimental condition. 5ml of injection media contained 4.7ml normal 
saline (0.9% sodium chloride, Baxter), 0.2ml heat inactivated FCS, 0.05ml DNase (at 
1mg/ml) and 0.05ml heparin (at 5000 units per ml).  FCS was heat inactivated by 
incubating in a 55°C waterbath for 40 minutes.  Control mice were injected with vehicle, 
which consisted of injection media without the MSC. 
7.2.2 Identification of appropriate mode of administration of MSC 
7.2.2.1 Pilot study assessing efficacy of MSC with intravenous (IV), subcapsular (SC) and 
IP administration  
A pilot study was performed to assess efficacy of different modes of administration of 
MSC.   Anaesthetic and surgical techniques used were as described in 6.2.2 and 6.2.3, 
and ischaemia was applied for 25 minutes to both kidneys.  There were six experimental 
groups, with 2-3 mice in each group and two control mice (no treatment received) (Table 
7.1).  IRI was induced over three days with no pattern to the order of surgery.  Two groups 
received retro-orbital (RO) IV injections after their abdominal wounds had been sutured.  
One group received 0.5 x 106 MSC in 250μl injection media, while the other group 
received injection media alone.  Both groups then had 0.5ml normal saline injected IP for 
hydration purposes.  It had previously been determined by our laboratory that 0.5 x 106 
was the highest dose of MSC that could be safely administered IV, and that 250μl was the 
largest safe volume to administer IV. 
Two groups received renal SC injections immediately after unclamping of the kidney.  1 
group received 0.25 x 106 MSC in 50μl injection media to each kidney, while the other 
group received 50μl injection media alone.  After closing the abdominal wounds, both 
groups then received 0.5ml normal saline injected IP for hydration purposes.  The volume 
of the SC injection was necessarily small due to the very small space available for injection 
and the need to avoid harming the kidney by the injection.  A 29 gauge needle was used 
(with a 0.3ml insulin syringe) for the SC injection.  The dose of MSC was chosen with 
regard to the volume, but also to enable consistency with the IV group. 
Two groups received IP injections after their abdominal wounds had been sutured.  1 
group received 8 x 106 MSC in 800μl injection media, while the other group received 
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injection media alone (vehicle).  A much larger number of MSC were able to be used 
safely because of the mode of administration.  It has previously been shown by the Bone 
Marrow Transplant Laboratory (MMRI) that up to 10 x 106 MSC are safe for IP 
administration (Alison Rice, personal communication).  It is thought that most of these cells 
do not reach the injured area, and the larger quantity is required for efficacy.  
Table 7.1: Pilot study design of methods of administering MSC in renal IRI. There were significant 
differences in the experimental conditions of each group due to specific features of the modes of 
administration.  However, each group had a matched control group which received vehicle without MSC, as 
a comparator (n=2-3 in all groups).   
Group Method of 
administration 
Timing of 
injection 
Dose of 
MSC 
Volume of 
injection 
Additional 
hydration 
1 Intravenous  (RO) After closing 
abdomen 
0.5 x 106 0.25 ml 0.5 ml 
2 Intravenous (RO) After closing 
abdomen 
0 0.25 ml 0.5 ml 
3 Kidney capsule (SC) At time of 
unclamping renal 
artery 
0.25 x 106 
each kidney 
0.05 ml each 
kidney 
0.5 ml 
4 Kidney capsule (SC) At time of 
unclamping renal 
artery 
0 0.05 ml each 
kidney 
0.5 ml 
5 Intraperitoneal (IP) After closing 
abdomen 
8 x 106 0.8 ml 0 
6 Intraperitoneal (IP) After closing 
abdomen 
0 0.8 ml 0 
7 (Control)     
 
It is acknowledged that there were significant differences between the experimental 
conditions described above.  However, the purpose of this study was not to directly 
compare MSC administration techniques, but rather to assess feasibility of administration 
of MSC and potential efficacy of MSC when compared to placebo across three different 
administration routes.  The dose of MSC must necessarily be lower in IV injection than IP 
injection as previous work in our laboratory has shown safety concerns with higher doses 
administered IV and lack of viable cells reaching target with smaller doses administered IP 
(data not shown).  There were also differences in hydration volume received which may or 
may not have some bearing on renal outcomes at 48 hours.  However, each experimental 
condition was matched with a strict comparator group which received vehicle without MSC 
with all other parameters being identical. 
128 
 
After the initial surgery all animals were monitored twice daily and scored as previously 
shown in Appendix 1.  No animal required early euthanasia due to severe illness.  All 
animals were sacrificed 48 hours after unclamping of the renal pedicles, and blood and 
organs were obtained as described in 6.2.3.   One kidney was placed in formalin for 
histological processing and the other kidney was snap frozen for assessment of 
quantitative real time polymerase chain reaction (qRT-PCR) for GFP 
7.2.2.2 Further investigation into the role of SC administered MSC in renal IRI 
A definitive study of the effects of SC administration of MSC was undertaken.  Anaesthetic 
and surgical technique used was as described in 6.2.2 and 6.2.3, except that the 
temperature controlled heat pad was increased to 37°C in order to maintain a core body 
temperature of 37°C (Humphrey’s Laboratory, Harvard Stem Cell Institute, Brigham and 
Women’s Hospital, personal communication). Ischaemia was applied for 25 minutes to 
both kidneys.  20 mice were divided into two groups, MSC and vehicle.  Surgery was 
performed on several days over a two week period and alternated between animals 
receiving SC MSC and animals receiving SC vehicle.  On unclamping, each kidney 
received a 50μl SC injection of 0.5 x 106 MSC in injection media, or injection media alone.  
Although the volume of injection was unchanged from the pilot study, the dose of MSC 
was increased, as there were no safety concerns in the pilot study.  A 0.3ml insulin syringe 
with a 29 gauge needle was used to administer the injections.  There were two 
experimental time points (24 and 48 hours), to further delineate the natural history of the 
renal impairment with and without MSC.  On sacrifice, a terminal cardiac bleed was 
performed with blood being initially placed on ice and then spun down for extraction of 
serum.  Both kidneys were sectioned, with a hilar cross-section of each kidney being 
retained for histopathology, and the remainder of the kidney tissue being snap frozen in 
dry ice for deoxyribonucleic acid (DNA) analysis.  N=4-5 in each of the 4 groups.        
7.2.3 Analysis of results in in vivo experiments 
The methods of analysis used for these experiments had one of two purposes: either to 
confirm the presence of MSC within the injured kidney or to assess the degree of renal 
injury. 
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7.2.3.1 Confirmation of MSC presence within injured kidney 
There are a number of ways to label cells or track them once injected.  For the purposes of 
these experiments GFP+ MSC were administered into GFP- mice, thus ensuring that any 
GFP+ cells within the animal reflected donor MSC.  Two methods were used to assess the 
presence of GFP.  Of note, non-renal organs were also collected and snap frozen on dry 
ice or placed in formalin for histopathology.  The same methodology as described below 
was used to assess presence of MSC in other organs, to be compared with the kidney.  
qRT-PCR for GFP 
The most sensitive methodology for analysing the presence of GFP+ cells within tissue is 
to extract the genomic DNA (gDNA) from that tissue and then assess it for the proportion 
of DNA which is GFP+ by qRT-PCR.  This gives a quantitative result which can be directly 
compared with other results.  Technical assistance was provided by Dr Matthew Cook, 
ASC Team, MMRI, for some of these experiments.  All DNA experiments took place in a 
dedicated room with a sterile technique and all components used were RNA free to avoid 
contamination.  Snap frozen tissues were stored at -80°C until required for analysis.  They 
were then weighed and homogenised in a cold mortar and pestle resting in a polystyrene 
container of dry ice.  Up to 50g of tissue was placed in a 1.5ml tube after homogenisation 
and digested at 56°C in Proteinase K solution (Qiagen) overnight.  Using a QIAamp DNA 
minikit (Qiagen) and the maufacturer’s protocol, gDNA was purified.  In brief, samples 
were incubated with a provided buffer and RNase A (100mg/ml) before being diluted in 
ethanol and applied to the QIAamp minispin column for several steps of centrifugation.  
The spin column was then incubated in provided buffers, re-centrifuged and the flow 
through collected.  gDNA yield and purity were assayed by the 260:280 nm ratio on a 
Nanodrop 3000. 
Detection of GFP using qRT-PCR had previously been optimised in our laboratory and   
laboratory standard protocol was followed.  A standard curve was generated using gDNA 
isolated from a known number of UBI-GFP C57 Bl/6 MSC (MSC from mice expressing 
GFP on every cell) and was diluted to specific concentrations ranging from 10 cell 
equivalents/μl to 5 x 104 cell equivalents/μl.  These gDNA dilutions were run concurrently 
with experimental tissue gDNA samples.  All reactions were performed on a Rotor-Gene 
RG-3000 (Corbett).  Detection of GFP from each sample was performed in a 20μl reaction 
volume (contents shown in Table 7.2).  Each reaction was amplified at 94°C for 5 minutes, 
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followed by 40 cycles of: 94°C for 15 seconds, 63°C for 30 seconds and 72°C for 60 
seconds.  Cell numbers within the sample were calculated from the standard curve (Rotor-
gene-6 software, Rotorgene, Corbett Research).  As each sample was a different weight 
and most samples did not consist of an entire organ, the total number of cells per sample 
was divided by the weight of the sample in mg to ascertain a value of GFP+ cells/mg 
tissue, which is directly comparable between different tissues.       
Table 7.2: Contents of tubes required for detection of GFP cells from 
gDNA. 6-carboxyfluorescin (FAM) and tetramethylrhodamine (TAMRA) GFP 
gene specific probes used to analyse aliquots of gDNA for GFP content. 
GFP gene specific probe: 5’ primer CTGCTGCCCGACAACCA 1.0 μM 
GFP gene specific probe: 3’ primer TGTGATCGCGCTTCTCGTT 1.0 μM 
Probe: FAM  -CCCAGTCCGCCCTGAGCAAAGAC - TAMRA 1.0 μM 
MgCl2 (Invitrogen) 10mM 
PCR buffer (Invitrogen) 10 X 
dNTPs (Promega) 40mM 
Tween-20 (Sigma-Aldrich) 10% 
Nucleic acid free water (Qiagen) 10.8 μl 
DNA 2 μl 
 
GFP microscopy 
All histopathology was processed at the QIMR Histology Facility.  Tissue in formalin was 
submitted to this Facility, where it was blocked and cut for slides.  Immunohistochemistry 
using a secondary antibody against GFP was optimised using a positive control of a 
healthy mouse kidney injected with millions of GFP+ MSC.  Slides were reviewed with light 
microscopy on an Olympus BX 50 teaching microscope.  
7.2.3.2 Renal outcomes after MSC administration 
Renal Function 
Renal function was assessed as described in 6.2.6.  In brief, blood samples were 
centrifuged to collect serum, which was then processed at the RBWH Pathology Services 
Unit and analysed for serum creatinine and serum urea.  In the same sample, serum was 
analysed for LDH. 
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Histopathology 
Histopathology was processed and scored as described in 6.2.7.  In these experiments, 
apical cytoplasmic vacuolisation was not included in the overall score, as it was found to 
be an inconsistent marker of injury.  No apical cytoplasmic vacuolation was seen in normal 
controls.  It appeared with mild injury and increased as the injury worsened.  However in 
the presence of severe tubular necrosis, apical cytoplasmic vacuolation was rarely 
visualised and falsely lowered the total score (data not shown).  Therefore the minimum 
possible histological score was 5, with a maximum possible score of 25.   
7.2.4 Statistics 
Data are presented as mean ± standard deviation.  All statistics were performed using 
GraphPad Prism 6.  Unless otherwise documented, significance was analysed by one way 
ANOVA tests, with analysis of multiple comparisons corrected by Tukey’s test.  Where 
significant, symbols for p values are graphically displayed as * (p<0.05), ** (p<0.01) and 
*** (p<0.001).   
7.3 Results 
7.3.1 Culture and characterisation of murine MSC 
7.3.1.1 Morphology of murine MSC 
Murine MSC were plastic adherent, displayed the characteristic fibroblastic appearance 
and were readily able to be cultured and expanded ex vivo (Figure 7.2). 
100μm
 
Figure 7.2: Murine MSC indistinguishable from human MSC by morphology, showing classic fibroblastic 
appearances.  Light microscopy, 100 x magnification. 
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7.3.1.2 Immunophenotype of murine MSC 
Staining murine MSC for the characteristic cell surface markers showed that murine MSC 
isolated and cultured using these techniques were consistently CD45 negative, CD11b 
negative and CD31 negative, but retained positivity for Sca-1 and CD44 (Figure 7.3).  As 
mentioned previously, Sca-1 is a marker of MSC.  CD44 is also found on MSC, among 
other cells including haematopoietic stem cells, where it functions to aid homing of the cell 
to the bone marrow.  Cell culture contamination with haematopoietic cells was excluded by 
confirming absence of CD45 (found on all leukocytes), CD11b (found on leukocytes) and 
CD33 (found on myeloid cells). 
 
Figure 7.3: Immunophenotype of murine MSC.  A) MSC were positive for Sca-1, but negative for CD45. B) 
MSC were positive for CD44 C) MSC were negative for CD11b (a macrophage marker) and D) MSC were 
negative for CD31 (a platelet endothelial cell marker). 
7.3.1.3 Functional Capacity of murine MSC  
Confirmation of the retained ability of MSC to differentiate to adipocytes, osteocytes and 
chondrocytes under appropriate stimulation confirmed that these cells, which had the 
characteristic appearance and cell surface markers of MSC, also functioned in ways 
typical for MSC.   
Figure 7.4 shows murine MSC after differentiation into cells of the mesodermal lineage.  In 
figure 7.4 A, MSC had differentiated into adipocytes, as shown by the presence of lipid 
droplets by Oil-red O staining.   Figure 7.4 B confirmed differentiation into osteocytes by 
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Alizarin red staining of calcium, and figure 7.4 C confirmed differentiation into 
chondrocytes by Alcian blue staining.  All differentiation was confirmed using negative 
controls which were cultured in standard media for the same time course (photographs not 
shown). 
 
Figure 7.4: Differentiation of MSC into mesodermal lineages.  A) Staining with Oil-Red O confirmed 
Adipocyte differentiation B) Staining with Alizarin red confirmed Osteocyte differentiation C) Staining with 
Alcian blue confirmed chondrocyte differentiation.  All photographs taken from light microscopy, A and B at 
40 x magnification and C at 100 x magnification. 
7.3.2 Pilot study assessing efficacy of MSC when administered by IV, SC and IP 
injection 
7.3.2.1 Distribution of MSC after renal IRI 
Quantification of GFP+ DNA within the kidney and other tissues 
DNA was extracted from tissues and analysed for GFP+ DNA.  Using the standard curves 
(figure 7.5A), absolute numbers of GFP+ cells within tissues were counted.  The results 
are graphically presented in Figures 7.5 and 7.6 as the number of GFP+ cells per mg of 
tissue.  Figure 7.5 B shows the distribution of GFP+ cells 48 hours after administration of 8 
x 106 MSC via IP injection.  Significantly greater numbers of MSC were found in the kidney 
compared to other tissues (p = 0.0097).  Specifically there was a mean of 246.3 (95% CI 
0-706) GFP+ cells per mg of tissue in the kidney compared to 15.5 (95% CI 0-40.6) in the 
spleen, 5.3 (95% CI 0-13.6) in the heart, 1.7 (95% CI 0-5.5) in the liver, 0.4 (95% CI 0-1.4) 
in the lung and 0.01 (95% CI 0-0.02) in bone tissue (p <0.05 for each organ when 
compared to the kidney but there were no statistically significant differences between the 
non-kidney organs).  The higher number of cells found in the kidney suggests that when 
injected IP, MSC home to injured tissue.   
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In the group that received SC MSC, there was no statistically significant increase in GFP+ 
cells seen in the kidney after 48 hours when compared to other organs, although there 
were small differences (Figure 7.5C, p= 0.09).  The highest number of MSC/mg tissue was 
seen in the kidney.  
After injection with MSC IV, very few MSC were found in the kidney at 48 hours (Figure 7.5 
D) but there was a statistically significant increase in GFP+ cells in the lung (p = 0.004).  A 
mean of 16.1 cells were found in the lung (95% CI 2.1-30.2), compared to 4.7 in the kidney 
(95% CI 0-46.2, p<0.05), 3.6 in the spleen (95% CI 0-35, p<0.05), 1.2 in the heart (95% CI 
0-3.2, p<0.01), 0.1 in the bone (95% CI 0-0.8, p<0.01) and 0.0 in the liver (95% CI 0-0, 
p<0.01).  Other than the lung, there was no statistically significant difference in the number 
of GFP+ cells found in the kidney and those found in other organs (p>0.05 for all 
comparisons). 
Figure 7.6 compares the absolute number of GFP + cells found in each organ 48 hours 
after renal IRI, for each mode of administration.  The absolute number of GFP+ cells in the 
kidney appears higher with IP administration of MSC at a mean of 246.3 cells/mg 
compared to 24.4 cells/mg and 4.7 cells/mg for SC and RO administration respectively 
(Figure 7.6 A). However this was not statistically significant (p=0.35).  Also, the IP group 
received 8 x 106 MSC as compared to 0.5 x 106 MSC in the SC and RO groups.  
Assuming that each mouse kidney is 200mg and the GFP+ cells were evenly distributed 
throughout the kidney, the percentage of administered MSC in the kidneys can be 
estimated.  Only a very small percentage of administered MSC were found in the kidney 
with any of the modes of administration, and it is highest with SC administration.  
Specifically, an estimated mean of 2.0% of MSC administered SC localise to the kidney 
(95% CI 0-5.3%) compared to a mean of 1.2% (95% CI 0-3.5%) with IP administration and 
0.4% (95% CI 0-3.7%) with RO administration (p=0.34). It is worth noting that the first 
dilution in the standard curve reflected DNA isolated from 20 GFP+ cells, so a value below 
20 is based on extrapolation from the standard curve and represents an estimated value 
only. 
135 
 
y = 1.1318x0.986
R² = 0.9989
1
100
10000
1000000
1 100 10000 1000000
A
n
al
ys
e
d
 G
FP
 c
o
p
ie
s 
/ 
u
l 
gD
N
A
Standard GFP Copies/ul gDNA
GFP PCR Standard Curve
A B
C
D
Figure 7.5: Absolute number of GFP+ cells found per mg of tissue in different tissue types after 
administration of MSC.  A) Example of standard curve, used for calculating GFP+ cell numbers. B) 
Intraperitoneal injection, p = 0.00097 (kidney compared to all other organs) C) Subcapsular injection, p = 
0.0945 D) Intravenous retro-orbital injection p = 0.004 (lung compared to all other organs). All statistics 
performed by GraphPad 6, with multiple comparisons corrected by Tukey’s test. N = 2-3 in each group. 
(mean 24.4, 95% CI 0-66.8), followed by the lung (15.8, 95% CI 0-67.7), the spleen (4.0, 95% CI 0-10.2), the 
heart (1.7, 95% CI 0-5.5), the liver (0.6, 95% CI 0-3.0) and finally the bones (0.02, 95% CI 0-0.04) (p>0.05 for 
each comparison) (Figure 7.5 B).  It is clear that despite the injection of MSC being SC, the cells were able to 
migrate to the circulation and were able to be found in other tissues in small numbers. 
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Figure 7.6: Distribution of MSC to various tissue types within the body after injury to the kidney and 
administration of MSC by three different routes.  A) Kidney B) Heart C)  Lung. D)  Liver. E)  Spleen. F)  Bone 
tissue.  p>0.05 in all graphs.  Data analysed with one way ANOVA (GraphPad Prism 6). N = 2-3 in each 
group. 
Only very small numbers of GFP+ cells were seen in the heart after any mode of MSC 
administration, with a mean of 1.3 (95% CI 0-3.2), 1.7 (95% CI 0-5.5) and 5.3 (95% CI 0-
13.6) GFP+ cells /mg of tissue found in RO, SC and IP groups respectively (p=0.17) 
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(Figure 7.6 B).  Higher numbers of GFP+ cells were seen in the lung tissue of groups 
receiving RO or SC MSC (mean 16.1 cells/mg, 95% CI 2.1-30.2 vs 15.8 cells/mg, 95% CI 
0-67.7 respectively) compared to IP MSC (0.4/mg tissue, 95% CI 0-1.4) although this 
difference was not statistically significant (p=0.35) (Figure 7.6 C).  These results are 
important as MSC trapping in the lungs has been an important safety concern with murine 
experiments.  As shown in Figure 7.6 D, minimal GFP+ cells were found in the liver.  After 
IP administration, a mean of 1.7cells/mg (95% CI 0-5.5) were seen.  After SC 
administration, a mean of 0.6 cells/mg (95% CI 0-3) were seen and after RO 
administration, a mean of 0 cells/mg (95% CI 0-0) were seen (p=0.32).  GFP+ cells are 
appreciably noted in the spleen (Figure 7.6 E) with a mean of 15.5 cells/mg (95% CI 0-
40.6) seen after IP injection, 4.0 cells/mg (95% CI 0-10.2) seen after SC administration 
and 3.6 cells/mg (95% CI 0-35) with RO administration of MSC (p=0.15).  Despite the fact 
that MSC are known to home to bone marrow, less than 0.1 GFP+ cells/mg of bone tissue 
were found (mean values 0.06 cells/mg, 95% CI 0-0.8, for RO and 0.01 cells/mg, 95% CI 
0-0.04 for both SC and IP, p=0.36, Figure 7.6 F). 
Importantly, these data shows that GFP+ MSC were found to some degree in all injured 
kidneys regardless of the mode of administration and the kidney was the predominant site 
for location of GFP+ cells at 48 hours when administered via IP or SC injection.  
Location of MSC within the kidney 
Having demonstrated that MSC could be found within the kidney after renal IRI, it was 
important to look at the location of the cells within the kidney.  Only rare cells were 
expected to be seen by immunohistochemistry as the absolute numbers of GFP+ cells 
within the kidney were few and the staining was done on one cross section of each kidney.  
Representative photographs of GFP+ cells within kidneys are shown in Figure 7.7 (200x 
magnification), Figure 7.8 (zoom in on photographs from Figure 7.7), Figure 7.9 and 7.10 
(both 400x magnification).   
For the positive control, a murine kidney was resected and then injected multiple times 
with a syringe containing many millions of MSC (Figure 7.7 A).  The nucleus of GFP+ cells 
stain a darker colour than the surrounding cells and are slightly larger.  Figure 7.7 B is a 
representative slide of kidney tissue 48 hours after renal IRI and IP injection of MSC.  This 
field is photographed from the outer medulla, where the majority of GFP+ cells were 
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visualised.  3 of the 5 GFP+ cells are identified by arrows, and on closer inspection (Figure 
7.8 A) these cells are mostly sitting within the tubular lumen, with some peritubular cells 
seen.  Occasional cells appear to be within the tubular epithelium. Figure 7.7 C displays a 
similar field in a kidney 48 hours after exposure to renal IRI and SC injection of MSC.  
Again, 5 cells are seen (2 indicated by arrows) and these are mostly within the tubular 
lumen, with some peritubular cells (Figure 7.8 B).  Very few GFP+ cells are seen in 
kidneys after RO IV injection of MSC.  Figure 7.7 D indicates the only cell seen on this 
field, which is within the tubular lumen (Figure 7.8 C).   
 
Figure 7.7: Representative slides showing GFP+ cells within the kidney.  A) Positive control. B) GFP+ cells 
48 hours after IP administration of MSC. C) GFP+ cells 48 hours after administration of SC MSC. D) GFP+ 
cells 48 hours after administration of RO IV MSC.  Immunohistochemistry staining for GFP (QIMR), all slides 
200x magnification. Arrows show representative cells. 
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Figure 7.8: Closer view of the cells identified in Figure 7.7, showing the position of the GFP+ cells relative 
to the tubules. A) MSC administered IP.  B) MSC administered SC. C) MSC administered RO IV 
Only 2 GFP+ cells were seen in glomeruli across the whole experiment, 1 from the group 
administered IP MSC and 1 from the group administered RO IV (Figure 7.9).   
 
Figure 7.9: Intraglomerular MSC after renal IRI.  A) GFP+ cell found within the glomerulus after IP 
administration MSC. B) GFP+ cell found within the glomerulus after RO IV administration of MSC.  In no 
other glomeruli were GFP+ cells seen, they were almost exclusively found in the outer medulla within 
tubular lumens and in the peritubular space.  400x magnification. 
Figure 7.10 shows further high-powered views of a GFP+ cell which appears to be 
positioned within the tubule itself (IP administration MSC, Figure 7.10 A) and a view of 
GFP+ debris scattered around a disrupted tubule (SC administration MSC, Figure 7.10 B).  
Debris was not uncommonly seen, both in intraluminal and peritubular positions.  It 
appeared more common in the group administered SC MSC. 
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Figure 7.10: GFP+ cell within a tubule, and GFP+ debris around a disrupted tubule after renal IRI. A) Close 
inspection of a GFP+ cell which appears to be within the tubular epithelium (IP administration MSC, 400x 
magnification) B) GFP+ debris shown around the circumference of a cross section of a disrupted tubule (SC 
administration MSC, 400x magnification). 
7.3.2.2 Renal outcome measures 
Renal function  
Serum was analysed for creatinine and urea, standard measures of renal function used in 
clinical practice.  Data were not available for all replicates, due to technical difficulties.  
Unfortunately this was the case for both animals in the RO MSC group, so no serum 
results are available for that group.  Data are only available for one replicate in the SC 
MSC group and in the IP vehicle group.  For that reason, no statistics have been 
calculated on these data.  Results are presented as data points with the mean without any 
further analysis.  There was an increase in serum creatinine compared to control in all 
groups except the SC MSC group (Figure 7.11 A).  The mean serum creatinine was 
29μmol/l for the control group and the SC MSC data point compared to 163μmol/l for the 
group administered RO vehicle, 189μmol/l for the IRI group administered IP vehicle, 
147μmol/l for the group administered IP MSC and 92μmol/l for the group administered SC 
vehicle (n=1-3).  There was significant variation displayed within groups, with the RO 
vehicle group ranging from 80μmol/l to 146μmol/l, and the group receiving IP MSC ranging 
from 85μmol/l to 201μmol/l.  The data were pooled from the different vehicle groups, on 
the basis that these groups all received bilateral renal IRI without any treatment which 
would be presumed to modify renal injury (Figure 7.11B).  There did not appear to be any 
mitigation of the renal injury with administration of IP MSC (serum creatinine 147μmol/l 
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compared to 140μmol/l in the pooled vehicle group).  The sole data point from the group 
administered SC MSC did not show renal impairment.   
 
Figure 7.11: Serum creatinine 48 hours after bilateral renal IRI showing no benefit in IP MSC compared to 
vehicle.  A) Comparison between each experimental group: Control (no IRI); RO Veh (RO IV injection of 
vehicle); RO MSC (RO IV injection of MSC) no data available due to technical reasons; IP Veh (IP injection of 
vehicle); IP MSC (IP injection of MSC); SC Veh (SC injection of vehicle) and SC MSC (SC injection of MSC). 
Raw data with mean (N=1-3). B:  The same comparison with pooled data from all vehicle groups.  RO MSC 
omitted due to lack of data. 
The results of the serum urea analysis are shown in Figure 7.12. More consistency within 
groups was seen, with all vehicle-administered animals increasing serum urea from control 
(mean 10mmol/l) to between 50mmol/l and 91mmol/l.  The mean serum urea was 
72mmol/l in the RO vehicle administered group, 62mmol/l in the IP vehicle data point, 
70mmol/l in the group administered IP MSC and 60mmol/l in the SC vehicle administered 
group.  Again the SC MSC data point did not show renal injury, with a serum urea of 
19.2mmol/l (Figure 7.12 A).  Figure 7.12 B shows the pooled data of the vehicle groups, 
confirming that the group administered IP MSC did not appear to be protected from injury 
(mean serum urea 69mmol/l compared to 65mmol/l in the vehicle group).       
Serum LDH was assessed as a marker of cell damage (Figure 7.13).  Again there were 
data points missing as the analysis was done from the same serum provided for renal 
function.  The mean LDH in the control group was 197mmol/l.  This was slightly increased 
in the SC MSC group (596mmol/l, n=1) and significantly increased in other groups 
(2031mmol/l in the group administered vehicle RO, 5230mmol/l in the group administered 
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vehicle IP, 2835mmol/l in the group administered vehicle SC and 2599mmol/l in the group 
administered SC MSC,).  However, there was wide variation in all groups (Figure 7.13 A).  
Pooling the vehicle data showed no difference between the groups receiving vehicle 
(mean LDH 3090mmol/l) and the group receiving IP MSC (2599mmol/l) (Figure 7.13 B).  
Overall, however, the LDH data was considered not useful due to the significant numbers 
of animals that did not increase their LDH after IRI. 
 
Figure 7.12: Serum urea 48 hours after bilateral renal IRI showing consistently elevated rea after renal IRI 
except in the lone data point for SC MSC.  A) Comparison between each experimental group: Control (no 
IRI); RO Veh (RO IV injection of vehicle); RO MSC (RO IV injection of MSC) no data available due to technical 
reasons; IP Veh (IP injection of vehicle); IP MSC (IP injection of MSC); SC Veh (SC injection of vehicle) and SC 
MSC (SC injection of MSC). Raw data with mean (N=1-3). B)  The same comparison with pooled data from 
all vehicle groups.  RO MSC omitted due to lack of data. 
 
Figure 7.13: Serum LDH 48 hours after bilateral renal IRI showing wide variation between individuals with 
no trends.  A) Comparison between each experimental group: Control (no IRI); RO Veh (RO IV injection of 
vehicle); RO MSC (RO IV injection of MSC) no data available due to technical reasons; IP Veh (IP injection of 
vehicle); IP MSC (IP injection of MSC); SC Veh (SC injection of vehicle) and SC MSC (SC injection of MSC). 
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Raw data with mean (N=1-3). B)  The same comparison with pooled data from all vehicle groups.  RO MSC 
omitted due to lack of data. 
 
Histopathology 
All the groups receiving IRI were found to have a statistically significant increase in 
histopathological score when compared to control (p=0.0004 by one way ANOVA) Figure 
7.14).  However, there were no significant differences among groups which had undergone 
IRI, regardless of MSC treatment.   
Specifically, the mean histological score for the group receiving IP MSC was 14.9 ± 1.7, 
which was not different from the group receiving IRI vehicle (13.7 ± 1.4, p>0.05).  The 
mean score for the group receiving RO MSC was 15.6 ± 0.14 which was not different from 
the group receiving RO vehicle (16.53 ± 0.35, p>0.05).  The mean score for the group 
receiving SC MSC was 13.7 ± 2.9, which again was not statistically different from the 
group receiving SC vehicle (15.4 ± 0.57, p>0.05). 
 
Figure 7.14: Histological scores of kidneys 48 hours after renal IRI with and without MSC treatment.  All 
groups statistically significant when compared to control (** p<0.01, *** p<0.001), no statistical difference 
between any other group (p>0.05). Statistics analysed by one way ANOVA using GraphPad Prism 6. 
Representative slides of this study are shown in Figure 7.15.  All groups experienced 
significant tubular damage, while retaining some areas of healthy looking tubules.  There 
were no differences evident between the groups. 
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Figure 7.15: Representative slides 48 hours after renal IRI and treatment as documented. A) IP Vehicle.  B) 
IP MSC C)SC Vehicle D) SC MSC E) RO Vehicle F) RO MSC. All photographs light microscopy (200x 
magnification). 
7.3.2.3 Summary 
In summary, this experiment showed that after administration of MSC by three different 
methods, MSC were able to be found in the kidney, particularly after IP and SC 
administration.  On analysing renal outcome measures, although the IP MSC group had 
the most cells within the kidney, there appeared to be no effect on renal function when 
compared to vehicle.  It was decided to continue with a definitive study assessing renal 
function and histopathology after IRI, comparing SC MSC and SC vehicle administration. 
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7.3.3 Further investigation into the role of SC administered MSC in renal IRI 
7.3.3.1 Renal outcome Measures 
As the pilot study reported in 7.3.2 consistently showed GFP+ cells within the kidney after 
SC administration, this experiment focused on the renal outcomes after IRI with SC MSC 
administration, rather than the fate of the administered GFP+ cells.  Analysis of this 
experiment was by assessment of renal function and histopathology and the results are 
presented here.  Of note, three animals in this study developed large subcapsular 
haemorrhages post-operatively and required euthanasia (2 from the MSC group, 1 from 
the vehicle group).  This was not thought to be related to the dose of MSC but to the 
injection itself, which was associated with a renal parenchymal bleed (a known 
complication of SC injection). 
Renal function  
Renal IRI led to statistically significant cell damage at 24 hours and renal failure at 48 
hours as seen in Figure 7.16.  However, there were no significant differences in serum 
creatinine, urea or LDH at either 24 or 48 hours between groups treated with SC vehicle 
and groups treated with SC MSC at the time of reperfusion (Figure 7.16).  The mean 
serum creatinine in the control group was 27μmol/l ± 2 (95% CI 22-32) (Figure 7.16 A).  
This was increased (although not statistically significantly) 24 hours after ischaemia 
(152μmol/l ± 46 (95% CI 36-267) in the group receiving vehicle and 156μmol/l ± 46 (95% 
CI 41-271) in the group receiving MSC, p>0.05 between groups and when compared to 
control).  At 48 hours the mean serum creatinine increased further in the vehicle treated 
group (258μmol/l ± 115 (95% CI 115-402), p<0.05 when compared to control) but only 
minimally in the MSC treated group (174μmol/l ± 132 (95% CI -153-501), p>0.05 when 
compared to control or to the vehicle treated group).  It is worth noting that one animal did 
not appear to develop renal failure in the MSC 48 hour group, and this is more likely to be 
a technical issue with the clamp than evidence of efficacy of MSC. The one way ANOVA of 
the whole analysis was not significant (p=0.054) 
Serum urea results are shown in Figure 7.16 B.  The mean serum urea of control mice 
was 10.4 mmol/l ± 0.06 (95% CI 9-11).  By 24 hours after ischaemia this had increased to 
52 mmol/l ± 12 (95% CI 22-82) in the vehicle group and 49 mmol/l ± 13 (95% CI 28-69) in 
the MSC group (p>0.05 compared to control and to each other).  At 48 hours, it was 
further increased, particularly in the vehicle group (mean serum urea 92 mmol/l ± 13 (95% 
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CI 76-108) in the vehicle group (p<0.001 compared to control) and 71 ± 41 (95% CI -30-
172) in the MSC group (p<0.01 compared to control, p>0.05 compared to the vehicle 
group).   
LDH analysis is shown in Figure 7.16C.  The mean LDH in the control group was 
206mmol/l ± 65 (95% CI 45-368).  There was a marked and statistically significant 
increase in LDH in both groups 24 hours after ischaemia (mean LDH 11135mmol/l ± 3203 
in the vehicle group (95% CI -17645-39915) and 10657mmol/l ± 5012 (95% CI -1793-
23106) in the MSC group, p<0.01 when each group is compared to control, but p>0.05 
between the two groups).  The LDH peaked at 24 hours and had started to fall by 48 hours 
(5784mmol/l ± 1646 (95% CI 3741-7827) in the vehicle group and 4860mmol/l ± 1683 
(95% CI -10260-19980) in the MSC group, p>0.05 between groups and when each group 
is compared to control).   
A B C
Figure 7.16: Serum markers of renal function and tissue damage 24 and 48 hours after bilateral renal IRI 
and SC injections of either vehicle (Veh) or 0.5 x 106 MSC. A) Serum Creatinine B) Serum Urea, C) Serum 
LDH.  No significant differences between vehicle and MSC at either 24 or 48 hours. * p<0.05, ** p<0.01, *** 
p<0.001. 
Histopathology 
Kidney sections were stained with PAS and analysed for histopathological score.  The 
results are shown in Figure 7.17.  There was no significant difference between any group 
at any time point (p=0.93 analysed by 1 way ANOVA, n=4-5 excluding control, where n=1).  
The mean histological score for the vehicle group analysed at 24 hours was 15.2 ± 3.8 
(95% CI 9.2-21.2).  The mean score for the group treated with MSC and analysed at 24 
hours was 14.5 ± 2.9 (95% CI 9.9-19),  (p>0.05 when compared to vehicle).  At the 48 
hour time point, the mean histological score was 14.2 ± 2.8 (95% CI 10.7-17.8), for the 
vehicle group and 15.2 ± 0.9 (95% CI 13.8-16.6) for the MSC group (p>0.05 when 
compared to vehicle).   
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Figure 7.17: Histopathology score after bilateral renal IRI with and without SC MSC treatment , p=0.93 (1 
way ANOVA).   
7.4 Discussion 
The aim of the work described in this chapter was firstly to isolate and culture cells which 
fit current definitions of murine MSC and secondly to administer them in a way that allowed 
investigation into their effect in renal IRI.  With respect to the first objective, cells were 
isolated and cultured using methods that were standard in our laboratory and in the ASC 
Laboratory at MMRI.  These methods have been published and are in line with methods 
used by other groups (261).  It was shown that the MSC cultured displayed characteristic 
cell surface markers and were able to differentiate into expected cell types.  These cells 
were indistinguishable from other murine MSC used in our laboratory. 
In both experiments presented in this chapter, MSC did not effectively protect against renal 
IRI, which is consistent with the one murine study in IRI at the time of the onset of the 
current work (27), but not with the rat studies available at the same time (142, 201, 202, 
204, 206).  The model of IRI led to statistically significant cellular damage at 24 hours and 
renal failure at 48 hours, as evidenced by serum LDH, creatinine and urea respectively.  
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Administration of MSC did not alter these results when compared to vehicle administration.  
It was demonstrated that MSC could be found in the kidney after IV RO, SC and IP 
administration.  They were predominantly found in the kidney after administration IP or SC, 
but not after RO IV administration, where they were predominantly found in the lung.  
However, it should be noted that after RO IV administration, very few MSC were found 
anywhere.  Both IP and SC administered MSC groups were found to have GFP+ cells 
within the outer medulla, largely around the renal tubules and within the tubular lumens.   
It is perhaps not surprising that MSC were predominantly found in the kidney in the SC 
group, as the MSC were injected directly into the kidney.  If they were unable to relocate 
they would be likely to still be in the kidney 48 hours later.  The fact that so few MSC were 
found in the kidney at 48 hours perhaps suggests that the majority of injected cells have 
moved or died.  Some GFP+ debris was found within the kidney but not in significant 
quantities.  GFP+ cells may have been phagocytosed and processed by other cells such 
as macrophages, although large numbers of macrophages and neutrophils were not 
appreciated microscopically.  GFP+ MSC were not able to be found in significant numbers 
in other tissues after SC administration, although their presence in small numbers 
suggests that after SC administration a proportion at least of injected MSC migrated to the 
circulation. It was reassuring that so many MSC were found in the kidney after IP injection, 
and the fact that the kidney was the predominant site for MSC to be found after IP injection 
fits with previous work suggesting MSC home to injured areas.  With the IV injection, only 
very rare cells were found in the kidney. 
It is possible that the numbers of MSC found in the kidney were too small to effect change 
with such a severe model of renal IRI.  If they do act in this situation by altering the 
immune environment, perhaps these alterations were overwhelmed by the immune 
activation taking place within the kidney.  In the second experiment looking at SC 
administration of MSC, the dose of MSC was doubled to optimise efficacy.  However, this 
did not appear to alter the results.  It may be that the high passage cells used for these 
experiments reduced their efficacy, although these cells were acting very much as an 
immortalised cell line, with excellent ex vivo survival and they had previously been shown 
to retain their immunosuppressive qualities at these levels (Dr Melinda Christensen, Bone 
Marrow Transplant team, MMRI, personal communication).  It is noted that the severity of 
renal failure observed clinically in the animals at 24 hours and more particularly at 48 
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hours was less apparent in the serum results, and other more sensitive biomarkers of 
renal impairment may have uncovered a difference between the vehicle and MSC groups, 
but this is considered unlikely.  A larger number of animals in each group would perhaps 
have improved statistical certainty but I suspect would not have changed the results.   
Given the trend of the published literature suggesting benefit of MSC in renal IRI, it was 
considered worthwhile to change the method of administration in a further attempt to 
demonstrate efficacy.  In some rat studies, intra-arterial administration of MSC afforded 
renoprotection (142, 201, 202, 206).  It was therefore decided to proceed with a study of 
MSC administered via intra-arterial (IA) injection in renal IRI.  For the next study, it was 
decided to use lower passage cells to ensure maximal cell activity.   
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Chapter 8 
Investigation of murine MSC delivered by intra-arterial 
injection in an animal model of renal IRI 
8.1 Background and objectives 
Previous experiments in this thesis have not shown efficacy of MSC in an in vivo model of 
renal IRI.  It is not clear whether this is due to the inherent lack of efficacy of these cells in 
this model or due to the inability of these cells to reach the required location at the 
appropriate time in critical numbers.  As described in Chapter 7, MSC have been found in 
the injured kidney in areas which display the most degree of damage.  However these 
analyses were done at 48 hours, and it is likely that the MSC need to reach the kidney 
early in the injury in order to have a significant impact.  In vitro work presented in Chapter 
3 indicates that the chain of molecular events leading to cell death begins in the first four 
hours of injury, so it is possible that cells arriving at the injured area after this time are 
unable to ameliorate this process.   
It was decided to perform a study of renal IRI with direct deposition of MSC into the aortic 
arch via the carotid artery.  These cells would then either be transported with the arterial 
circulation directly to the kidney or be flushed through into the left ventricle, from where 
they would be pumped into the aorta with the next systolic contraction.  The cells would 
therefore be readily available in the circulation and at least some cells would be expected 
to arrive at the injured area immediately.  The goal of this study was to ascertain whether 
or not MSC are efficacious in this murine model of renal IRI.  This procedure is very 
technically challenging surgery on a mouse due to the size of the animal, and required a 
surgeon of some skill.  The Dwyer Laboratory, Immunology Research Centre, St Vincent’s 
Hospital, kindly agreed to collaborate for this project, and all surgery was undertaken by 
specialist animal surgeon, Dr Bo Lu in Melbourne. The Dwyer Laboratory have a well 
validated and published model of uninephrectomy and unilateral IRI.  Some consideration 
was given to adhering to the previous model of bilateral IRI versus using a different, 
unilateral model.  It was felt that using the bilateral model in a different laboratory with 
different conditions would require revalidation and therefore it was decided to use the 
standard model of unilateral IRI for that laboratory.   
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8.2 Materials and methods 
8.2.1 Culture and characterisation of murine MSC 
MSC used in this study were isolated and cultured as described in Chapter 7, and 
displayed the same characteristic features of MSC.  Lower passage cells were selected, in 
case repeated cell division altered the immunological phenotype of the cell.  This was a 
precautionary measure, as previous work had shown no difference in the 
immunosuppressive capabilities of murine MSC at high passage.  For this study, MSC 
were resuspended in injection media at passage 9, the first passage at which ready growth 
was observed.  Injection media was identical to that described in 7.2.1.4.  A dose of 0.5 x 
106 MSC was selected, as this dose had previously been shown to be safe for IV 
administration.   
As this experiment took place in Melbourne, the cells required transport.  Cells were 
isolated and cultured in Brisbane.  A flask of appropriate passage cells (with the flask 
completely filled with growth media) was packed in paper towels in a polystyrene container 
inside a transport case.  Immediately on arrival in Melbourne, the cells were transported to 
the laboratory and placed overnight in an incubator.  The next morning, cells were 
passaged and counted before being re-suspended in injection media and placed on ice for 
surgery.  
8.2.2 Intra-arterial administration of MSC compared to vehicle 
All surgery was undertaken by Dr Bo Lu.  The experiment was authorised by the St 
Vincent’s Hospital animal ethics committee prior to starting.  The basic protocol used was 
Dr Lu’s standard unilateral nephrectomy, contralateral renal IRI protocol, which differs from 
that used in our laboratory, and has been published (256).  In short, C57Bl/6 mice were 
anaesthetised with IP ketamine (85mg/kg) and xylazine (15mg/kg).  The surgery was 
performed on a heating pad to ensure a core body temperature of 37 degrees throughout 
the procedure.  A midline abdominal incision was performed and the renal pedicles were 
bluntly dissected.  A right nephrectomy was undertaken.  An atraumatic microvascular 
clamp was placed on the left renal pedicle for 20 minutes, and during this time the animal 
was placed in an incubator set at 37°C and hydrated with warm normal saline IP.  The 
shorter duration of ischaemia used has been well established in the Dwyer Laboratory and 
is likely due to the increased temperature achieved during ischaemia with the availability of 
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the incubator.  At 20 minutes the clamp was removed and reperfusion confirmed.  The 
midline incision was closed with 2 layers of sutures. 
The novel methodology in this experiment was the administration of MSC or vehicle by 
carotid artery cannulation.  This procedure was undertaken immediately after removal of 
the vascular clamp from the renal pedicle.  The right neck was exposed and a sagittal 
incision made.  Blunt dissection was used to expose the carotid artery, and ligatures 
passed under the artery proximally and distally.  An atraumatic vascular clamp was applied 
proximal to the ligature, effectively removing all circulation to the carotid artery. At that 
stage a small incision was made within the artery and a cannula passed down the artery.  
The vascular clamp was released, allowing for the administration of either 0.5 x 106 MSC 
in 50μl injection media or injection media alone (vehicle).  Each injection was rapidly 
followed by 200μl normal saline to ensure flushing of the MSC down the common carotid 
artery into the aortic arch.  After this injection, the vascular clamp was re-applied, and the 
carotid artery was ligated using the previously placed ligatures.  This is possible owing to 
the well-developed Circle of Willis in the mouse, leading to significant collateral circulation.  
The neck was then sutured and the animal was placed in the incubator to recover. 
10 mice underwent unilateral nephrectomy, renal IRI and carotid artery cannulation with 
infusion of MSC (n=5) or vehicle (n=5).  Mice were sacrificed at 24 hours which is standard 
practice with this model of IRI.  The kidney was sectioned for histopathology and placed in 
formalin, and the remaining kidney tissue was snap-frozen for GFP qRT-PCR analysis.  A 
terminal cardiac bleed was taken at sacrifice for assessment of renal function. Other 
organs were collected and snap frozen for analysis of GFP qRT-PC and placed in formalin 
for light microscopy.  
8.2.3 Transport of tissue and serum to Brisbane for analysis 
Once the animal surgery was completed, the samples were relocated to Brisbane for final 
analysis.  Blood was centrifuged at 4°C and serum removed by syringe to Eppendorf 
tubes.  All snap frozen tissue was placed in small plastic tubes. These were then placed in 
a -80°C freezer.  All remaining MSC and injection media were discarded.  The tissues 
placed in formalin were transferred to 70% ethanol at 24 hours.  Prior to leaving Melbourne 
the frozen serum and tissue samples were packed in a polystyrene container in dry ice 
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and placed inside the transport case with the fixed tissue.  On returning to Brisbane the 
frozen samples were immediately placed in a -80°C freezer until analysis. 
8.2.4 Analysis 
Analysis for this experiment was performed as described in 7.2.3.  Briefly, DNA was 
extracted from kidney and other tissue and GFP gDNA was quantified.  Fixed kidney 
tissue was stained with PAS and other organ tissue stained with H and E by QIMR 
Histology Facility.  All organs were stained for GFP with immunohistochemistry.  Serum 
was analysed for renal function at the RBWH Pathology Services Unit and histopathology 
was assessed using methods previously described.  As in Chapter 7, the goal of the 
analysis was to confirm the presence of the MSC within the injured kidney, and then to 
analyse renal outcomes. 
8.2.5 Statistics 
Data is presented as mean ± standard deviation.  All statistics were performed using 
GraphPad Prism 6.  Significance was analysed either with unpaired t test (if comparing two 
groups only) or by one way ANOVA test (analysis of multiple comparisons corrected by 
Tukey’s test).  Where significant, symbols for p values are graphically displayed as * 
p<0.05, ** p<0.01 and *** p<0.001.   
8.3   Results 
8.3.1 Distribution of MSC after renal IRI 
8.3.1.1 Quantification of GFP+ DNA within the kidney and other tissues 
GFP+ cells were quantified in the kidney and in other organs of mice administered MSC.  
The highest number of GFP+ cells per mg tissue was found in the lung (mean 31 cells ± 
30, 95% CI 0-68) (Figure 8.1).  The organ with the second highest density of GFP+ cells 
was the kidney with a mean of 14 cells/mg tissue ± 7 (95% CI 5-22).  The only other 
organs with any appreciable number of GFP+ cells were the heart, at 4 cells/mg tissue ± 2 
(95% CI 1-6) and the spleen, at 4 cells/mg tissue ± 1 (95% CI 2-6).  One way ANOVA of 
this experiment was significant, at 0.012, due to the significantly greater number of cells 
found in the lung than in the heart (p<0.05), liver (p<0.05) and spleen (p<0.05).  There was 
a wide range of results for the lung within this experiment (5-75 cells/mg tissue) when 
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compared to the kidney (6-23).  Even smaller ranges were found with the other organs.  
The range of cells/mg tissue found in the heart was 1-2, in the spleen was 3-6 and in the 
liver was 0-0.1.  Only one data point was available for the brain, which is displayed for 
interest only (0.2 cells / mg tissue). 
  
Figure 8.1: Distribution of MSC in the mouse 24 hours after renal IRI and intra-arterial injection into the aortic arch.  
p = 0.012 by one way ANOVA, although the only significant comparisons are lung vs heart (p<0.05), liver (P<0.05) and 
spleen (p<0.05).    N= 5 for all groups except the brain (n=1). 
8.3.1.2 Location of MSC within the kidney 
Slides were stained for immunohistochemistry with a secondary GFP antibody in the QIMR 
Histology Facility as previously described.  Only rare MSC were directly visualised in any 
organ.  Figure 8.2 shows representative slides of the distribution of GFP+ cells within the 
kidney, with Figures 8.2 A and B showing the negative and positive controls, respectively.  
In the experimental groups, GFP+ cells were visualised in every kidney which received 
MSC.  However, they were only rarely identified.  MSC were most commonly seen in 
peritubular positions, as shown in Figures 8.2 C and D.   Close inspection of the cluster of 
cells shown in Figure 8.2 C (200x magnification) revealed what appeared to be both cells 
and GFP staining debris (Figure 8.2 D, 400x magnification).  Debris was not uncommonly 
seen, suggesting MSC destruction.  GFP+ cells were also seen in tubular lumens (Figure 
8.2 E) and in one field, debris was found within a tubular structure (Figure 8.2 F).  Although 
cells were more commonly seen in the outer medulla, they were found in the outer cortex 
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and the inner medulla on occasion.  There did not appear to be any trends or patterns 
associated with GFP+ cell location.      
 
Figure 8.2: Location of GFP+ cells within the kidney after renal IRI and intra-arterial injection of MSC.  A) 
Negative control (200x magnification) B) Positive control (200x) C) Cluster of GFP positive cells and debris in 
peritubular region of the outer medulla (200x) D)  The same view as C but at 400x D) GFP+ cells within 
tubular lumen (200x) E:  Intratubular GFP+ debris shown by arrow (200x). 
8.3.1.3 GFP+ immunohistochemistry staining in non-renal organs 
When measured quantitatively, GFP+ cells were most abundant in the lung, followed by 
the kidney, the spleen and the heart.  The immunohistochemistry results were slightly 
different.  GFP+ cells were rare in any tissue, but they were able to be directly visualised 
most often in the kidney, the spleen and the heart.  Figures 8.3 A and B show the only 
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GFP+ cell that was visualised by immunohistochemistry in the lung.  Figures 8.3 C and D 
are representative slides depicting GFP+ cells found within the heart.  These cells 
appeared to be randomly scattered throughout the heart.  All of the sections of spleen 
were found to contain GFP+ cells and 1 representative slide is shown in Figure 8.3 E.  
Figure 8.3 F shows the only GFP+ cell found within the sections of liver. 
 
Figure 8.3: Distribution of GFP+ cells in non-renal organs after renal IRI and intra-arterial injection of 
MSC.  A) GFP+ cell in lung (40x magnification) B) the same cell at 200x. C) and D) GFP+ cells within the heart 
(200x). E) 2 GFP+ cells seen in the spleen (200x).  F) The only GFP+ cell seen in the liver on any slide (200x). 
8.3.2 Renal outcome measures 
8.3.2.1 Renal function  
Serum creatinine and urea were analysed to assess renal function.  The mean serum 
creatinine of mice receiving vehicle after unilateral nephrectomy and unilateral renal IRI 
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was 80 μmol/l ± 35 (95% CI 36-123 μmol/l).  There was no protective effect seen from 
MSC administration, with the mean serum creatinine 82 μmol/l ± 34 (95% CI 39-123) in 
this group (p=0.94 analysed by unpaired t-test, Figure 8.4 A).  The mean serum urea 
found in the vehicle group was 38 mmol/l ± 12 (95% CI 22-52mmol/l).  The group 
administered MSC displayed almost identical results, with a mean serum urea of 40μmol/l 
± 11 (95% CI 27-53) (p=0.77, Figure 8.4 B).  Serum LDH was investigated as a marker of 
cell damage.  There was a mean LDH of 1838 mmol/l ± 606 (95% CI 1085-2591mmol/l) in 
the group administered vehicle.  This was unchanged after administration of MSC, with the 
mean LDH 2018 mmol/l ± 573 (95% CI 1106-2929) (p=0.67, Figure 8.4 C).   
 
Figure 8.4:  Renal function and LDH 24 hours after renal IRI and administration of vehicle or MSC via 
intra-arterial injection through the carotid artery. N=5 in each group  A) Serum creatinine p=0.94 by 
unpaired t-test. B) Serum urea p=0.77 by unpaired t-test. C) Serum LDH p=0.67 by unpaired t-test. 
8.3.2.2 Histopathology 
Slides from the unilateral kidney which received IRI were stained with PAS and analysed 
for histopathological score as previously described.  The mean score for the group 
administered vehicle was 10.5 ± 3.3 (95% CI 6.4-14.6) out of a maximum possible score of 
25.  There was no difference found in the group administered MSC, where the mean 
histopathological score was 11.74 ± 3.25, 95% CI 7.7-15.8 (p=0.566 by unpaired t-test, 
Figure 8.5). The range of scores seen in the vehicle group was 7-14.5, almost the same as 
in the MSC group (8.3-15.6).  Representative slides are shown in Figure 8.6.  
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Figure 8.5: Mean histological score 24 hours after renal IRI with administration of vehicle or intra-arterial 
MSC. N=5 in each group (p=0.57 by unpaired t-test). 
 
 
Figure 8.6: Representative slides showing no difference in histopathological renal injury with intra-
arterial MSC.  A and B) representative slides from group receiving vehicle. C and D) representative slides 
from the group receiving MSC. All slides at 200x magnification, Periodic acid Schiff staining. 
159 
 
8.4 Discussion 
This experiment took place in a different laboratory using different methods of IRI.  This 
was considered scientifically valid as the purpose of this experiment was not to compare 
IA MSC injection with other modes of administration previously studied.  The purpose of 
this experiment was to compare IA MSC injection with vehicle injection looking for efficacy 
of MSC.  Had the results been different to the previous chapter, it would have been 
important to consider the different model as well as the route of administration of MSC as 
possible contributing factors.  However, the results were in fact not different to the previous 
chapter suggesting that even with a unilateral model of IRI, MSC were not effective. A 
limitation of this experiment was the lack of a control arm.  However published data 
contemporaneous with this work from the same laboratory using the same IRI model found 
statistically significant renal impairment when compared to sham operated mice at 
essentially the same levels of serum creatinine and urea found here (256).   
By using IA administration of MSC, this experiment aimed to deliver MSC to the injured 
kidney rapidly, so that they were in position to ameliorate IRI as soon as possible.  MSC 
were found within the kidney at 24 hours, and also within other organs including the lung.  
Given that the cells were deposited into the aortic arch, the fact that they were found in the 
lung indicates that they were circulating within the blood stream.   
Despite the fact that the MSC were able to reach the kidney very soon after the injury, 
there was no evidence of protection against renal IRI.  The serological markers of renal 
injury, serum creatinine and urea, were no different in the group receiving MSC when 
compared to the group receiving vehicle.  LDH, a sensitive marker of tissue damage, was 
the same in the two groups.  Histological analysis of the injured kidney showed that there 
was no benefit in the group receiving MSC.   
These results are consistent with the results shown in Chapter 7 and indicate that the lack 
of efficacy of MSC seen in Chapter 7 was not likely to have been due to the method of 
administration.  It seems more likely, given the weight of evidence presented, that these 
cells are not efficacious in protecting C57 Bl/6 mice from renal IRI.  This result is also 
consistent with the findings in the in vitro work presented in this thesis, where MSC 
application to the model did not protect HK2 cells from injury induced by H2O2.  Further 
discussion of these results within the context of recently published studies in MSC in renal 
IRI is presented in Chapter 9.  
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Chapter 9  
Discussion 
Renal IRI is a real world clinical problem, where for many reasons, patients experience a 
temporary loss of blood supply to the kidneys and then re-establishment of that blood 
supply.  The injury to the kidney occurs both from the loss of blood supply and from the 
inflammatory response triggered by reperfusion.  The cascade of oxidative stress 
experienced after reperfusion also contributes significantly to damage.  In the clinical 
scenario, up to 23% of hospitalised patients experience AKI (263), and renal IRI is a strong 
contributing factor in 91.2% of cases of AKI in patients admitted to the intensive care unit 
(5).  Hoste et al found a clear association between severity of AKI and mortality.  Moderate 
AKI was significantly associated with hospital mortality (odds ratio (OR) of 2.945, 95% CI 
1.382-6.276, p 0.005) with severe AKI associated with even higher risk of hospital mortality 
(OR 6.884, 95% CI 3.876-12.228, p<0.001).  The severity of AKI was defined by the 
Kidney Disease: Improving Global Outcomes (KDIGO) criteria (264).  There is no specific 
treatment or prevention known for AKI, other than treating the underlying cause, and there 
can be long lasting adverse effects including death, chronic kidney disease and dialysis.  
Renal IRI has a significant impact on the health dollar in all developed nations and an even 
heavier burden of morbidity and mortality in developing nations, where there is little or no 
access to dialysis.  The data above suggests that any reduction in severity of AKI should 
improve mortality.   Cellular therapy is an attractive treatment possibility, particularly MSC, 
which have been shown to be safe and feasible to infuse after large scale ex vivo 
expansion (265). 
At the time of commencement of the current work, it was established that MSC were 
immunomodulatory, anti-inflammatory and likely to have paracrine effects in repair and 
regeneration of damaged tissues.  As reviewed in 2.2.3, MSC were effective in a number 
of rodent models of renal IRI, although the large majority of these studies were in rats.  
Experiments described in this thesis sought to look further at the effects of allogeneic 
human MSC on human HK2 TEC in a cell culture method, with particular attention to the 
interaction between MSC, CD4+ cells and DC in that culture.  This thesis also aimed to 
test a model of syngeneic MSC efficacy in murine renal IRI. 
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A severe model of renal IRI in vitro was developed, using H2O2 administration to mimic 
oxidative stress, a well-established method of studying IRI in vitro.  BM MSC and Plac 
MSC were cultured by standard practice and characterised prior to application to the 
model.  In all studies BM MSC and Plac MSC behaved in the same way and led to the 
same results.  MSC were ineffective at preventing HK2 cell death or cytotoxicity in both 
direct and indirect cell culture models.  Pre-stimulating the MSC with inflammatory 
cytokines (IFNγ and TNFα) did not lead to HK2 protection.  This is in contrast to some 
animal studies showing that MSC cultured in hypoxic settings (199) or preconditioned with 
cytokines produced by oxidative stress (266) led to improved nephroprotection compared 
to MSC cultured in standard media.  In the current work, administration of MSC CM led to 
persistent reduction in LDH levels, suggesting reduced cellular damage.  There was 
however no effect on cell viability, although a non-statistically significant trend to reduction 
in necrotic cells was demonstrated.  This MSC CM protection from cell damage was lost 
when the CM applied was from MSC cultured with IFNγ and TNFα.  It is possible that the 
inflammatory cytokines within this CM were in themselves damaging to the TEC, although 
any effect was likely to be minor in the setting of the severe IRI.   
In summary, MSC applied to HK2 cells injured by H2O2 were not effective in an in vitro 
model of renal IRI, although MSC CM reduced LDH, a marker of cellular damage, without 
altering cell viability outcomes.  The next area of study was the assessment of effect of 
MSC in the presence of CD4+ T cells and DC.   
The initial hypothesis was that MSC would require the presence of DC and CD4+ T cells to 
be effective.  Published work as reviewed in Chapter 2 found that MSC reduce 
differentiation and maturation of DC, leading to the probability that the T cell phenotype 
would be skewed towards a Th2 phenotype, reducing the inflammatory mediator burden.  
The hypothesis was that this would protect against renal IRI.  DC used in these 
experiments were generated from monocytes, with positive monocyte selection from 
PBMC using microbeads and then inducement of differentiation into DC using specific DC 
media for several days.  CD4+ cells were naive cells isolated by lineage depletion from 
PBMC.  First, CD4+ cells and DC were applied to the model in the absence of MSC, to 
ensure that they themselves did not impact on PTEC outcome.  There was no alteration in 
cell viability or cytotoxicity with CD4+ cells and / or DC in the absence of MSC.  When 
MSC were added to the model, no additional protection was found. Using MSC CM did not 
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alter the cell viability outcomes in the presence of CD4+ cells and/or DC.  The reduction in 
LDH levels suggesting reduction in cytotoxicity by MSC CM, seen in previous experiments, 
was persistent through the CD4+ cells and DC experiments.  However, no additional 
protection from cell damage was seen by CD4+ cells or DC in the presence of MSC CM.   
As previously discussed there were a number of limitations in these studies.  This was a 
very severe model of renal IRI. Further experiments with a more moderate model of IRI 
may be useful to unmask potential effects of MSC overwhelmed by the severity of the 
injury in the current IRI model.  The cell viability in the initial development of the model was 
greater than that in the following experiments, which led to the choice of the model.  There 
was large intra-well variability despite these experiments being repeated numerous times, 
and this increases the possibility of a type II error.  In all the cell viability experiments, MSC 
were exposed to H2O2 media to ensure an early exposure to the damaged cells.  However, 
H2O2 is known to also damage MSC and may well have abrogated the ability of MSC to 
secrete anti-inflammatory cytokines.  MHC typing was not performed in these allogeneic 
experiments, and numerous donors were involved in all aspects from PTEC to MSC to 
PBMC.  Despite the immunosuppressive qualities of MSC, there may have been immune 
activation or immune recognition by the CD4+ cells and DC.  MSC were previously thought 
to be immunoprivileged, but it is becoming increasingly clear that they can generate cell 
mediated and humoral responses, and have more recently been labelled as “immune 
evasive” (138, 267).  One murine study in graft versus host disease found that allogeneic 
MSC lost the immunosuppressive potential of syngeneic MSC and were rejected rather 
than differentiating into bone (268).  Togel et al treated animals who had undergone renal 
IRI with both allogeneic and syngeneic MSC and only found effect with syngeneic MSC 
(211).  Therefore it is possible that the diverse MHC expression profile likely to have been 
present on the cells used in the current experiments impacted the results.   
The consistent improvement in cytotoxicity with MSC CM in the current work is very 
interesting given the direction of the field in the last 5 years.  It is now clear that MSC 
secrete extracellular vesicles (EV) such as microvesicles and exosomes (269).  The 
possibility that MSC secreted EV into CM as the mechanism of the improvement in 
cytotoxicity demonstrated should not be ignored.  This could also explain the heterogeneity 
in the findings, as it is now understood that MSC from different donors and in different 
environments secrete different quantities and phenotypes of EV (270, 271).   
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There remains very little published data on in vitro experiments of renal IRI and MSC.  Our 
own laboratory looked at the application of 0.4mM H2O2 (a slightly lower concentration 
than used in the current work) on rat renal TEC in a transwell model with rat BM MSC 
(198).  Statistically significant reduction in apoptosis and increase in mitosis was found 
when MSC were applied to the model, compared to H2O2 alone.  Recently, Yuan et al 
studied rat TEC in a transwell system with and without MSC.  To mimic hypoxia-
reperfusion an ischaemia hypoxia medium containing high concentrations of glucose was 
used. The culture plates were filled with low oxygen gas (5% CO2, 95% N2) and sealed 2 
hours before O2 was added and the culture medium was changed to DMEM + FBS.  There 
were two groups of MSC applied to this model, standard MSC or MSC pretreated with 
hypoxia prior to application. Analysis of cell viability was performed using annexin V and PI 
at 24, 48 and 72 hours.  There was statistically significant increase in cell viability and 
reduction in apoptosis at 72 hours in both MSC groups pretreatment of MSC led to an 
increase in cell viability and reduction in apoptosis over and above the standard MSC 
(199).  There were small differences in cell viability and apoptosis at 24 and 48 hours but 
these were not statistically significant.  This outcome does lead me to consider whether a 
longer time point might have shown more significant results in the current in vitro model 
(as only 24 hour data was analysed), although their injury model was also less severe than 
ours, which may have impacted on the results.  Interestingly, a cross-species model 
analysed the effect of human adipose MSC in co-culture with freshly isolated murine TEC 
(273) and found that after pretreatment with TGFβ1, adipose derived MSC were 
associated with increased Ki67 (suggesting cell proliferation) and vimentin (suggesting 
epithelial to mesenchymal transdifferentiation, perhaps as a prelude to regeneration of 
TEC). 
The work described in this thesis is novel, with no other studies reporting on human MSC 
treatment of human epithelial cells in an IRI model.  Traditionally in translational science, a 
new therapy would be carefully studied in a cell culture model prior to moving to animal 
models and thence clinical trials.  In this case, human clinical trials were begun with a 
paucity of in vitro work and previous heterogeneous results in in vivo animal models (274).  
After analysing the effects of human MSC in the current in vitro model, the focus of the 
work shifted to establishment of a murine model of renal IRI with administration of 
syngeneic GFP+ murine MSC. 
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Firstly, a murine model of bilateral renal IRI was developed in our laboratory. Given that 
published work (particularly in the rat model) had suggested a possible discrepancy in 
results depending on the mode of administration of MSC, three different modes of MSC 
administration were assessed in a pilot study.  At that time, the only published murine 
study in renal IRI/MSC used IV administration of MSC via the tail vein (27).  In the current 
work, MSC were injected IV through the retro-orbital sinus, an established technique in our 
laboratory.  Only 0.5 x 106 MSC were administered using this approach as 1 x 106 MSC 
had previously been found to be unsafe by the ASC Team in our research institute with 
early murine demise due to MSC trapping within the lungs.  Some other groups (272, 275-
277) have not experienced this problem and were able to administer 1 x 106 MSC IV 
without documented adverse outcomes.  The current study also looked at IP 
administration of MSC and in this case a high dose was used (8 x 106) as it was expected 
that it would be safe (based on previous work by the Bone Marrow Transplant Team at our 
research institute) and that many of the cells would be likely to die prior to reaching the 
injured area.  Only one published study in murine renal IRI has used IP administration of 
MSC and they used 3 x 106 MSC (275). For the renal SC administration of MSC 0.25 x 106 
cells were used in each kidney, giving rise to the same total dose as in the IV group.   No 
murine MSC renal IRI studies have looked at renal SC or intraparenchymal dosing of 
MSC.   
To answer the question of cells arriving at the site of injury, GFP DNA was analysed in a 
number of different organs.  In all three experimental conditions, GFP cells were found in 
the kidney, although in the IV group, more cells were located in the lungs than in the 
kidney.  In both the SC and the IP group MSC were preferentially found in the kidney 
although absolute numbers were very small particularly in the SC group.  Certainly the 
very small absolute quantity of GFP DNA was at times below the lower margin of the PCR 
standard curve, such that meaningful comparison between different groups at this level 
could not be made.  Using GFP DNA we were unable to separate live cells from 
phagocytosed cells or cellular debris, and it is likely (given the immunohistochemistry 
findings) that some of the GFP positivity does not relate to live, biologically active, MSC. 
 Preliminary data on efficacy suggested that there was no reduction in serum creatinine, 
urea or histological score in any group compared to control IR, with the possible exception 
of the SC group.  A further larger study was then performed using renal SC administration 
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of MSC in all animals.  No difference was found in creatinine or urea at 24 hours.  
Although there was a trend to a reduction in both at 48 hours compared to control, this was 
not statistically significant.  There was no difference in histological score at either 24 or 48 
hours.  This was a small pilot study designed to point the direction to the next experiment, 
and as such was underpowered to draw meaningful conclusions.   
Given the lack of any positive results, further experimental models were researched.  It 
was noted that five of seven published rat MSC renal IRI studies (at the time of 
commencement of this work) administered the MSC IA via the carotid artery (142, 201, 
202, 206, 211).  It was considered that IA administration may be superior to other methods 
in the murine model, by ensuring MSC deposition in the kidney via the renal artery.  This is 
delicate surgery in the mouse, and this novel methodology was carried out by Dr Bo Lu, an 
experienced murine microsurgeon.  The model of renal IRI used had already been 
optimised in his laboratory and published and was a significantly different model with a 
unilateral nephrectomy and then 20 minutes of warm renal ischaemia.  0.5 x 106 MSC 
were administered IA immediately following reperfusion.  At 24 hours, GFP+ cells were 
detected primarily in the lung and the kidney, in very small numbers.  At 24 hours there 
was clearly no difference in the serum creatinine, urea or histological injury score in the 
MSC group compared to the control IR group.  Unfortunately a sham operated group was 
not included, but comparison with previous published data showed renal failure was 
consistently established.  One limitation of this experiment was the lack of a later time 
point, and in retrospect analysing the outcomes at 48 hours would have been interesting.  
Again, only small numbers of animals were included, largely to due the highly complex and 
technical nature of the surgery.  Had there been a signal that there may have been benefit 
of MSC it would have been important to confirm this with a larger study.  Overall, however, 
the results were very consistent between groups and consistent with previous experiments 
and there really was no signal that MSC were likely to be effective. 
In summary, the current work consistently showed no benefit of syngeneic MSC in several 
murine models of renal IRI.  This was a little surprising given the encouraging results 
published at the time the work commenced.  There are a number of possibilities for this 
outcome ranging from the scientific method used to the possibility that the literature results 
could not be extrapolated to the current model.  With respect to the scientific method, 
multiple dose strategies of MSC were used and administered via multiple methods in a 
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robust attempt to replicate previous positive results.  The literature has progressed while 
the current work was undertaken and we now have the opportunity to review many more 
papers for their methods. It should be noted that many of the positive results previously 
published were in different models of AKI – in particular, the cisplatin nephrotoxicity model, 
in which MSC were consistently effective (188, 200, 216).  MSC in Renal IRI had been 
less well published, particularly in the murine model. 
From one published paper using a murine renal IR/MSC model in 2005, there are now 10 
reports from 2005-2018 (Table 9.1). Five of these found efficacy of MSC (55.6%), as 
assessed by serum renal function and histological analysis, with one showing no effect 
and four possibly showing effect.  Of these latter four studies, three only analysed 
histology and did not report renal function.  All three studies found improvement in 
histology either in tubular injury (273, 278), in reduction in necrosis (279), or in reduction in 
collagen deposition / fibrosis (273).  The fourth study with uncertain results did find effect 
of MSC, but only if the MSC were modified with the survivin gene, an inhibitor of apoptosis 
designed to improve resilience of MSC exposed to the highly inflammatory environment of 
AKI.  It is not clear from that paper whether the standard unmodified MSC led to a 
statistically significant effect, but if it did it appears it was a small effect (276).   
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Table 9.1: All studies examining efficacy of MSC in a murine renal IRI model 2005-2018.  Efficacy is defined 
as an improvement in both renal function and histopathology. Where only one of these is reported or 
positive it is labelled as “maybe” effective. 
Mesenchymal Stem Cells in Murine Models of Renal Ischaemia Reperfusion Injury
REFERENCE
EFFICACY OF 
MSC?
MSC DOSE
MSC 
ADMINISTRATION
SOURCE MSC?
Duffield 2005 (27) No < 1 x 106 IV Syngeneic
Li 2010 (278) Maybe < 1 x 106 IV
Syngeneic and 
allogeneic
Furuichi 2012 (279) Maybe < 1 x 106 IV Syngeneic
Hu 2013 (280) Yes 106 or > ? Syngeneic
Xing 2014 (272) Yes < 1 x 106 IV Syngeneic
Jang 2014 (275) Yes 106 or > IV and IP Syngeneic
Yuzeng 2014 (276) Maybe 106 or > IV Syngeneic
Yuan 2017 (199) Yes 106 or > IA Syngeneic
Zhu 2017 (273) Maybe ? IV Xenogeneic
Bai 2018 (277) Yes 106 or > IV Syngeneic
 
In terms of dose and administration of MSC, as shown in Table 9.1, of the five papers 
showing efficacy, four of them used doses of 1 x 106 or higher and these were 
administered using a range of different methods.  Of the studies using lower doses (< 1 x 
106), one showed good effect, one showed no effect and two were possibly efficacious. 
There may be a dose effect, although with the small number of papers and the 
heterogeneity of results it is difficult to be certain.  Most studies used IV MSC 
administration (8/10 studies).  Three of these papers found efficacy of MSC, four were 
possibly efficacious and one showed no effect.  Of the two studies using other methods, 
the IP administration was effective as was the IA administration (Table 9.1).  Again, this 
intimates that non IV methods might be more effective but to date, there an inadequate 
number of studies to form a definite conclusion.  Finally, of the five studies showing 
efficacy of MSC, four confirmed this effect at 24 hours (199, 275, 277, 280), with only one 
study not showing an effect of MSC until 48 hours (272). Thus, the results of the current 
work are in keeping with this heterogeneous group of murine renal IRI/MSC studies. 
There have been many more studies in rat renal IRI / MSC published since the current 
work commenced, with a total of 25 papers currently available. Of those, 19 (76%) showed 
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efficacy of MSC, two were probably effective and six did not find that MSC were effective 
in terms of reduction in serum creatinine and urea and / or improvement in histological 
injury scores (Table 9.2).  Note that two papers each presented two substudies, one of 
which was effective and one which was ineffective.  Togel et al found no effect with 
allogeneic MSC despite good nephroprotection with syngeneic MSC (211) and Burst et al 
found no effect with IV administration of MSC but good nephroprotection with intrarenal 
administration (281).  
In terms of dose of MSC, the majority used 1 x 106 MSC (Table 9.2). Of the 17 studies 
using this dose or lower, 12 studies confirmed efficacy, three did not, and two were 
probably efficacious. Of the five papers using medium doses (1.5 x 106), three showed 
efficacy and two did not.  In the four papers using high dose MSC (>1.5 x 106), three 
showed efficacy, and one showed efficacy if administered intrarenally but not if 
administered IV (281).   Overall, these results suggest that MSC dose is not critical in 
achieving efficacy in the rat IRI model, with 70.6% of the lower dose, 60% of the medium 
dose and 80% of the higher dose papers showing efficacy, as compared to the total 
percentage of rat studies showing efficacy (70.4%). 
With respect to the mechanism of administration of MSC, 12 papers presented results 
from IV MSC, 10 papers presented results from IA MSC and five papers injected the MSC 
directly into the renal parenchyma (Table 9.2). Interestingly, of the 10 studies using IA 
MSC, five were from the same research group (142, 201, 202, 211), suggesting that they 
had access to an experienced microsurgeon and had developed a useful and consistent 
model.  Of the 12 IV MSC studies, eight showed efficacy of MSC, three did not and one 
probably did, although serum renal function was not analysed. Of the 10 IA studies, six 
showed efficacy and three did not, with the remaining study possibly efficacious with a 
reduction in creatinine at 24 hours but no change in histology. Finally, of the five studies 
that directly injected MSC into the renal parenchyma four showed MSC efficacy and one 
did not. Again I think no conclusion can be drawn about the relative benefits of different 
methods of administration given that the outcomes were not significantly different from the 
overall outcomes (efficacy in 66.7% of IV studies, 60% of the IA studies and 80% of the 
few studies looking at renal parenchymal injections, as compared with overall efficacy in 
70.4% of studies). 
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Table 9.2:  All studies examining efficacy of MSC in a rat renal IRI model 2005-2018.  Efficacy is defined as 
an improvement in both renal function and histopathology. Where only one of these is reported or positive 
it is labelled as “maybe” effective.  MSC dose is labelled “low” if it is 1 x 106 or less, “medium” at 1.5 x 106 
and “high” if >1.5 x 106 .   
Mesenchymal Stem Cells in Rat Models of Renal Ischaemia Reperfusion Injury
REFERENCE
EFFICACY OF 
MSC?
MSC DOSE
MSC 
ADMINISTRATION
TIMING EFFICACY 
NOTED
Togel 2005 (142) Yes Low IA 48 hours
Lange 2005 (201) Yes Medium IA 48 hours
Semedo 2007 (204) Yes Low IV 24 hours
Ittrich 2007 (202) Yes Medium IA 48 hours
Hagiwara 2008 (206) Yes Low IA 48 hours
Togel 2009 (211)
Yes (syngeneic)
No (allogeneic)
Low, medium IA 24 hours
Semedo 2009 (205) Yes Low IV 24 hours
Burst 2010 (281)
Yes (intra-renal)         
No (IV)
High IV, intrarenal 24 hours
Zhuo 2011 (282) Yes ? ? 24 hours
Chen 2011 (283) Yes Low intrarenal 24 hours
Masoud 2012 (266) No Medium intrarenal
Liu 2012 (198) Maybe Low IV
Yu 2013 (284) No Low IA
Sadek 2013 (285) Yes ? IV 48 hours
Zhuo 2013 (286) Yes Low, high IV, IA 24 hours
Tsuda 2014 (287) Yes Low IV 24 hours
Cai 2014 (288) No Low IV, IA
Qiu 2014 (289) Yes High Intrarenal 24 hours
Zhang 2014 (290) Yes Low IV 24 hours
Zhao 2016 (291) Yes Low Intrarenal 24 hours
Hussein 2016 (292) Yes Low ? 24 hours
Zhang 2017 (293) Yes High IV 48 hours
Erpicum 2017 (294) No Medium IV
Fahmy 2017 (295) Yes Low IV
Liu 2017 (296) Maybe Low IA
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In terms of scientific method, it is important to look at the time point at which MSC were 
found to be effective.  Studies which demonstrated a nephroprotective effect of MSC can 
largely be divided into those which confirmed efficacy at 24 hours (12/18 papers) and 
those which did not find efficacy at 24 hours, but did at 48 hours (6/18 papers, Table 9.2).  
Most studies with longer time frames showed persistence of effect at 72 hours, but it was 
generally lost after this as the control groups improved towards baseline.  The most 
consistent pattern seen across these papers was a blunting of the peak creatinine and 
urea such that both MSC and control groups developed a significant AKI, but the peak 
values were lower in the MSC administered groups.  Of note, one negative study (288) 
and one probably positive study (198) looked at evidence of renal injury only at 24 hours. It 
is possible that both of these studies may have gone on to confirm efficacy should they 
have added a further time point.  A further study (266) only looked at creatinine clearance 
after one week, at which time a positive effect of MSC may well have been missed.  The 
other negative studies did look at multiple time points and were consistently negative.   
Two of the six papers which did show efficacy of MSC at 48 hours did not perform these 
analyses at 24 hours, so the effect could potentially have been earlier (206, 293). Finally, 
one study which confirmed effect did not test until 30 days, so the onset of effect was not 
clear (295). It is important to note that many of these papers had alternative primary 
purposes rather than establishing efficacy of MSC, hence the different protocols used.  
Overall, with the benefit of hindsight and further literature, I would like to have tested 
efficacy of our IA model at 48 hours as well as 24 hours. However, we did look at both time 
points in the other models with no change and it is likely that this would not have affected 
outcomes.   
As well as the increased number of studies in the rodent literature, two papers have been 
published with larger animal models.  Brunswig-Spickenheier et al studied both autologous 
and allogeneic BM MSC in a pig model of bilateral IRI using a balloon catheter to occlude 
the renal arteries. 2 x 106 MSC / kg were infused IA to the suprarenal aorta at reperfusion. 
There was no difference in serum creatinine in either the autologous or the allogeneic 
MSC groups compared to the control IRI group, at any time point (tested daily for 8 days). 
There was no difference in renal histological scores at day 28 post ischaemia (297). They 
did find that the porcine MSC failed to inhibit the MLR (in contrast to known effects of 
human and rodent MSC) and led to significant IL6 production, a pro-inflammatory cytokine.  
Rosselli et al administered allogeneic adipose MSC and BM MSC from one cat donor into 
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recipient cats via jugular vein catheter immediately after reperfusion in a model of 
unilateral IRI (210). After 24 hours and at six days there was no statistically significant 
difference in renal function noted and no difference in renal histology.  It would have been 
interesting to MHC type the donor and recipients here as alloimmunogenicity may have 
contributed to the lack of effect. 
Finally, since the current work was commenced, there have been two clinical trials in 
humans analysing the effect of MSC in renal IRI.  Togel and Westenfelder completed a 
pilot study primarily to look at safety and feasibility of MSC administration in 16 high risk 
patients undergoing cardiopulmonary bypass surgery (cited in 298, preliminary data 
published in 274).  Allogeneic BM MSC were administered in either low, medium or high 
doses via a femoral catheter into the distal thoracic aorta.  They found the MSC 
administration was safe at all tested doses and was associated with a reduction in hospital 
stay and need for readmission by 40%.  Post- operative renal function remained at 
baseline in all patients and no patient required dialysis whereas 20% of historical controls 
developed AKI.  It is interesting that this work has not been directly published since 
completion of the study, and therefore further information is not available. 
Very recently, Swaminathan et al reported the results from a multi-centre phase 2 
randomised double blind placebo controlled trial of 156 patients who had undergone 
cardiac surgery and developed AKI within 48 hours of coming off the cardiopulmonary 
bypass machine (265).  Patients received 2 x 106 MSC / kg or placebo via an intra-aortic 
catheter with the tip just proximal to the renal arteries, within 48 hours of IRI.  The primary 
outcome was time to recovery of kidney function with the secondary endpoints of all cause 
mortality or provision of dialysis at 30 and 90 days and the proportion of patients who 
required dialysis within 30 days.  They found no significant difference in recovery time 
following AKI (15 days in the MSC group vs 12 days in the placebo group), peak rise in 
creatinine or long term kidney function.  There was no difference in all cause mortality or 
dialysis treatment, hospital mortality, ICU length of stay or total hospital length of stay.  It 
should be noted that this was a group of patients who already had established AKI, and 
the MSC was administered as late as 48 hours after the IRI insult, which may have 
affected the results. However, they are not encouraging with respect to therapeutic 
consideration for MSC in this setting. 
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In the last ten years, the focus of the MSC field has shifted to some extent. It remains clear 
that these cells have potential as a treatment for IRI, but the overall outcome of these 
studies suggests that more work is needed to be done.  A number of groups are modifying 
or pretreating the MSC in an attempt to enhance their affect, and many of the very recent 
studies reviewed above have used modified or treated MSC.  For example, MSC have 
been modified with the survivin gene, to enhance their viability in different environments 
(276), they have been pre-treated with SNAP (S-nitroso N acetyl penicillamine), a nitric 
oxide donor, to mimic oxidative stress (266) and they have been cultured in ischaemia 
hypoxia medium and then exposed to a hypoxic environment prior to application (199).  In 
all of these situations, the effect of the modified or pretreated MSC was greater than that of 
MSC alone.  In fact, the survivin modified MSC were effective where the standard MSC 
were ineffective.  This has biological plausibility, as it has been found that characteristics 
of MSC change depending on their microenvironment and in a stressed environment they 
may be more likely to upregulate proteins such as hepatic growth factor and Insulin like 
growth factor-1 which may increase nephrotection (299).   
There is however a significant body of work emerging which appears to show more 
consistent results, while also providing an explanation for some of the previous 
inconsistencies and provide exciting avenues of study for the future.  The discovery in 
2009 that MSC secreted EV came after studies in the cisplatin model of AKI had shown 
that infusing MSC CM alone was effective in protecting against AKI (217). Bruno et al 
performed ultracentrifugation of MSC CM at 100 000g for 60 minutes, resulting in pellets 
which were characterised and found to contain vesicles between 80nm-1μm in size (300).  
They termed these “microvesicles”, but have since decided that “extracellular vesicles” is a 
more appropriate term, including both exosomes (30-100nm membrane bound vesicles 
arising from budding of intracellular endosomes) and microvesicles (membrane bound 
vesicles up to 500nm in size, arising from cell surface plasma membrane) (301).  These 
EV contain bioactive factors which interact with cell surface receptors on damaged cells, 
modifying the actions of those cells.  Ribonucleic acid (RNA) and microRNA (miRNA) have 
been found to be critically important in the effects of EV, as studies have demonstrated 
abrogation of effect with EV pretreatment with RNase (300).  It is likely that the content of 
the MSC EV impacts on angiogenesis, extracellular matrix remodelling, regulation of 
inflammation, cell proliferation, cell migration and many more factors involved in 
regeneration and repair. 
173 
 
If effective in models of AKI, EV have the advantage over MSC in that there will not be 
capillary lung trapping of cells, they cannot lead to ectopic tissue or maldifferentiation and 
the effective EV dose reaching tissue can be better calculated and administered.  
Fascinatingly, in one study, human BM MSC were found to express HLA class I, but the 
EV collected from the supernatant of these MSC in culture did not have any HLA class I 
expression, suggesting an immune privilege (302).  Neither expressed HLA class II 
molecules.  Finally, future work could involve loading the contents of the vesicles or 
transfecting the genetic material to suit therapeutic needs. To date, there have been 8 
published studies on MSC EV in renal IRI (Table 9.3), all of which have shown efficacy, 
despite disparate doses of EV and slightly different IR models.   
As summarised in Table 9.3, six of the eight studies were in rats, with two using different 
mouse models.  Seven of the eight studies used EV sourced from human MSC, with only 
one study using syngeneic MSC EV and this did not appear to affect the results.  
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Table 9.3:  All studies examining efficacy of MSC derived extracellular vesicles in an in vivo model of renal IRI rat renal IRI model 2011-2018.  EV = extracellular 
vesicles.  SD rat = Sprague-Dawley rat.  Efficacy is defined as an improvement in both renal function and histopathology. Where only one of these is reported or 
positive it is labelled as “maybe” effective.   
Mesenchymal Stem Cell derived Extracellular Vesicles in Animal Models of Renal IschaemiaReperfusion Injury
REFERENCE EV SOURCE
EV SIZE &
DOSE
ANIMAL IRI MODEL EV ADMIN EFFICACY EV OUTCOMES TIME
Gatti 2011 (302)
Human BM 
MSC
135nm, 
30μg
SD rat Unilateral IV Yes
Improved renal function. Improved 
tubular damage. Increased cell 
proliferation. Decreased apoptosis
48 hr
Kilpinen 2013 (303) HUCB MSC
20-500 
nm, ? μg
SD rat Bilateral IA Yes
Improved renal function. Decreased 
acute tubular necrosis
24 hr
Zou 2014 (304) HUCB MSC
? Size, 
100μg
SD rat
Unilateral, delayed 
nephrectomyof non 
ischaemic kidney
IV Yes
Unchanged renal function at D2, D3 but 
improvement after nephrectomy of non 
ischaemic kidney. Increased cell 
proliferation. Decreased apoptosis
2 week
Zhang* 2014 (305) HUCB MSC
? size, 
100μg
SD rat
Unilateral, delayed 
nephrectomyof non 
ischaemic kidney
IV Yes
Unchanged renal function at D2, D3 but 
improvement after nephrectomy of non 
ischaemic kidney. Increased cell 
proliferation. Decreased apoptosis
2 week
Ju 2015 (306) HUCB MSC
142nm, 
30μg
SD rat Unilateral IV Yes
Improved renal function, Increased cell 
proliferation. Decreased apoptosis. 
Decreased fibrosis.
2 week
Shen 2016 (307)
BalbC murine 
BM MSC
? Size, 
200μg
BalbC mice Unilateral Renal SC Yes
Improved renal function. Improved 
tubular damage. 
72 hr
Zou 2016 (308) HUCB MSC
211nm, 
100μg
SD rat
Unilateral, 
contralateral 
nephrectomy
IV Yes
Improved renal function. Improved 
tubular damage. Increased cell 
proliferation. Decreased apoptosis. 
24hr
Zhu 2017 (309)
Human Ad-
MSC
? Size, 
50μg
100μg
200μg
C57Bl/6 
mice
Unilateral
IV
At 24hr
Maybe
No renal function reported. Western 
blot αSMA and PDGFRβ reduced with 
100 and 200μg EV
7 day
175 
 
Human MSC sources have included BM MSC, human umbilical cord blood (HUCB) MSC 
and adipose derived MSC (Ad-MSC), again without noticeable effect on the results.  EV 
‘doses’ have ranged from 30 μg to 200 μg of protein quantification, with varying mean 
vesicular size likely due to the heterogeneity of EV source populations.  Only one study 
reported a ‘dose finding’ study, and they found effect only at the higher doses, but did not 
report serum creatinine, urea or histological scores (273).  The IRI models used were 
mostly unilateral ischaemia with one healthy kidney left in situ, but despite these non-
uraemic models, all the studies that reported renal function (7/8) found improvement in the 
groups administered EV. EV were administered IV (6/8), IA (1/8) and SC (1/8).  Given the 
tiny size of these molecules, it would not be expected that there would be any safety 
concerns with IV dosing.   
The results as shown in Table 9.3 were markedly consistent, with 7/8 studies finding 
improved renal function, 4/8 studies reporting reduction in histological tubular damage and 
5/8 studies reporting increased cell proliferation and reduced apoptosis. No studies found 
that MSC EV did not lead to improvement when compared with control IR groups.  It 
should be noted that references 304 (Zou et al) and 305 (Zhang et al) are from the same 
research group, with almost identical authors and identical methods.  Their results were 
reported only minimally differently and the possibility that this is in fact one piece of work 
reported twice cannot be ruled out. Both studies go on to look at different features of the 
effect of EV.  However, the degree of consistency in the outcomes overall is notably 
different from the MSC IRI data as reviewed above, and removing one of these papers 
from the analysis does not alter the results. 
Much work remains to be done.  MSC EV populations are as heterogeneous as MSC 
themselves.  Different methods have been used to isolate and characterise them and it is 
by no means clear that one study analysing MSC EV is looking at the same biological 
effects as another study purporting to assess the same thing.  There are significant 
differences between the very small exosomes and the much larger microvesicles.  Bruno 
et al (310) found in a glycerol model of AKI that BM MSC exosomes were renally 
protective but microvesicles from the same donor MSC population were ineffective.  
Collino et al (270) looked at 3 populations of BM MSC EV, and further separated them by 
density gradient.  They found three different populations, expressing different exosome 
markers which were shown to have different effects on cell proliferation and apoptosis.  
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Kilpinen (271) stimulated HUCB MSC with IFNγ for 24 hours prior to collection of EV and 
compared the results with EV from standard MSC.  This was a natural progression from 
the studies described above suggesting that pretreatment of MSC improved results. 
Interestingly, the nephroprotection afforded by the standard EV was lost when those EV 
were sourced from MSC exposed to IFNγ.  They went on to analyse the protein content of 
the EV and found that they were significantly different if the source MSC were exposed to 
IFNγ, with 246 proteins found in both groups of EV, 448 proteins found only in the 
stimulated EV group and 220 proteins found only in the standard EV group. They also 
found that EV from MSC exposed to IFNγ for 24 hours expressed HLA Class I molecules, 
and EV from MSC exposed to IFNγ for 24 hours expressed HLA Class II molecules also.  
EV from unstimulated MSC did not express HLA molecules.  These results imply that the 
creation and secretion of EV is a highly dynamic process with significant external effects 
which are likely to affect outcomes. 
This recent work in EV is very interesting when viewed next to the current study.  I found 
reduction in cytotoxicity in an in vitro model of renal IRI with MSC CM but not with MSC.  
This result was unaffected by the presence of CD4+ cells and DC but was lost when the 
CM was sourced from MSC which were stimulated with IFNγ and TNFα.  It is likely that 
this was a real result, perhaps reflecting an effect of the EV which would have been 
contained within the CM.  This was by no means a concentrated population and the 
number and substance of the EV could well have been different in each aliquot of CM, 
leading to result heterogeneity.  The current work presents novel methodology in both in 
vitro and in vivo studies and adds to the body of knowledge on MSC in renal IRI.  This 
work then sits well within the literature, confirming the difficulties attached to studying MSC 
treatment and efficacy (particularly in a murine model) and the probability that secreted 
factors are important.  The overarching conclusion from this work, and a review of current 
literature in the field, leads to the conclusion that the focus within MSC research should be 
on further identifying, characterising and testing MSC-derived EV rather than focusing on 
MSC as a cellular therapy.   
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   Appendix 1 
   Post Treatment Condition Assessment for Mice 
Experimenter’s name  Phone Number  
Mouse Number  Treatment Type (Date)  
Experimental Group  AEEC Number  
Anaesthetic used? 
Type? 
 Recovery time from 
anaesthesia 
 
DATE        
TIME        
DAY        
Appearance: 
Fur: ruffled, not groomed 
Nose and Eyes: discharge, blood, blue or dark 
colour 
Posture and behaviour: 
Hunched 
Unusually quiet/listless 
Aggressive 
Comatose ** 
Respiration: rapid shallow breathing or unusual 
noise on breathing *** 
       
Digestive: 
Body Weight (g) 
% BW change from pre-operative body weight **** 
Food intake: Reduced 
Water intake: Reduced/ Excessive 
Urine and Faecal output: any changes? 
       
Drugs:        
Signature (initials):        
Action: 
** euthanase,  
*** discuss with chief investigator or HMRF director, consider euthanasia 
**** body weight decrease progressive over 3 days, or >20% at 3 days, discuss with chief 
investigator or HMRF director, consider euthanasia.  
 
Scoring by TICK in any category: 
1-2: normal in immediate post-treatment period and up to 48h: continue to monitor 
3: notify CHIEF INVESTIGATOR or HMRF Director; monitor twice daily, consider euthanasia   
4 or greater:  euthanase 
 
